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Abstract
In this thesis the potential for lentiviral vectors as tools for gene manipulation 
was investigated. This thesis aims to answer the question of whether lentiviral 
vectors can be used to infect human stem cells with high efficiency without 
affecting their ability to differentiate and whether these vectors are able to 
deliver short hairpin RNA interference targeting a clinically relevant gene.
The introduction covers first the basics of the areas involved in this thesis, 
starting with stem cell biology and RNA interference before discussing vector 
biology and then Kaposi’s sarcoma-associated herpesvirus.
Human stem cell biology is a novel and rapidly moving field. The applications 
of lentiviral vectors range from determining mechanisms of cell growth and 
differentiation to tissue engineering. The first application for these vectors 
investigated was therefore optimisation of the infection of human stem cells 
and determining that these cells retain their biological function after infection.
Lentiviral vectors to deliver short hairpin RNA were developed and a 
knockdown in human stem cells demonstrated. Kaposi sarcoma-associated 
herpesvirus (KSHV), a cause of virally driven malignancies in humans, was 
chosen as a target to demonstrate the therapeutic potential of these lentiviral 
vectors. Lentiviral shRNA vectors knocked down latent genes within KSHV in 
vitro and showed promising therapeutic potential.
The final section of this thesis documents the progression of this work to form 
an in vivo therapeutic against a KSHV-driven malignancy, primary effusion 
lymphoma (PEL) in a murine model.
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Chapter 1 -  Introduction
This thesis aims to answer the question of whether lentiviral vectors can be 
used to infect human stem cells with high efficiency without affecting their 
ability to differentiate and whether these vectors are able to deliver short 
hairpin RNA interference targeting a clinically relevant gene.
The work presented here involves several fields including stem cell biology, 
RNA interference (RNAi) and Kaposi’s sarcoma-associated herpesvirus 
(KSHV).
This introduction forms an overview of all of the fields investigated in this 
thesis, covers the current opinion in published literature and attempts to link 
these subjects together. The first section (1.1) is an introduction to stem cells, 
and explains first what constitutes a stem cell, what we can gain from 
investigation of stem cells and reviews the current vectors used to manipulate 
gene expression in these cells. This relates to Chapter 3.
The second section (1.2) covers RNA interference, a novel technique for 
knocking down gene expression in mammalian cells. The work presented in 
Chapter 4 involves the development of a lentiviral vector capable of knocking 
down gene expression using RNA interference.
Section 1.3 is an introduction to retroviral and lentiviral vector biology, 
including the life cycle, requirements and recent advances in the field. The 
potential for these vectors for in vivo therapeuics is also covered here.
The final section of the introduction (1.4) covers KSHV biology, it’s associated 
morbidities and current opinion regarding the oncogenic abilities of the virus. 
Chapters 5 and 6 present the knockdown of KSHV latent genes both in vitro 
and in vivo, and this section of the introduction is relevant to these chapters.
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1.1 Human Stem Cells
1.1.1 What is a stem cell?
1.1.1.1 The role of stem cells in growth and development
1.1.1.2 The role of stem cells in tissue regeneration
1.1.1.3 The link between stem cells, ageing and cancer
1.1.2 Control of stem cell differentiation
1.1.3 Research into the clinical applications of human stem cells
1.1.4 Manipulation of gene expression in stem cells
Human stem cell biology is a rapidly moving field. The ability of lentiviral 
vectors to infect human stem cells is showing importance in research 
involving these cells, and the results presented in Chapter 3 show that these 
vectors can express foreign transgenes without affecting the potential of 
these cells to differentiate. This section covers an introduction to human stem 
cells, their biological function and role in research and how we can 
manipulate these cells in vitro.
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1.1 Human Stem Cells
1.1.1 What is a stem cell?
It is difficult to assign a universally understood meaning to the term ‘stem cell’. 
In 1894, Bizzozero classified tissue in the human adult as belonging to one of 
three groups- renewing (such as the skin and epithelium), expanding (such as 
the liver) and static (such as the nervous system). These classifications are 
not completely comprehensive -  we now recognise neural stem cells, and the 
fact that the adult nervous system is capable of renewing its cells when 
previously it was classified as static. This highlights the problems with trying 
to classify all 200 cell types within the human body.
There are three attributes which characterises a stem cell. A ‘stem cell’ is a 
cell found in either an embryo or an adult which is unspecialised, capable of 
long-term self renewal and also of differentiating into specialised daughter 
cells.
Stem cells are unspecialised - stem cells do not have any tissue-specific 
structures that allow them to perform specialised functions.
Stem cells are capable of dividing and renewing themselves for long periods. 
Unlike myocytes or neurons which do not normally replicate themselves or 
primary cells which have a limited life span, stem cells may proliferate 
indefinitely. If the daughter cells continue to be unspecialised, they are said to 
be capable of long-term self-renewal. The specific factors and conditions that 
allow stem cells to remain unspecialised in vivo are relatively unknown.
Stem cells can also give rise to specialized cells when grown under the 
correct conditions. Adult stem cells such as haematopoietic stem cells (HSC) 
and mesenchymal stem cells (MSC) are termed multipotent meaning that 
they can differentiate into cells from more than one lineage. When stimulated 
in culture, MSC can form adipocytes (fatty tissue), osteocytes (bone) and
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chondrocytes (cartilage). Human embryonic stem cells (hESC, or hES) by 
comparison are termed pluripotent as they have the potential to differentiate 
into all tissue types, however cannot form a placental body and therefore 
cannot grow into a foetus. Totipotent stem cells are capable of forming a 
foetus when grown in utero. Although murine embryonic stem cells (mES) are 
able to form placental tissues in vitro they cannot perform this function in vivo 
and so are pluripotent. There are currently no embryonic cell lines which are 
totipotent.
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1.1.1.1 The role of stem cells in growth and development
Knowledge of embryogenesis and the cellular functions of the human body 
have led to a view of the differentiating organism beginning with the ovum 
and progressing through fertilisation, zygote, morula, blastocyst and 
implantation. At each stage, cell division results in a larger number of more 
specialised cells. At the morula stage (12-16 cells), each cell is said to be 
totipotent. A totipotent stem cell is one which has the ability to form both any 
cell in an organism and the organism itself when implanted in utero. It is 
useful to classify cells at this stage into embryonic and extraembryonic. 
Embryonic cells go on to form the foetus and extraembryonic cells to form the 
placenta. This division helps when considering the concept of a pluripotent 
stem cell, which is embryonic, and cannot form extraembryonic tissues.
By the time a blastocyst is formed (16-64 cells), an outer layer which will 
become the placenta and an inner cell mass which will become the foetus is 
present. Cell lines established from the inner cell mass at this stage of 
embryogenesis are pluripotent, and include human embryonic stem cells. A 
pluripotent stem cell has the ability (theoretically) to give rise to every type of 
cell found in a living organism, however cannot form the organism itself if 
implanted in utero, because the cells cannot form the embryonic component 
of the placenta.
An important distinction to be made here is the difference between embryonic 
stem (ES) cells and embryonic carcinoma (EC) cells. EC cells hold all three of 
the properties assigned to stem cells, they are unspecialised, self-renew and 
they are pluripotent -  yet they are not stem cells. They are usually derived 
from a teratocarcinoma, a malignant tumour of germ line cells. Although they 
hold properties associated with stem cells, EC lines behave very differently 
for unknown reasons. They differentiate in different directions in response to 
different cues (Cadrin et al., 1988; Jones-Villeneuve et al., 1983; McBurney et 
al., 1982). They are not stem cells because they are derived from an 
abnormal (malignant) tissue and often contain chromosomal abnormalities
- 1 9 -
such as translocations and deletions. This means they are not as useful to 
investigate stem cell behaviour.
As embryonic growth proceeds, cells within the blastocyst become gradually 
more specialised. It is unknown how many ‘levels’ of differentiation and 
specialisation which occur, how many intermediates, and where the definition 
‘stem cell’ stops and ‘differentiated cell’ begins. There are several 
documented intermediates, including multipotent stem cells, progenitor cells, 
tissue stem cells and precursor cells (or satellite cells).
Multipotent stem cells have the ability to form more than one distinct type of 
daughter cell and include the mesenchymal and haematopoietic stem cells 
(MSC and HSC) (Pittenger et al., 1999; Marks and Kovach, 1966). These 
cells are all morphologically and immunohistochemically distinct. To make 
matters more complicated, it has been proposed that multipotent adult 
progenitor cells (MAPC) are pre-MSC/HSC derived from bone marrow (Jiang 
et al., 2002). They can form cells from any embryonic lineage and they have 
been classed as pluripotent, and are an intermediate between hES and the 
multipotent cells.
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1.1.1.2 The role of stem cells in tissue regeneration
The presence of ‘stem cells’ in the growing embryo can be deduced without 
investigation - one cell becomes all of the cells of the human body, and some 
form of proliferation and differentiation must be required. However for cells 
which are constantly renewing, such as the epithelial lining of the 
gastrointestinal cavity, the presence of precursor cells is essential. These 
precursors are restricted to a single lineage and lack the ability to specialise 
further- they are therefore not stem cells. Human bone marrow contains a 
myriad of precursor and stem cells and there are even cells which give a hint 
in vitro at being pluripotent (Jiang et al., 2002). These cells are the precursors 
for many tissues - injected bone marrow cells have also been shown to 
integrate into tissues throughout the whole body (Liechty et al., 2000; 
MacKenzie and Flake, 2001).
Some stem cells are also known to migrate into the peripheral circulation in 
response to certain hormones. The use of granulocyte monocyte colony 
stimulating factor (GM-CSF) to mobilise HSC in order to harvest them for 
‘bone marrow transplant’ is now preferred to traditional surgical methods. The 
presence of these cells in the periphery has led to theories about 
regeneration around wound sites involving stem cells. An animal study after 
bone injuries indicates that MSC indeed mobilise to the periphery and then 
form new osseous tissue (Tsuchida et al., 2003) and that MSCs improve 
healing in an animal model of diabetes (Sivan-Loukianova et al., 2003; 
Stepanovic et al., 2003).
Healing therefore is not only proliferation of cells surrounding an injury. Some 
mechanisms, such as hypoxic stimulation of angiogenesis to reperfuse the 
injured area (Knighton et al., 1981) are readily explained, however the 
complete regeneration of a deep wound requires a diverse range of cells 
growing in co-ordination. That stem cells may be passive in this -  dividing 
only as required - is now called into question. A group in New York described 
signalling factors (IGF, insulin like growth factor and WNT5, Wnt oncogene
-21 -
analogue 5) released by murine ES cells which rescue mouse embryos with 
cardiac defects (Fraidenraich et al., 2004). These cells manage this without 
integrating into the embryonic heart. Another report that introduction of MSCs 
into a damaged brain both promotes proliferation of existing cells (Lu et al., 
2001) and induces expression of neuronal markers by MSCs (Mahmood et 
al., 2004) indicates that there is a co-stimulation between injured cells and 
stem cells to coordinate appropriate wound healing.
Stem cells would appear therefore not just to be a source of new 
differentiated cells during the healing process, but also to interact via 
chemical messengers with injured tissue to encourage appropriate and 
necessary cell proliferation. This property seems to be held by both 
embryonic and adult stem cells.
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1.1.1.3 The link between stem cells, ageing and cancer
Human bodies lose certain functions as they age - elderly people are more 
prone to develop osteoporosis, even in nutritionally equivalent environments 
(Crockett, 1960), skin wounds take longer to heal as we age (Reed, 1998) 
and the functions of the immune system decline (Janssens and Krause, 
2004).
Both the ageing process and development of cancer have been linked to 
stem cells (Bell and Van Zant, 2004). In the laboratory, HSC and MSC have 
limited lifespans -  past around 15 passages, the cells will no longer divide or 
differentiate in vitro (Pittenger et al., 2000). There is also a significant 
difference in the ability of ‘old’ and ‘young’ stem cells cells to proliferate in vivo 
(Parsch et al., 2004), and there is evidence to suggest that people with 
osteoporosis or osteoarthritis (either young or old) have significantly 
decreased osteogenic function in their MSCs (Stenderup et al., 2001; Murphy 
et al., 2002).
Cancer may also be related to stem cells. Many cancer cells share some of 
the properties of stem cells. Although the theory behind stem cells initiating 
cancer is several years old (Reya et al., 2001), the idea of cancer as a stem 
cell disorder is gaining more popularity. Recent evidence has emerged linking 
haematopoietic (Huntly and Gilliland, 2005), brain (Singh et al., 2004) and 
breast (Al Hajj et al., 2003) cancers to tissue-specific stem cells. The 
knowledge that stem cells are involved in the initiation or the underlying 
pathology of a tumour may allow novel pathways for study and therapeutic 
intervention.
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1.1.2 Control of stem cell differentiation
In humans, the exact mechanism by which stem cells can self-renew, and 
how they ‘choose’ to become differentiated are relatively unknown. We can 
assume much from studies of Drosophila, Caenorhabditis elegans and yeast 
growth.
Molecular cues from the external environment stimulate stem cell activity 
(Reddy et al., 1997) (Eaves et al., 1999). This in vitro stimulation causes cell 
growth at a rate comparable to in vivo results (Oostendorp et al., 2000). 
Cytokines have been shown to activate numerous cell signalling pathways 
which are linked to cell division including the important Jak/Stat pathway 
(Heim, 1999). Growth factors such as epidermal growth factor (EGF) and 
basic fibroblastic growth factor (bFGF) have also been linked to stem cell 
division and maintenance of stem cell identity (Moghal and Sternberg, 1999; 
Szebenyi and Fallon, 1999), and bFGF has been shown to increase 
proliferation and stimulate differentiation potential in MSCs (Tsutsumi et al., 
2001; Sugi et al., 2003).
From a cell cycle point of view, it has been proposed that passage through 
the cell cycle determines the fate of the stem cell, and chromatin remodelling 
during S phase restores stem cell multipotency (McConnell and Kaznowski, 
1991). Yeast studies indicate that chromatin remodelling factors are recruited 
during M/Gi transition and the changes that occur in S phase become 
apparent during the subsequent Gi phase (Cosma et al., 1999; Krebs et al., 
1999). The genes that are involved in differentiation have yet to be fully 
characterised. Evidence exists that some genes are required for 
differentiation into a lineage (Yang et al., 2001), and other genes which play a 
vital role in the process can be used as markers for differentiation (Hong et 
al., 2004). An example is the POU family transcriptional regulator oct3/4, 
which shows expression restricted to germinal and embryonic tissue (Pesce 
et al., 1998) and is also essential for maintenance of pluripotency (Nichols et
- 2 4 -
al., 1998) and the undifferentiated state (Pesce and Scholer, 2001) in 
embryonic stem cells.
The restriction of stem cells to one lineage is thought to be determined by 
epigenetics or chromatin remodelling (Fisher, 2002). There are some 
indications that adult stem cells are capable of forming tissue not within their 
lineage. This may occur by the cells de-differentiating to a more pluripotent 
cell. An example of this is oligodendrocyte precursors which can revert to 
multilineage neural stem cells (Kondo and Raff, 2000). Another process is 
termed transdifferentiation, or the differentiation of a cell directly to a different 
lineage. Haematopoietic stem cells have been shown to regenerate 
hepatocyte populations, despite this being a mesodermal lineage (Jang et al., 
2004), and mesenchymal stem cells can give rise to neurons and glia (Mezey 
et al., 2000).
In theory, all that would be required for a stem, or even a terminally 
differentiated cell, to become pluri- or even toti- potent would be a reversal of 
the chromatin remodelling which resulted in it being lineage restricted (Kondo 
and Raff, 2004). Stem cell research would benefit from the ability to create 
pluripotent stem cells from an adult sample as this would avoid many ethical 
problems currently associated with embryonic stem cells.
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1.1.3 Research into the clinical applications of human stem cells
Because the scope of differentiation for stem cells is unlimited the potential 
uses for stem cells in clinical settings is diverse. Stem cells have the ability to 
accelerate healing (Lee et al., 2000) and generate tissue (Kassem, 2004). 
Since they are the precursors of cells throughout the body, stem cell 
manipulation may also prove to be the key to treatment of many hereditary 
conditions. Genetic alteration of stem cells has led to human therapy for X 
chromosome linked severe combined immunodeficiency (X-linked SCID) 
(Cavazzana-Calvo et al., 2000) and treatment in animal models for 
haemophilia (Karlsson et al., 2002), p thalassaemia (Puthenveetil et al., 2004) 
and Parkinsons disease (Levy et al., 2004), amongst others. Both multipotent 
and pluripotent stem cells have been considered for use in a clinical setting, 
although currently most research concentrates on the multipotent stem cells, 
because they are easier to obtain and culture and because of ethical 
implications. One of the barriers to the use of hES has been the difficulty of 
propagating and differentiating these cells in vitro. When cells from a 
blastocyst are isolated, they tend to differentiate spontaneously. If all the 
undifferentiated cells are not removed from a sample of ES cells prior to use 
in vivo, the sample is tumourigenic. In 1998, the University of Wisconsin 
(Thomson et al., 1998) became the first group to culture hES successfully in 
an undifferentiated state. Along with several other groups who were also 
investigating this, they used irradiated murine feeder cells to provide the 
growth factors essential to keep the cells undifferentiated. This has become a 
concern because of the possibility of transmission of infectious particles from 
animal feeder cells. Recently, feeder free growth of hES using conditioned 
medium (Xu et al., 2001) or supplemented medium (Amit et al., 2004) has 
been demonstrated. These cells lines still required the use of animal feeder 
cells for derivation, although hES have been derived which are completely 
free from contact with animal cells (Klimanskaya et al., 2005). Currently, we 
are also facing a lack of understanding of the processes which govern the 
differentiation of hES. We can stimulate MSC, HSC and MAPC to differentiate 
into specific lineages (Pittenger et al., 1999; Eaves et al., 1992; Sutherland et
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al., 1989; Jiang et al., 2002), but controlling the division of hES into pure cell 
populations that could be used therapeutically still eludes us.
One of the barriers to the use of stem cells in a clinical setting is the 
possibility of an adverse immune response (Bradley et al., 2002). It is not 
known exactly how immunologically active transplanted stem cells will be. An 
example of this is MSC, which appear to express different human leukocyte 
antigen (HLA) molecules according to the culture environment (Gotherstrom 
et al., 2004). hES cells do not seem to express HLA molecules, although the 
reason or biological role for this is unknown. HLA molecules may also 
upregulate upon differentiation (Li et al., 2004). Certainly, if we are to use 
these cells to create tissues and therapies then these issues will need to be 
addressed.
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1.1.4 Manipulation of gene expression of stem cells
Although using stem cells for research by manipulation of culture conditions 
holds much promise, this does not represent their full potential. Driving stem 
cells towards a pure population by regulating gene expression (Furumatsu et 
al., 2004; Tai et al., 2004), investigation of the mechanisms of differentiation 
and unlocking the secrets of why some stem cells are immortal require the 
ability to alter gene expression within stem cells.
Like other primary cells, stem cells are refractory to transfection by standard 
laboratory methods- although hES do seem to show some amenity to 
transfection with lipid based agents (Zwaka and Thomson, 2003). MSCs, 
HSCs and MAPCs are difficult to transfect with high efficiency, however 
introduction of transgenes using viral vectors has been demonstrated. Many 
viral vectors have been tested, including adenoviral (Cournoyer et al., 1991; 
Mitani et al., 1995), adeno-associated virus (AAV) (Lebkowski et al., 1988), 
herpesvirus (Dilloo et al., 1997), retroviral (Mitani et al., 1993), and lentiviral 
(Akkina et al., 1996) vectors.
Much work has been done with all these vectors, and some vectors hold more 
promise than others. The most efficient transfer to stem cells is with retroviral 
or lentiviral vectors, however these methods have safety and packaging 
difficulties which may make adenoviral or AAV vectors more suitable. For 
hES, only adenoviral (Smith-Arica et al., 2003) and lentiviral (Ma et al., 2003; 
Gropp et al., 2003) vectors have shown efficient transduction in vitro.
These vectors can be used in hES without a loss of ability to differentiate 
(Gropp et al., 2003). There is evidence that vector used at high multiplicity of 
infection (MOI) of above 20 to achieve high transduction efficiency reduces 
the ability of hES to differentiate (Clements et al., 2006). This may be a 
barrier to lentiviral vector use in these cell types.
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1.2 RNA interference
1.2.1 Introduction
1.2.2 The mechanism of RNAi
1.2.3 Applications of RNAi
1.2.4 Synthesis and Delivery
1.2.5 Prospects for RNAi as a therapy in humans
The use of primary and stem cells as models for diseases and as 
therapeutics is currently limited by our ability to manipulate them. The recent 
discovery of RNA interference (RNAi) in mammalian cells gives us the ability 
to reduce the expression of endogenous genes. In Chapter 4, the use of 
lentiviral vectors to deliver functional RNAi is shown and then demonstrated in 
human primary and stem cells. Chapters 5 and 6 then show the potential of 
lentiviral shRNA as a therapeutic both in vitro and in vivo. This introduction 
covers the principles behind RNA interference and explains also why it is of 
great significance to scientists in a broad range of fields.
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1.2.1 Introduction
The ability to disrupt gene expression using long strands of antisense RNA in 
vivo was first reported in 1985 (Rosenberg et al., 1985). Not long after, its 
application to human pathogenic viruses and cancer began: antisense RNA 
was used to study the biological role of the human papillomavirus transcripts 
in cervical cancer (Schwarz et al., 1985), to knockdown the expression of p53 
(Shohat et al., 1987) and c-myc (Nepveu et al., 1987), and to inhibit the 
replication of simian virus 40 (SV40) (Jennings and Molloy, 1987). In 1988, 
the potential to treat human cancers with antisense oligonucleotides was 
described as an approach, which
“although interesting, is paved with considerable conceptual and technical 
difficulties”
(Paoletti, 1988).
These difficulties included an incomplete understanding of the complex 
cellular processes driving human oncogenesis, unstable and incomplete 
silencing of genes using antisense or DNA oligonucleotides and difficulties 
delivering these oligonucleotides in vivo.
‘RNA interference’ (RNAi), or post-transcriptional gene silencing, utilizes small 
21-22 nucleotide fragments (Elbashir et al., 2001b) and has emerged as a 
promising new hope to silence genes in vitro and in vivo. Although dsRNA 
fragments were shown to inhibit gene expression in C. eiegans with effects 
an order of magnitude more efficient than antisense RNA (Fire et al., 1998), it 
was not known whether mammalian cells would also undergo the 
phenomenon of RNAi. It is well documented that mammalian cells elicit an 
interferon reaction to exogenous long double stranded RNA (>30bp) 
molecules as part of the natural cellular antiviral response. Tuschl and 
colleagues showed that short dsRNA molecules escape the interferon 
response in mammalian cells (Elbashir et al., 2001a).
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1.2.2 The mechanism of RNAi
The term ‘RNAi’ actually describes a cascade of cellular responses which 
results in the selective degradation of homologous target mRNAs (Figure 
1.2.1). RNAi initiates when dsRNA is cleaved into 21- to 23-bp fragments 
called small interfering (si) RNAs by an RNase Ill-like cellular enzyme called 
Dicer. These resulting small dsRNA molecules (or small interfering RNA, 
siRNA) associate with cellular proteins forming a complex known as the RNA- 
induced silencing complex (RISC). RISC is known to include members of the 
Argonaute family, Qde2 and Rde1 (Fagard et al., 2000). This silencing 
complex is phosphorylated and the inactive strand is released. This now 
activated RISC-RNA complex hybridizes to target mRNAs containing a 
complementary sequence to the active strand of the siRNA. The target 
mRNAs and the RISC are cleaved and subsequently degraded.
It is thought that the dsRNA molecule is reconstituted (Sijen et al., 2001) or 
amplified, either by degradation of RISC, or the action of RNA-dependent 
RNA polymerases on the released strand. This may explain why dsRNA is 
more robust than antisense RNA at silencing gene expression. In Drosophila, 
35 dsRNA molecules per cell can efficiently silence a gene whose mRNA 
copy number is over 1000 (Kennerdell and Carthew, 1998).
Although the proposed mechanism of RNAi means it should be specific to the 
mRNA sequence being targeted, several groups have called into question the 
specificity of RNAi and whether or not there are more widespread 
downstream effects. Adverse effects of siRNA molecules on non-targeted 
genes have been suspected through transitive RNAi or non-specific activity of 
dsRNA molecules.
Transitive RNAi is a process during which a cellular RNA dependent RNA 
polymerase (RdRP) produces non-specific off target dsRNA molecules (Sijen 
et al., 2001). This effect is theoretically unlikely to occur in human cells
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because of the lack of RdRP, however there is a recent report of RdRP-like 
activity within human cells (Cheng et al., 2005).
Specificity of the effect on the targeted gene have been investigated more 
thoroughly, however the reports have fallen on both sides of the fence- some 
indicating specificity (Chi et al., 2003; Elbashir et al., 2001c; Du et al., 2005; 
Bilanges and Stokoe, 2005), others suggesting non-specific silencing at the 
RNA (Jackson et al., 2003) and protein levels (Scacheri et al., 2004). These 
conflicts have yet to be resolved, and there are reports emerging that stable 
RNAi can be used in stem cells without affecting their biological potential 
(Vallier et al., 2004). This implies that any off-target actions may be minimal 
or unimportant.
- 3 2 -
Figure 1.2.1 Proposed mechanism of RNA interference in mammalian cells
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1.2.3 Applications of RNAi
Because this technology is sequence-specific, cancers that arise from 
gene point mutations (Brummelkamp et al., 2002b) and translocations 
such as chronic myeloid leukaemia (Wilda et al., 2002), Ewing’s sarcoma 
(Dohjima et al., 2003), and infections such as human immunodeficiency 
virus type 1 (HIV-1) (Jacque et al., 1998; Coburn and Cullen, 2002), 
hepatitis A (Kanda et al., 2005), B (Shlomai and Shaul, 2003; Ren et al., 
2005; Moore et al., 2005) and C (Kapadia et al., 2003; Yokota et al., 
2003), and human papilloma virus (HPV) (Jiang and Milner, 2002; Jiang 
and Milner, 2005) are obvious candidates for intervention using RNAi. 
Even new pathogens which emerge as potential epidemics like the Severe 
Acute Respiratory Syndrome Corona Virus (SARS-CoV) have been 
targeted (Wu et al., 2005).
Different viral and cellular genes can be targeted to interfere with viral 
entry, replication, pathogenicity and virion release (Hu et al., 2002; Milner,
2003). This approach is being vigorously explored for HIV research. HIV-1 
gag functions in several stages of the viral life cycle; from Gag-Pol 
expression, through to viral genome replication, packaging and virion 
production. Ablation of the gag gene which codes for the capsid, 
nucleocapsid, matrix and p6 proteins, should target different stages of viral 
infection. In independent studies, siRNA against gag resulted in HIV-1 
gene expression that was 10% of that of control cells and the viral titre 
dropped 25-fold (Park et al., 2002; Capodici et al., 2002).
Other HIV genes have also been targeted. siRNA directed against tat, the 
transactivator of HIV, necessary for gene expression, or rev, responsible 
for gene regulation and correct packaging of unspliced mRNA, inhibited 
HIV replication around 10-fold. Moreover, co-transfection of both siRNA 
constructs into 293 cells resulted in a 10,000-fold reduction in viral titre in 
the supernatant (Lee et al., 2002). Suppression of the co-receptors 
CXCR4 and CCR5 in HIV susceptible cell lines also resulted in resistance 
to infection when delivered both by small molecules (Anderson and 
Akkina, 2005) and viral vectors (Lee et al., 2003). Inhibiting cellular factors
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required for infection has also proved successful (Chiu et al., 2004; Ping et 
al., 2004). Reduction of the expression of CD4, one of the HIV-1 cellular 
receptors, resulted in a 4-fold decrease in the expression of that protein 
(Novina et al., 2002). Targeting different viral sequences may be 
synergistic and prevent the development of resistance (‘escape mutants’), 
in a similar way to the use of a cocktail of anti-HIV therapies in HAART 
(highly active antiretroviral therapy).
dsRNA against hepatitis B RNA has shown a decrease in both hepatitis B 
surface and core antigen in vivo (McCaffrey et al., 2003). Similarly, 
targeting Hepatitis C virus inhibits viral replication in vitro (Yokota et al., 
2003; Kapadia et al., 2003).
Viruses have not been the only focus of RNAi-driven technology. The 
ability to inhibit a component of a cellular pathway to investigate the effect 
of its loss and determine its function has also been explored (Nair et al., 
2005; Rodda et al., 2005). Novel techniques involving screening libraries 
of dsRNAs targeting known genes allows us to characterise pathways in 
more depth by discovering new functional components (Berns et al.,
2004), and to establish completely novel functions for known genes 
(Paddison et al., 2004). Techniques for producing such libraries is also 
now advancing (Cleary et al., 2004), as is the number of applications. New 
components of the pathways involved in endocytosis (Pelkmans et al.,
2005) and regulators of apoptosis (Mackeigan et al., 2005) have been 
identified using RNAi screens.
RNAi has shown potential benefits in disease models of neurological 
conditions (Xia et al., 2004; Lu, 2004; Singer, 2004; Burton, 2005) and 
regulation of gene expression with RNAi is also proving valuable in 
cancers which are not virally driven (Hata et al., 2005; Wilda et al., 2002).
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1.2.4 Synthesis and Delivery
The easiest and most common way to induce RNAi is to synthesise small 
dsRNA molecules in vitro and introduce them into cells in culture, using 
cationic lipid carriers. They can even be injected directly into mouse tail 
veins (Song et al., 2003) or into embryos (Calegari et al., 2002). Although 
the effects of siRNA can be amplified intracellularly, introducing RNA still 
remains a transient, self-limiting effect. DNA-based hairpin approaches 
offering stable expression have been engineered (Brummelkamp et al., 
2002a; Sui et al., 2002). These DNA constructs are designed to transcribe 
an mRNA molecule containing internal complementary sequences, which 
anneal to each other to form a hairpin. Dicer is thought to cleave this 
hairpin into small dsRNA molecules (Bernstein et al., 2001), which are 
capable of RNAi (Figure 1.2.1). Using DNA to induce RNAi allows for the 
possibility of stable integration of DNA into the target cell’s genome and 
thus permanent knock-down of the gene of interest. These DNA 
constructs benefit from the advances made in traditional gene based 
delivery systems, including the use of viral vectors to deliver the DNA- 
based silencing construct (Xia et al., 2002; Stewart et al., 2003; Grimm et 
al., 2005; Hosono et al., 2005; Hurtado et al., 2005; Nicholson et al.,
2005). These systems even allow the delivery of stable RNAi to stem cells 
(Zaehres et al., 2005). The recent discovery that RNA polymerase II 
promoters and inducible polymerase III promoters can deliver short 
hairpins reliably enough to enable short hairpin production (Zhou et al., 
2005; Matthess et al., 2005) allows both a much greater scope for 
targeting these vectors to a specific cell type and much greater plasticity 
for controlling levels of expression.
Delivery of RNA interference as dsRNA has also been extensively 
investigated with modifications to the chemical structure of the dsRNA 
molecule. These modifications mostly centre on improving both serum 
stability (Czauderna et al., 2003) and duration of action (Amarzguioui et 
al., 2003) of these molecules. A recent attempt to prepare dsRNA for in 
vivo use involved producing conformationally stable nucleotide analogues
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in a dsRNA template. The chemical structure of the nucleotides is altered 
so that the 2’-oxygen and the 4 ’-carbon atoms are linked with a methylene 
chemical group. This gives them better thermal and chemical stability and 
increases the avidity with which they bind complementary RNA sequences 
(Vester and Wengel, 2004). These locked nucleic acids (LNA) have 
previously been used for antisense RNA (Wahlestedt et al., 2000), but 
were shown to improve duration and potency of action and minimal toxicity 
as dsRNA templates for RNAi (Elmen et al., 2005).
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1.2.5 Prospects for RNAi as a therapy in humans
Exploiting RNAi as a therapy is plagued with similar problems to those 
previously demonstrated for antisense: the delivery of double stranded 
RNA to all infected cells in vivo is currently only a dream. Although 
massive doses of dsRNA have been injected into the tail veins of mice, 
and were successfully delivered to hepatocytes (McCaffrey et al., 2003), 
such systemic delivery in humans is not currently feasible. Double 
stranded RNA has a short half life and repeated delivery will not be 
practical, although one advantage of targeting foreign or mutated genes is 
that cytotoxicity in vivo should be limited. The development of DNA 
plasmids or viral vectors that lead to stable dsRNA delivery may achieve 
long-term silencing. Targeting dsRNA to a specific cell type may be 
possible by generating pseudoviruses with envelopes for specific cell 
types, or by expressing short hairpin RNA (shRNA) with tissue-specific 
promoters. dsRNA molecules which are resistant to degradation (Layzer et 
al., 2004; Elmen et al., 2005) and the development of new delivery 
systems such as use of peptide-based approaches (Kichler et al., 2003; 
Simeoni et al., 2003) and gel based application (Jiang et al., 2004) hold 
promise for translating RNAi from laboratory to the clinic.
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1.3 Lentiviral vectors
1.3.1 Viral vectors as gene delivery tools
1.3.2 Retroviral and lentiviral vectors
1.3.2.1 The retroviral life cycle
1.3.2.2 The unique characteristics of lentiviruses
1.3.2.3 Development of retroviral and lentiviral vectors
1.3.2.4 Infection of primary and stem cells
1.3.2.5 Limitations of HIV-1 as a lentiviral vector
1.3.2.6 Vector induction of interferon responsive genes
1.3.3 Current gene therapy trials
Development of lentiviral vectors for efficient infection of stem cells and for 
delivery of shRNA is the basis of the work presented here. This section 
aims to cover the basic biology of retroviruses and lentiviruses and the 
application of lentiviral vectors as gene delivery vectors.
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1.3.1 Viral Vectors as Gene Delivery Tools
Many of the advances that have been made in science have called for the 
ability to enhance, alter, inhibit or complement the expression of the 
genetic code within a system. As our models of human systems improve, 
and our abilities to culture new and exotic cells such as primary and 
human embryonic stem (hES) cells advance, traditional methods are no 
longer sufficient for the purpose. Most primary and stem cells are 
refractory to transfection, electroporation or even mechanical manipulation 
to enable gene delivery. Promoters which function strongly in cell lines are 
silenced in stem cells when they differentiate. These difficulties have 
driven the development of new methods of gene delivery.
One rapidly advancing field is the use of viral vectors. An extraordinary 
variety of viruses exist- almost all cell types in animal, human and even 
prokaryotic systems are the host or target for a virus. We are able to use 
the mechanisms by which they propagate their genetic material within their 
hosts to deliver novel genetic material.
Different viral vectors within the laboratory setting exploit the weaknesses 
and strengths of the viruses upon which they were based (see Table 1.3.1 
for an overview). This Table is by no means comprehensive, with many 
vectors based on different viruses reported in the literature; however a 
detailed discussion of these vectors available for gene transfer is beyond 
the scope of this introduction. The remainder of this introduction centres 
on the development of retroviruses as viral vectors. These viral vectors are 
of special interest because of their ability to express transgenes reliably 
and stably.
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Table 1.3.1 Comparison of some commonly used types of viral vectors for gene delivery
Virus Titre
(Approx.)
Envelope Tropism Capacity Immune
Response
Expression Advantages Disadvantages
Adeno-associated
Virus
10® - Broad <5kb Weak Episomal 
(90%) and 
integrated
Non-immunogenic and 
non pathogenic, stably 
integrates at specific 
location
Relatively small 
packaging capacity will 
limit gene transfer
Adeno-virus 1013 Broad 8 kb Strong Episomal Very efficient delivery 
in most tissues, very 
high titre production 
possible
Induces strong T cell 
response.
Herpes Simplex Virus 1010 + Narrow, 
but vectors 
are strong 
for 
neurons
40kb Strong Episomal Large packaging 
capacity. Strongly 
neurotropic.
Immune response.
T ransient expression 
in non neural cells.
Retrovirus 107 + Dividing 
cells only
9kb Weak Integrated Persistent gene 
expression in infected 
cells
Only transduces 
dividing cells and 
potentially oncogenic
Lentivirus 109 + Broad 9kb Weak Integrated Stable expression in 
almost all tissues
Potentially oncogenic. 
Safety concerns 
regarding 
recombination
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1.3.2 Retroviral and lentiviral vectors
Retroviruses are unique in their ability to integrate their genetic code reliably 
into the host cell. AAV’s will only typically integrate in 5-10% of infected cells 
(Huser et al., 2002). Retroviruses require the integration of their genetic 
material to complete their life cycle. Because of this, they are natural vectors 
which are ideal for the purpose of both in vitro and in vivo gene transfer. 
They have in fact been delivering genetic material to humans for millions of 
years in the form of human endogenous retroviruses (HERV, ERV, or 
retrotransposons). One recent report indicates that over 10% of our DNA may 
in fact be retroviral in origin (Bannert and Kurth, 2004).
There are many known retroviruses, although their hosts are mostly animals - 
the first human exogenous pathogenic retrovirus was not identified until 1981 
(Poiesz et al., 1981). Classification of retroviruses can be according to genetic 
similarity (Table 1.3.2) (Hunter et al., 2000) or morphologically (Table 1.3.3).
The most commonly used vectors are based upon the gammaretrovirus 
murine leukaemia virus (MLV, a C type retrovirus) or the lentivirus human 
immunodefiency virus type 1 (HIV-1). Unless otherwise stated, when 
discussing retroviral and lentiviral vectors, I refer to MLV and HIV based 
vectors, respectively. The next section covers the life cycle and properties of 
retroviruses and lentiviruses and then discusses the production of safe gene 
transfer vectors from these viruses.
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Table 1.3.2 Taxonomy of retroviruses
Family Genus Type Species Hosts
Retroviridae Alpharetrovirus Avian leukosis virus (ALV) Vertebrates
Beta retrovirus Mouse m am m ary tum our virus (MMTV) Vertebrates
Gam m aretrovirus Murine leukaemia virus (MLV) Vertebrates
Deltaretrovirus Bovine leukaem ia virus Vertebrates
Epsilonretrovirus W alleye dermal sarcoma virus Vertebrates
Lenti virus Human immunodeficiency virus 1 (H IV -1 ) Vertebrates
Spumavirus Chimpanzee foam y virus Vertebrates
Metaviridae Metavirus Saccharomyces cerevisiae Ty3 virus Fungi
Errantivirus Drosophila m elanogaster gypsy virus Invertebrates
Pseudoviridae Pseudovirus Saccharomyces cerevisiae T y l virus Invertebrates
Hemivirus Drosophila m elanogaster copia virus Invertebrates
Table 1.3.3 Morphological classification of retroviruses
A-type Non-enveloped, immature particles only seen inside cells. Exist possibly as a result of endogenous
retrovirus-like (ERV) genetic elements.
B-type Enveloped virions with a condensed, acentric core and prominent envelope spikes, e.g. MMTV.
C-type As B-type, but with a central core and barely visible spikes - e.g. most mammalian and avian
retroviruses (MLV, ALV)
D-type Usually slightly larger (to 120nm) and spikes less prominent, e.g. Mason-Pfizer monkey virus
(MPMV)
(Adapted from Coffin et al. 1997)
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1.3.2.1 The retroviral life cycle
A typical retroviral genome (Fig 1.3.1, top) contains three genes which code 
for the core proteins (‘gag1 from group specific antigen), the viral enzymes 
(pol, from polymerase) and the envelope (env). The pol gene is sometimes 
divided from the viral protease (pro) in diagrams. These genes are present in 
all retroviruses, and are grouped according to function. They do not 
necessarily show strong sequence homology between different retroviruses. 
Some retroviruses contain a gene which is known to cause cancer in its host 
(viral oncogene) -  examples include the human T cell lymphotrophic viruses I 
and II (HTLV-I and II) (Fig 1.3.1, bottom). Other retroviruses, such as the 
spumaviruses encode additional genes which are not always essential for 
viral replication. Lentiviruses also contain regulatory genes (such as tat and 
rev) and accessory genes (in HIV there are four -  nef, vif, vpr, and vpu).
In mature virions, the retroviral genome is always carried in the form of two 
plus strand RNA sequences (except in spumaviruses where reverse 
transcription occurs in the virion and a significant amount of DNA is present) 
and is surrounded by a lipid bilayer derived from the plasma membrane of the 
previous host cell. The virion also contains the products of both gag and pol 
genes, with env products embedded in and across the lipid bilayer.
The life cycle of a retrovirus is shown in figure 1.3.2. During infection, mature 
virions bind to a surface receptor on the cell membrane or through interaction 
with cell surface proteins. The viral core is released into the cell by fusion of 
the viral and host cell membranes. The viral core is transported to the 
cytoplasm by binding to cytoskeletal elements. During transport through the 
cytoplasm reverse transcription of the viral RNA into cDNA begins through the 
action of the viral enzyme reverse transcriptase (RT). The viral RNA, DNA 
and proteins are together termed the pre-integration complex (PIC) until it 
integrates into the host genome.
- 4 4 -
The retrovirus enters the nucleus during S phase transition when the nuclear 
membrane breaks down (Lewis and Emerman, 1994). Once inside the 
nucleus, viral integrase (IN) begins incorporating the new cDNA into the host 
genome. After integration into the host genome, the viral DNA becomes 
known as a provirus, and when the cell becomes transcriptionally active, viral 
genes are transcribed and translated by the host cell. Although integration 
has previously been believed to be random, it is now thought that different 
retroviruses integrate more frequently in different areas of the genome. An 
example is HIV-1, which appears to integrate more frequently in 
transcriptionally active areas of the genome (Reviewed in Mok et al. 2005).
Transcription of the viral genome is driven by the viral promoter in the 5’ 
(upstream) long terminal repeat (LTR). The poly-A signals in the 3’ LTR cause 
transcription to terminate (Guntaka, 1993). The entire genome is transcribed 
on a single mRNA transcript and retroviruses employ a variety of tactics such 
as splice variation and frameshift translation to allow this single transcript to 
code for multiple gene products.
In the cytoplasm, spliced mRNA is translated into viral gene products. Gag 
and pol are translated into a single protein molecule known as a Gag-Pol 
precursor. The viral proteins and genomic RNA undergo assembly at the cell 
membrane (in B and D type viruses this occurs in the cytoplasm), when they 
are packaged with the env gene products (SU and TM) to form immature 
virions. Retroviruses rarely cause cells to lyse, with budding being the primary 
method of virion release. This budding gives the virus its lipid bilayer 
envelope. After immature virions bud from the cell membrane they undergo 
maturation. This involves viral protease cleaving Gag-Pol protein products 
into the core proteins and enzymes involved in the life cycle. These virions 
are now said to be mature.
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Fig 1.3.1 The retroviral genome
(a) Common retroviral elements
LTR Gag Env LTR
Pol
-10  kilobase pairs
LTR -  long terminal repeat
Gag -  group specific antigens gene
Pro -  codes for viral protease
Pol -  codes for viral enzymes (integrase and polymerase) 
Env -  viral envelope gene
(b) The genome of HTLV-I
Tax -  transactivator/ x-region (oncogene)
Rex -  codes for RexRE binding protein
(Adapted from Coffin et al., 1997)
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Fig 1.3.2 The retroviral life cycle
Mature virions are produced during 
maturation, where the viral enzymes 
are cleaved from the Gag-Pol poly­
protein. After maturation, virions are 
ready to begin a new life cycle.
Retrovirus
Capskt
g P '20  gp4|
New immature virions containing 
RT, the genome and the Gag-Pol. 
polyproten, which is uncleaved
Q )
Budding
Host cell plasma membrane
Entry into cell and 
loss of envelope
RNA
Loss of viral capsid \ ^
\  DNA
\
Synthesis of a DNA RNA and 
then a dsDNA double helix 
by reverse transcriptase
dsDNA
Cytosol
Assembly
9 0
~ '  /  
- Translation
Translation
DNA is integrated into the host genome, and multiple copies 
of the viral mRNA produced by cellular transcription factors.
Legend:
Reverse transcriptase is a multifunctional enzyme that makes a dsDNA copy 
of the RNA genome. The integration of this DNA into the host chromosome is 
catalyzed by a viral protein called integrase. Retroviruses are examples of 
enveloped viruses, in which the protein shell is further enclosed by an outer 
lipid bilayer membrane. The envelope contains proteins that enable the virus 
to bind to cells, and that aid its entry into a cell. The virus is released from the 
cell by a process of budding from the plasma membrane, taking some of this 
membrane with it.
(Adapted from Alberts et al., 1994)
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1.3.2.2 The unique characteristics of lentiviruses
HIV-1 can be used as a model for the lentiviral life cycle. There are several 
key differences from the retroviral life cycle. The steps involved in entry, 
reverse transcription, assembly and budding are similar for retroviruses and 
lentiviruses. Lentiviruses have the ability to infect quiescent cells, as they do 
not need the nuclear membrane to break down in order for the PIC to enter 
the nucleus. This may be due to unique nuclear localisation sequences (NLS) 
within the lentiviral proteins. There is some evidence, however, that the 
transition between Go and Gib is necessary for viral replication (Korin and 
Zack, 1998). Lentiviruses also encode several accessory genes. These 
genes have broad functions from enhancing viral assembly to suppressing 
host immune responses (see below).
Whether NLS’ hold the key to the ability of HIV to infect quiescent cells or not 
is currently under scrutiny. Although sequences within the HIV genome which 
promote nuclear localisation definitely exist -  in the gene vpr (Popov et al., 
1998), and proteins IN (Bouyac-Bertoia et al., 2001) and MA (Haffar et al., 
2000), there is some debate as to how important they are for nuclear 
transport of the PIC. A recent report of the effect of adding a NLS to a 
retroviral vector showed that this did not enhance nuclear transport in 
nondividing cells (Caron and Caruso, 2005), and another that mutations of 
the NLS within MA did not diminish nuclear transport (Mannioui et al., 2005).
Rev (one of the accessory genes) also encodes a NLS, however the function 
of this is to allow entry of Rev/lmportin-p into the nucleus prior to assembly. 
This complex binds to the factor Crm1, releasing importin-p. Rev binds the 
rev-response element (RRE) in unspliced HIV-1 mRNA and transports this 
into the cytoplasm (Askjaer et al., 1998). Rev therefore enhances the export 
of unspliced HIV-1 mRNA. After nuclear export, assembly budding and 
maturation happen exactly as for retroviral vectors.
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Throughout the life cycle, the accessory genes tat, nef, vif, vpu, vpr, (and vpx 
for HIV-2) perform their roles in the life cycle. Only the Vif, Vpr and Nef 
proteins are present in the mature virions. The other accessory genes are 
expressed from the viral mRNA at other times in the life cycle.
Tat (transcriptional activator) helps HIV overcome a limitation in its 
transcription. Normally, transcription driven by the LTR is relatively slow and a 
hairpin structure within the genome prevents efficient production of full length 
mRNA. Once a small amount of Tat is produced, this activates cellular factors 
and allows HIV to overcome this limitation (Kim and Sharp, 2001). It causes a 
positive feedback effect on its own protein levels. Tat may also have a more 
direct role in the pathogenicity of HIV. The protein is released by cells in 
culture, and is often found in the blood of HIV positive individuals. Tat is 
sufficient to cause apoptosis in T cells in culture without infection with HIV 
(Xiao et al., 2000).
Nef, or negative regulatory factor, is a gene involved in T cell activation to 
ensure continued production of viral progeny and downmodulation of MHC 
class II, CD4 and CD28. It has also been recently documented that Nef may 
have a role in the transcription and expression of viral proteins (Reviewed in 
Joseph et al., 2005).
Vif, or viral Infectivity factor, encodes for a small protein whose exact function 
is unclear. It is known to be important for viral replication and determines how 
the viral RNA and Gag bind together. It also inhibits various cellular proteins 
involved in RNA processing (Reviewed in Strebel, 2003).
VpR, or viral protein R, plays an important role in regulating nuclear import of 
the HIV-1 pre-integration complex (Popov et al., 1998), and is required for 
virus replication in non-dividing cells. Vpr has an immunomodulatory effect, 
possibly due to its ability to induce cell cycle arrest in proliferating cells 
(Bukrinsky and Adzhubei, 1999).
- 4 9 -
Vpu, or viral protein unknown, is involved in enhancing viral budding from an 
infected cell (Klimkait et al., 1990). Vpu also causes downregulation of CD4 
on infected T cells (Geleziunas et al., 1994).
For viral vectors, these accessory genes are mostly unnecessary, as they are 
involved in immune system modulation or enhanced LTR driven transcription 
and are not usually included. This adds to the safety of these vectors.
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1.3.2.3 Development of retroviral and lentiviral vectors
The most basic retroviral vectors have the entire gag-pol-env component of 
the genome removed. The cDNA of interest is placed after the packaging 
signal (y) and its expression driven by the 5’ LTR. These vectors require co­
transfection with other plasmids to provide the viral proteins, and they usually
have a high rate of recombination. Viral preparations usually contain small 
quantities of replication competent virus (RCV, or replication competent 
retrovirus, RCR). These vectors are usually produced with packaging cells to 
make production easier. These packaging lines often provide the retroviral 
gag-pol and sometimes env sequences, eliminating the need to transfect 
these to produce vectors.
More complex vectors have emerged from an understanding of the structure 
of the retroviral genomic RNA (Fig 1.3.4). It is now known which components 
of the genome are essential for retroviral vectors, and which can be removed 
to increase packaging size and vector safety.
Efficient integration requires the following components (Fig 1.3.5):
• A promoter and polyadenylation signal in the viral genome
• Viral packaging signal (y)
• The primer binding site (PBS) and poly purine tract (PPT) which initiate 
first and second strand DNA synthesis (reverse transcription) 
respectively
• The R region at both ends of the RNA
• Short partially inverted terminal repeats (ITR) in the U5 and U3 regions 
(which are required for integration)
Extensive deletions of the elements which are not required for efficient 
integration has led to a second and third generation of vectors. The most 
recent retroviral backbones have been termed self-inactivating (SIN). They 
were constructed by deleting transcriptional enhancers in the U3 region. As
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the viral RNA is reverse transcribed, this deletion is copied into both 3’ and 5’ 
LTRs and therefore the provirus is transcriptionally inert (Fig 1.3.5). An 
internal promoter cloned into the provirus will still be able to express a 
transgene, and the retained presence of y, the PBS and PPT, the R regions 
and ITRs mean that reverse transcription and integration still occur 
(Dougherty and Temin, 1987; Hawley et al., 1987). This means that they are 
much less likely to recombine with elements of wild type viruses or 
transcriptionally activate an endogenous oncogene. The drawback to these 
vectors is that the viral titre is markedly reduced.
There are many vector systems currently available based on viruses from 
most animal families. On of the most common retroviral vectors is based upon 
the gammaretrovirus Moloney murine leukaemia virus (MoMLV). It is an 
ecotropic virus, infecting only murine cells. Both replication competent (Lobel 
et al., 1985) and defective vectors (Gruber et al., 1985) have been reported. 
This virus has also been pseudotyped with the envelope from the vesicular 
stomatitis virus G (VSVG). This envelope binds non-specifically to cell 
membranes, increasing the tropism of the vectors, and also has the 
advantage that it is stable enough for ultracentrifugation to concentrate vector 
stocks (Burns et al., 1993).
The increased difficulty of synthesising lentiviral vectors due to their more 
complex genome has been successful mostly because of their ability to infect 
nondividing cells and their efficiency when infecting slowly growing cells such 
as stem cells.
The first HIV-1 based lentiviral vectors were crude vessels with virtually intact 
genomes which could only infect T cells and were dangerous to produce and 
handle. They contained only a marker gene driven by an internal or 
heterologous viral promoter (Page et al., 1990; Buchschacher, Jr. and 
Panganiban, 1992). All HIV-1 genes were provided in cis (from the same 
construct), whereas the env gene was provided in trans (expressed from a 
different construct). Packaging cells for HIV-1 based lentiviral vectors are
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difficult to produce, as many HIV-1 proteins themselves are toxic. There has 
been some success in manufacturing producer cells expressing HIV-1 Gag- 
Pol on its own (Haselhorst et al., 1998) or in combination with the 
amphotrophic MLV envelope (Ikeda et al., 2003). The role of some accessory 
genes such as tat and rev in vector function complicates the requirements of 
lentiviral vectors.
Breakthroughs in our understanding of HIV biology have resulted in far more 
versatile vector systems. The cell range of these virions was increased by 
pseudotyping with the VSVG envelope (Yee et al., 1994) or the amphotrophic 
MLV envelope (Page et al., 1990). The first ‘usable’ lentiviral vector was 
based on HIV-1 (Naldini et al., 1996b). This vector was shown to transduce 
retinal cells, hepatocytes and neural tissue (Blomer et al., 1997; Naldini et al., 
1996a; MacKenzie et al., 2002; Miyoshi et al., 1997).
The parts of the HIV-1 genome required for functional vector production have 
been characterised. The packaging signal is now better understood (McBride 
et al., 1997), meaning that gag is no longer required for vector function. The 
inclusion of other viral promoters eliminates the need for tat, which is required 
for transcription of the viral genomes driven by the HIV-1 LTRs. In some 
vectors, even rev and the RRE can be replaced with similar sequences from 
the Mason-Pfizer monkey virus although this sequence may not be as 
efficient at nuclear export of mRNA (Srinivasakumar et al., 1997). Hybrid 
vectors mean that the possibility of recombination with wild type HIV in 
humans can become vanishingly small. Most lentiviral vectors do not include 
the HIV-1 accessory genes as these are not required for the vector function.
The self-inactivating (SIN) lentiviral vectors utilise this technology from 
retroviral vectors. This can fortunately be performed in lentiviral vectors 
without a significant decrease in the final titre of the vectors, and the resulting 
vectors are considered safer (Chang et al., 1999; Logan et al., 2004).
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Fig 1.3.4 The retroviral genomic RNA structure
5 ’ 3 ’
PBS
c .p  ■ ■ ■ ■  "
R U5 Leader gag pol env PPT U3 R
The retroviral RNA structure, from 5’ Cap to 3’ Poly-A tail.
R region A short (18-250nt) sequence which forms a direct repeat at both ends of
the genome. Responsible for transfer of DNA synthesis between first and 
second strand reverse transcription 
U5 A unique non coding region which is the first part of the genome to be
reverse transcribed
PBS Primer binding site- 18nt complementary to the 3’ end of the tRNA used by
the virus to initiate transcription 
Leader An untranslated region (90-500nt) downstream of the transcription site
present at the 5’ end of viral mRNAs 
PPT Poly-purine tract. A short (-15-20) purine nucleotide sequence which
initiates + strand synthesis during reverse transcription 
U3 A unique noncoding region which forms part of the LTRs of the provirus,
and contains the promoter elements which drive transcription of the 
provirus
(Adapted from Coffin et al., 1997)
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Figure 1.3.5 Essential elements in the retroviral genome and SIN vectors
5' LTR 3’LTR
*
PBS Transgene +
DNA
U3 R U5 v PPT U3 R U5
Transcription
▼
*
PBS Transgene |
RNA w— mmmm----------------------------
R U5 ^ PPT U3 R
Reverse transcription
▼
* *
▼ PBS Transgene I
DNA mmmmm
PPT U3 R U5 v pp t  U3 R U5
The elements shown (U3, R, U5, PBS, \\i) are essential components of 
plasmid DNA (top) for production of retroviral vectors. The U3 and U5 regions 
needs to contain an ITR (not shown). This diagram also demonstrates the 
principal of self-inactivation. Deletions in the U3 region (marked *) are copied 
to the RNA strand during transcription and then during reverse transcription 
are duplicated at both 5’ and 3’ LTR, resulting in a transcriptionally inactive 
provirus.
(Adapted from Coffin et al., 1997)
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1.3.2.4 Infection of primary and stem cells
Lentiviral vectors are capable of stable expression in primary cells (Naldini et 
al., 1996b; Gropp et al., 2003). Previous experiments with retroviral vectors 
have indicated that the retroviral genome can be modified to enhance 
infection and expression of the transgene (Delenda, 2004). Additional 
elements often enhance the function of retroviral genes or replace the 
function of components which have been removed. Many of these elements 
can be directly translated across to lentiviral vectors.
These elements can be broadly divided into two groups. The first enhance the 
transport of the viral mRNA through the cytoplasm or the nuclear membrane. 
Examples in this group include the central poly purine tract (cPPT) / DNA flap, 
which is an element of the HIV-1 genome which improves the infection 
efficiency of viruses encoding it. This may either be by enhancing reverse 
transcription or by improving the efficiency of nuclear transport (Sirven et al., 
2000; Fuentes et al., 1996). The second group enhances the expression of 
the transgene. This group includes post-transcriptional regulatory elements of 
hepatitis B virus (HBRE) or, more commonly, the woodchuck hepatitis virus 
(WPRE) (Zufferey et al., 1999). The precise mechanism of action of these 
elements is unknown, although is has been theorised that they lengthen the 
poly-A tail on the mRNA which allows the accumulation of mRNA in the cell 
(Huang and Liang, 1993). These elements can also function in the producer 
cells, increasing the titre of the virus produced. The constitutive transport 
element (CTE) (Mautino et al., 2000) is thought to enhance expression by 
replacing or enhancing the function of Rev and the RRE which can then be 
left out of vectors to increase safety (Gasmi et al., 1999).
Until a few years ago, very few promoters were widely used. In adherent 
cells, the cytomegalovirus immediate-early (CMV) promoter was universally 
used. Other promoters such as the CAG (a combination of the chicken p-actin 
and cytomegalovirus immediate early promoters), phosphoglycerokinase 
(PGK) and thymidine kinase (TK) were in use, but recent tailoring of gene
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expression to target cell groups (De Palma et al., 2003; Follenzi et al., 2004; 
Nash et al., 2004) shows just how versatile these vectors can be. The first 
reports of manipulation of human embryonic stem (hES) and haematopoietic 
stem cells (HSC) with retroviral vectors show that elements such as the 
cPPT and WPRE are essential for efficient infection and expression in these 
cells, and that even then some degree of silencing is usually seen during 
differentiation (Klug et al., 2000; Cheng et al., 1998). Infection of primary and 
stem cells with retroviral vectors have also shown low efficiencies when 
compared to lentiviral vectors (Leurs et al., 2003; Serrano et al., 2003). 
Lentiviral vectors also do not experience silencing in stem cells (Gropp et al.,
2003).
There has been continuous refinement of lentiviral vectors since their 
discovery. New features such as the cPPT have been better characterized 
(De Rijck et al., 2005), while novel methods of producing virus using 
adenoviral vectors (Kuate et al., 2004) or optimising titre by inhibiting protein 
kinase R in target cells (Pernod et al., 2004) are being developed. With safety 
an ever present consideration, viruses which are integrase deficient and 
persist episomally have emerged (Vargas, Jr. et al., 2004). There are also 
groups developing lentiviral vectors which are easier to use. One of the 
practical barriers with these vectors has been the size of the resulting plasmid 
(some >10kb). This has left few cloning options since restriction sites are 
limited and blunt end cloning has extremely low efficiency with plasmids this 
size. One vector of note (Fussenegger et al., 1998) has been created using 
two different internal ribosomal entry sites (IRES) to allow expression of three 
genes from a single promoter. The vector contains individual cloning sites for 
each gene locus. This type of vector is now also becoming commercially 
available.
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1.3.2.5 Limitations of HIV-1 as a lentiviral vector
The advantages of lentiviruses over other viral vectors have increased their 
use in vitro. Vectors have now been derived from simian immunodeficiency 
virus (SIV) (Rizvi and Panganiban, 1992), equine infectious anaemia virus 
(EIAV) (Olsen, 1998) , feline immunodeficiency virus (FIV) (Poeschla et al., 
1998b), caprine arthritis encephalitis virus (CAEV), (Olsen, 2001) HIV-2 
(Poeschla et al., 1998a) or even hybrids of different lentiviruses (Strappe et 
al., 2005; Khan et al., 2005; Corbeau et al., 1998; Rizvi and Panganiban,
1993) or hybrids of a retrovirus and a lentivirus (Steidl et al., 2004) . One of 
the main concerns regarding these vectors remains safety. The first 
generation of lentiviral vectors contained all the viral accessory genes and 
intact LTRs. These vectors readily recombined, both during vector production 
and in the wild and there were unacceptably high amounts of replication 
competent lentivirus (RCL) in the vector preparations. Removal of the 
accessory genes and the development of SIN vectors has also increased 
their safety.
In the laboratory, second generation and self-inactivating vectors in the UK 
are handled in a containment level 2 (CL2) laboratory, however in the USA 
regulation is different and vectors derived there often contain intact LTRs. 
These vectors are considered containment level 3 (CL3) in the UK. In 
addition, all cell lines infected with these vectors should be handled in CL3 
facilities.
Contamination of vector stocks with replication competent lentivirus (RCL) is 
not usually a problem since all modern vectors are produced using plasmid 
transfection systems. Problems exist in vivo surrounding concomitant 
infection. Although the components required for production of RCL are not 
present in the plasmids, evidence from studies suggests that coinfection with 
wild-type HIV-1 might supply the missing sequences (Vanin et al., 1994; 
Purcell et al., 1996; Bukovsky et al., 1999), and that surprisingly little 
homology (10 identical base pairs) is required for this to happen (Otto et al.,
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1994). This may result in the production of replication competent viruses 
containing the transgene, and is therefore undesirable.
Insertional mutagenesis or oncogenesis from the action of reverse 
transcription on the host DNA raises questions for both gene therapy and for 
in vitro experiments. Viral vectors often integrate multiple times into target 
cells (Woods et al., 2003), and the site of integration which was thought to be 
random may show preference. MoMLV may show preferential integration in 
vivo near promoter regions. This has been highlighted by the recent 
demonstration of retroviral integration near the promoter for the oncogene 
LM02 in vivo (Hacein-Bey-Abina et al., 2003). LM02 has a role in 
haematopoiesis (McCormack et al., 2003), and is associated with T cell acute 
lymphoblastic leukaemias (T-ALL) (Hammond et al., 2005). Recently, 
evidence that in utero injection of lentiviral vectors raise the rate of tumours in 
mice has emerged (Themis et al., 2005). HIV-1 is currently believed to show a 
preference for transcriptionally active sequences (Mok and Lever, 2005).
Another practical consideration for the use of retroviral and lentiviral vectors in 
vivo is the titre of the virus produced. Adenovirus and adeno-associated virus’ 
can be produced in high quantities- both in volume and titre. Retroviral and 
lentiviral vectors cannot easily be produced in quantities high enough for in 
vivo use in humans. Many of the applications proposed for lentiviral vectors 
are therefore currently impractical in man. Some groups are attempting to 
address this with new production techniques (Ni et al., 2005; Sena-Esteves et 
al., 2004; Ikeda et al., 2003). Current ongoing clinical trials with retroviral 
vectors therefore involve ex vivo manipulation of cells.
The possibility of producing an AIDS-like syndrome by using lentiviral vectors 
has been discounted as the mechanisms of both these vectors and wild type 
HIV-1 are better understood. This has not stopped a drive away from HIV-1 
based vectors towards animal viruses which are considered non-pathogenic 
in man. These systems may offer safety advantages, and in some cases have 
been shown to be more efficient than HIV-1 based vectors (Beutelspacher et
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al., 2005), however they still suffer from many of the limitations of HIV-1- 
based vectors.
For both in vitro and in vivo experiments, the expression of multiple genes is 
often desired for optimum results. With plasmid transfection systems, 
coexpression with two plasmids is easily guaranteed, however infection with 
viral vectors does not follow this. One solution is to place two promoters in the 
same construct. The size of the lentiviral backbone can make this approach 
difficult. An option which links expression and is more convenient in terms of 
size is the use of an internal ribosomal entry site (IRES), although the 
expression levels from the IRES are not guaranteed.
IRES are mRNA hairpins which have a structure allowing ribosomes to attach 
to the mRNA strand and then translate the second gene (Borman et al.,
1994). The first and second genes are translated from the same strand, the 
transcription of which is driven by the same promoter. Some older systems 
showed cell specific efficacy due to the requirement of co-factors for IRES 
function (Jang et al., 1990). However, newer IRES function across a broader 
cell range (Hellen and Wimmer, 1995).
An important limitation of all viral vectors is the undesirable non-specific 
effects on target cells. This is discussed in the next section.
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1.3.2.6 Vector induction of interferon responsive genes
Interferon refers to a cytokine which is produced as part of the immune 
response to viral infection. There are five kinds of interferons, four type 1 
proteins (a, p, co, x) and one type 2 interferon (y). Interferons act at a cell 
surface receptor and stimulate a host of intracellular pathways (Dubreuil et 
al., 1988). Importantly, a group of genes called the interferon response 
factors (IRF) are upregulated (Fujita et al., 1988). The upregulation of IRFs 
acts to push cells into an anti-viral state, and forms part of the natural anti­
viral response. The anti-viral activity is mediated in part by upregulation of 
protein kinase R (PKR) and RNAse L (Samuel, 2001; Taniguchi et al., 1988). 
These enzymes degrade the viral RNA and inhibit infection. Other cellular 
pathways have also been linked to IRF upregulation, including inhibiting the 
activity of mitochondria (Shan et al., 1990).
Important for viral vectors, de novo production of interferon and activation of 
the interferon receptor both activate the IRFs (Fujita et al., 1989), and cause 
cells to enter an ‘anti-viral state’.
The effect is rapid (within an hour), transient and short lived (-10  hours) 
(Lewis et al., 1989). The level of activation varies greatly between subtypes of 
virus, and many viruses have evolved mechanisms to inhibit production of the 
IRFs (e.g. tat for HIV-1) (Roy et al., 1990).
This anti-viral state is undesirable. The pathways activated cloud results, and 
cells which are in an anti-viral state are difficult to transfect and are refractory 
to further infection. It is not known if cells suffer long term effects from this, 
and whether this effect represents a barrier to the use of these vectors for 
gene therapy (Tan et al., 2005).
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1.3.3 Current gene therapy trials
The number of gene therapy trials has been increasing since the 1980s, and 
until 2001 looked set to continue that trend (Figure 1.3.6). Many different 
vectors have been chosen (Table 1.3.4), each exploiting the strengths of the 
vectors for their particular application. There have been some notable 
successes and setbacks using viral vectors for gene therapy. There are 
currently 261 retroviral and 260 adenoviral trials underway. The two most 
widely publicised gene therapy trials were both successful in their goals but 
suffered unexpected setbacks. The first involved the treatment of ornithine 
transcarbamylase deficiency (OTC) with an adenoviral vector. Unfortunately, 
the result was the death of an 18 year old called Jesse Gelsinger, who 
suffered a fatal anaphylactic reaction after being given 4x1013 IU of 
adenovirus (Marshall, 1999; Raper et al., 2003).
The more recent of the two trials involved the treatment of children with X- 
linked SCID with a retroviral vector. It was carried out first by Alain Fischer of 
the Necker Institute for Sick Children in Paris and then at Great Ormond 
Street Hospital., London (Cavazzana-Calvo et al., 2000; Qasim et al., 2004). 
The results of this showed a significant improvement in the health of the 
treated children, however three years after the trial began two of the children 
in the French cohort developed leukaemia, and genetic analysis showed a 
preferential integration of the vector near the oncogene LM02 (Hacein-Bey- 
Abina et al., 2003).
Gene therapy is currently controlled in the United Kingdom by the Department 
of Health. The DoH is advised on current advances in technology and the 
ethical and practical issues involved in proposals by the Gene Therapy 
Advisory Committee (GTAC). The committee is composed of scientists from 
institutions around the country. The original group (The Clothier Committee) 
recommended in 1992 that gene therapy be “limited to life threatening 
diseases and disorders”. Since then, advice on the advances and ethics of 
gene therapy has kept the UK at the forefront of both technology and safety.
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Lentiviral vectors have great potential for gene therapy. They can infect 
almost any cell in the human body, and offer stable expression. Lentiviral 
vectors are not used more extensively at the moment mostly due to fears over 
the safety of these vectors.
There are applications for these vectors in therapeutic models. Animal models 
for Friedreichs Ataxia (Fleming et al., 2005), Parkinsons disease (Lo et al., 
2004), Wiskott-Aldrich syndrome (Charrier et al., 2005), small cell lung 
carcinoma (Sumimoto et al., 2005), p thalassaemia major (Puthenveetil et al.,
2004), and haemophilia B (Waddington et al., 2004) are examples where 
lentiviral vectors have shown benefit. These diseases are all conditions which 
are debilitating, potentially life threatening and for which current traditional 
therapies are insufficient.
The use of lentiviral vectors is increasing and research to overcome the 
barriers to their use is inevitable. Unfortunately, as we search for evidence of 
their safety, we are uncovering potentially worrying complications of gene 
therapy with these viruses. One recent report indicates that in utero injection 
of an EIAV based vector increases the background rate of tumours in mice 
(Themis et al., 2005).
This evidence adds weight to the arguments that lentiviral vectors for in vivo 
therapy need to be used wisely and as more knowledge about these vectors 
becomes available then their potential will be realised.
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Figure 1.3.6 The progression of gene therapy in recent years
a)
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
1990
1989
N/C
103
Number of Gene Therapy Clinical Trials 
Approved Worldwide 1989-Jan 2005
124
The journal of Gann Mndicine, C  2005 John Wtlny and Sons lid ’.wilay.co.uk/garMned/cfinical
N/C = not communicated (trial details unknown)
b)
Phases of Gene Therapy Clinical Trials
WU£Y
Phase I 63% (n*643)
•  Phase I/ll 21% (n”209)
•  Phase II 13% (n“139)
•  Phase ll/lll 1.1% |n—11)
•  Phase III 1.7% (n= 18)
Tho journal of Gann Mndtcinn, f t  2005 John Wifny and Sons Ud www.wflny.eo.tA/gonm*d/el»mcai
from www.wiley.co.uk/genmed/clinical
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Table 1.3.4 The choice of vector for registered gene therapy trials in 2004
Total 1020
Adeno-associated virus
Adenovirus
Gene gun
Herpes simplex virus
Gene Therapy Clinical Trials
Number
N/C = not communicated (trial details unknown)
Table taken from www.wiley.co.uk/genmed/clinical
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1.4 Kaposi’s Sarcoma-Associated Herpesvirus (KSHV)
1.4.1 Related gamma herpesviruses
1.4.1.1 Epstein-Barr virus
1.4.1.2 Herpesvirus saimiri
1.4.1.3 Murine herpesvirus 68
1.4.2 KSHV associated morbidity
1.4.3 KSHV gene expression profiles
1.4.4 Targets for therapeutic intervention
KSHV is a gammaherpesvirus which causes significant morbidity and 
mortality in immunocompromised individuals. Although it is not common in the 
United Kingdom, probably due to the widespread availability of effective 
antiretroviral drugs, it is problematic in Africa and Asia. KSHV was chosen as 
a therapeutic target for lentiviral delivered shRNA (Chapters 5 and 6) and this 
section covers the biology of KSHV and the reasons why disrupting the latent 
genes was expected to have therapeutic potential.
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1.4.1 Related gamma herpesviruses
The human herpesviruses (HHVs) are a family of enveloped, double stranded 
DNA viruses. Their genomes vary greatly in size with cytomegalovirus (CMV) 
having the largest at about 230 kb. They are broadly classified into alpha-, 
beta- or gamma- herpesviruses originally based upon their target cell during 
latency and characteristic life cycle (Figure 1.4.1). The alpha herpesviruses 
include herpes simplex virus (HSV) -1 and 2 and varicella zoster virus (VZV). 
They have a short replicative life cycle (12-18 hours), a broad cell tropism, 
remain latent in neurons and induce cytopathology in monolayer cell cultures. 
The beta herpesviruses - cytomegalovirus (CMV), herpes lymphotrophic virus 
(HHV-6) and human herpesvirus 7 have a longer replicative cycle (several 
days) and a narrower cell tropism. They remain latent in lymphocytes 
(particularly T) and monocytes. The gammaherpesviruses are Epstein-Barr 
virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV, HHV-8). 
They have a very restricted host cell type. Their latent cell type has not been 
conclusively determined, although for EBV this is believed to be B 
lymphocytes (Ooka, 1985).
The herpesvirus’ life cycle involves receptor-mediated binding, nucleocapsid 
transport to the nucleus, transcription, synthesis and assembly. Transcription 
is complex, with three types of protein being produced, categorised by their 
appearance within the life cycle as immediate-early, early or late proteins. 
(Alberts et al., 1994).
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Figure 1.4.1: Phylogenetic tree of some related herpesviruses
EHV2 **VS KSHV
HSV1
EBV HSV2100
100 100
100 EHV1
PRV
100
VZV
HHV7
0.2 Divergence
HHV6 CMV
(Divergence refers to the percent of base pairs which differ between 
genomes, numbers on graph indicate the number of times, as a percent, 
that this branch appeared in 100 replicates)
EHV2 Equine herpesvirus 2
HVS Herpesvirus saimiri
HSV Herpes simplex virus types 1 and 2
EHV1 Equine herpesvirus 1
VZV Varicella zoster virus
HHV6 Human herpesvirus 6
HHV7 Human herpesvirus 7
CMV Cytomegalovirus
PRV Pseudo rabies virus
(Adapted from Moore et al., 1996)
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1.4.1.1 Epstein-Barr virus
EBV is a gammaherpesvirus which infects B lymphocytes both in vitro and in 
vivo. In vivo infection with EBV has been associated with infectious 
mononucleosis, hairy leucoplakia and several lymphoproliferative neoplastic 
disorders, including Burkitts lymphoma and nasopharyngeal carcinoma (NPC) 
(Gunven et al., 1970), Hodgkin's lymphoma (Gledhill et al., 1991) and post­
transplant lymphoproliferative disease (PTLD) (Nalesnik et al., 1988). In vitro, 
where a small proportion of infected cells establish latent infection, the virus 
induces cellular transformation and these cells contain multiple copies of the 
EBV genome (Adams and Lindahl, 1975). The DNA is circular (episomal), 
and is tethered to the host cell DNA via the protein Epstein Barr virus nuclear 
antigen 1 (EBNA-1) (Kaschka-Dierich et al., 1976), which is essential for the 
stability and proliferation of the episome (Yates et al., 1985). Latently infected 
cells in vitro are termed lymphoblastoid cell lines (LCLs). LCLs only express a 
handful of the 100 genes present in the EBV genome including EBNAs 1-6, 
the latent membrane proteins (LMP) 1-3 and two non-translated RNAs termed 
EBER1 and 2. This is in contrast to latent infection in vivo, where the only 
expressed gene is often EBNA-1. (Rowe et al., 1987). EBNA-1 is unique 
amongst the EBV genes in that it does not invoke an immune response when 
expressed on HLA. This is believed to be due to glycine-alanine repeats in it’s 
molecular structure (Murray et al., 1988). EBV shares some characteristics 
with KSHV in terms of it’s gene expression profile and cellular tropism, but 
although results from EBV studies hold some correlation with KSHV, EBV has 
limited use as a model for KSHV
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1.4.1.2 Herpesvirus Saimiri (HVS)
HVS is a relatively close viral relative of KSHV on the phylogenetic tree 
(Figure 1.4.1). Its natural reservoir is squirrel monkeys (Melendez et al., 
1968). It was isolated following observation of squirrel monkey cells in culture, 
and was just one of several novel herpesviruses isolated from primate tissues 
during this time. HVS remains latent in lymphocytes (like other 
gammaherpesviruses) and in permissive hosts it produces a life long 
infection. It has never been linked to any neoplastic disorder in squirrel 
monkeys, however it has been documented to cause both diverse 
lymphoproliferative disorders in other new world monkeys (Fleckenstein and 
Desrosiers, 1982).
HVS is also capable of infecting human cells, and has been shown to form 
lytic infection in human fibroblasts and latent infection in human T cells. Both 
human CD4+ and CD8+ T cells can be infected, and in both a latent infection 
is formed (Johnson et al., 1980). The virus has a 155 kbp dsDNA genome 
which bears a strong similarity in structure to that of KSHV. Because of the 
evolutionary and genomic similarity, HVS is a better model for KSHV than 
EBV.
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1.4.1.3 Murine Herpesvirus 68 (MHV68)
MHV68 is a rodent virus which was isolated from voles (Blaskovic et al., 
1980). In a laboratory setting, the virus infects B lymphocytes and in 
experimental animals establishes latent infection in the spleen and causes 
acute interstitial pneumonia (Sunil-Chandra et al., 1992). Infection is also 
associated with lymphoproliferative disorders (Sunil-Chandra et al., 1994).
Genomic analysis indicates that MHV68 is closer to KSHV than EBV (Virgin 
et al., 1997), and there is evidence that, like KSHV, it does not infect 
exclusively B cells (Week et al., 1996). The virus can also infect blood vessels 
containing smooth muscle (Week et al., 1997). KSHV is the only other 
gammaherpesvirus which is known to infect vasculature. MHV68 infection is 
considered to be a direct animal model of KSHV and is, therefore, often used 
to draw direct comparisons with KSHV.
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1.4.2 KSHV associated morbidity
1.4.2.1 Kaposi’s Sarcoma
Moriz Kaposi defined an illness in 1872 occurring predominantly in elderly 
Mediterranean or East European men involving tumours affecting mainly the 
skin of the lower limbs. Although more aggressive forms presented, including 
lesions within pharynx, small intestine, stomach, liver and colon; the skin 
lesions were by far the most common symptom. He called this disease 
Kaposi’s Sarcoma (KS).
KS-like lesions have been associated with several clinical groups, and four 
subgroups of KS are recognised:
• Classic KS affects predominantly elderly Mediterranean or East 
European men. Classic KS occurs more often in men than women with 
distinct geographical distributions (Franceschi and Geddes, 1995)
• Endemic KS is a more aggressive form found in sub Saharan Africa 
(D'Oliveira and Torres, 1972). It often affects lymph nodes and occurs 
in children and adults. Again, there is a distinct geographical 
distribution for endemic KS.
• Iatrogenic (or post-transplant) KS occurs in patients who have been 
immunosuppressed, especially post-transplant (Harwood et al., 1979).
• AIDS-related KS has been recognised since patients with HIV were 
noticed to develop KS-like lesions, and also have an increased risk of 
primary effusion lymphoma (PEL) and multicentric Castleman’s 
disease (MCD) (Whitby et al., 1995; Ascoli et al., 2001). KSHV 
associated KS, PEL or MCD is considered AIDS defining in HIV 
positive individuals by the World Health Organisation (WHO).
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(http://www.who.int/hiv/strateaic/en/cdc 1993 hivaids def.pdf).
The aetiological agent responsible for KS was discovered by representational 
difference analysis (RDA) in 1994 and was officially classified as human 
herpesvirus 8 (HHV-8) or Kaposi’s Sarcoma-associated herpesvirus (KSHV) 
(Chang et al., 1994). Rapid research into detection, characterisation and 
epidemiology of KSHV linked it with at least two further conditions MCD 
(Soulier et al., 1995) and PEL (Nador et al., 1996).
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1.4.2.2 Multicentric Castleman’s Disease
Castleman’s disease was characterised in 1956 as the development of solid 
growths within the lymphatic tissue (Castleman et al., 1956). These growths 
are benign and contrast strongly with multicentric Castleman’s disease 
(MCD). MCD is a malignant lymphoproliferative disease with a poor 
prognosis. In HIV positive individuals, almost all cases of MCD are associated 
with KSHV infection. MCD does occur in HIV negative individuals where 
around 50% are associated with KSHV infection. In KSHV positive 
individuals, the severity of the disease correlates closely with KSHV viral load 
(Oksenhendler et al., 2000).
Castleman’s disease has two subtypes- the hyaline vascular and the plasma 
cell variants. The hyaline vascular sub-type accounts for 90% of cases of 
Castleman's disease and patients are generally asymptomatic. Histologically, 
there is extensive capillary proliferation within the affected lymph nodes, and 
a lymphocyte predominant infiltrate surrounding small germinal centres.
The plasma cell variant typically has more generalized (thoracic, mesenteric, 
and retroperitoneal) lymph node involvement and the disorder tends to be 
disseminated. The capillary proliferation seen in the hyaline vascular sub-type 
is absent on examination of enlarged nodes. Dysregulation of interleukin-6 is 
implicated in the pathogenesis of plasma cell Castleman’s disease, and anti- 
IL6 antibody therapy has been suggested (Beck et al., 1994). MCD is a 
severe form of plasma cell variant Castlemans disease. KSHV is present in 
plasmablastic MCD (both hyaline vascular and plasma ell subtypes) and this 
form of the disease is referred to as plasmablastic or KSHV associated MCD.
Treatment of MCD combines steroids, chemotherapeutic agents or even 
rituximab (anti CD-20 antibody) (Corbellino et al., 2001). Prognosis is poor 
with a median survival of 26 months from diagnosis. Patients with multicentric 
disease and an associated neuropathy have an extremely poor prognosis, 
despite treatment with steroids and chemotherapy. Disruption of KSHV within
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the enlarged nodes of MCD may provide a therapeutic option for those who 
develop MCD, even with HAART and an adequate CD4 count and resistance 
to current treatment options.
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1.4.2.3 Primary Effusion Lymphoma
PEL, a form of body cavity-based B-cell lymphoma (BCBL), is a rare non- 
Hodgkin’s-like malignant lymphoproliferation found primarily in body cavities. 
PEL occurs primarily in the severely immunocompromised and is associated 
strongly with HIV infection. Although there is not usually any solid mass focus, 
there have been several documented cases of PEL with an extra-cavity 
tumour (Chadburn et al., 2004; Mate et al., 2004). Effusions can be found in 
pleural, peritoneal, pericardial or even the subarachnoid space (Ely et al., 
1999). Development of PEL has been linked to infection with KSHV (Nador et 
al., 1996).
Cells found with the effusions are large immunoblast-like cells which do not 
express common B lymphocyte specific markers. This distinguishes these 
cells form those of MCD, which usually express CD20. These cells are 
thought to be derived from germinal or post-germinal B cells because of their 
Ig gene rearrangement. PEL cells contain 100-150 copies of the KSHV 
genome, which is significant because in KS lesions the copy number of KSHV 
is much smaller, less than 10 copies per cell (Ansari et al., 1996; Cesarman 
et al., 1995). The KSHV gene expression profile within PEL is distinct from 
other KSHV-associated tumours (Parravicini et al., 2000).
These cells are also frequently associated with EBV infection, however 
coinfection is not essential for development of PEL, and the role of EBV is not 
known (Fassone et al., 2000). There are not usually any rearrangements or 
alterations in c-myc, bcl-2, ras or p53 in PEL cells.
The prognosis of PEL is also very poor- with a median survival of less than 6 
months. There are currently no effective protocols for the treatment of PEL, 
although a variety of antiviral and chemotherapeutic regimes have been 
tested. Patients who are not on HAART who develop PEL may benefit from 
anti-retroviral treatment (Hocqueloux et al., 2001). Alpha interferon (Monini et 
al., 1999) and rituximab (Perez and Rudoy, 2001) have also been tried as
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therapeutics. Novel approaches that inhibit latent gene expression (Curreli et 
al., 2005; Godfrey et al., 2004) may offer new therapeutics.
Several cell lines for PEL exist, although many are coinfected with EBV (see 
Table 1.4.1), compared to very few KS cell lines and no MCD lines. 
Unfortunately, all currently available cell lines derived from KS lesions do not 
contain detectable copies of the genome (Flamand et al., 1996). There are 
also mouse models of PEL (Staudt et al., 2004; Boshoff et al., 1998), which 
means that PEL is more easily studied both in vitro and in vivo.
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Table 1.4.1 The KSHV and EBV status of commonly used PEL cell lines
Cell line Origin Host HIV-1 
serostatus
HHV8 DNA EBV DNA
BC-1 AIDS-PEL Positive Positive Positive
BC-2 AIDS-PEL Positive Positive Positive
BC-3 PEL Negative Positive Negative
BCBL-1 AIDS-PEL Positive Positive Negative
JSC-1 AIDS-PEL Positive Positive Positive
BCP-1 AIDS-PEL Positive Positive Negative
CRO/AP3 AIDS-PEL Positive Positive Negative
CRO/AP5 AIDS-PEL Positive Positive Positive
CRO/AP6 AIDS-PEL Positive Positive Negative
HBL-6 AIDS-BL Positive Positive Positive
Table 1.4.1: Table showing the origin of commonly used primary effusion 
lymphoma (PEL) cell lines. These cells are believed to have a B cell lineage, 
and are derived from PEL samples in HIV positive (AIDS-PEL) or negative 
(PEL) individuals, or from a Burkitt’s Lymphoma biopsy shown to be HHV-8 
positive (HBL-6, marked BL). The EBV status is significant as some viral 
genes between EBV and HHV-8 have conserved function, and so is shown in 
the final column.
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1.4.3 KSHV gene expression profiles
The KSHV genome is about 140 kbp long and contains around 85 open 
reading frames (Fig 1.4.2). Around 15 of these are currently thought to be 
unique to KSHV (designed K1-K15), and many of the others are pirated 
cellular genes, or cellular homologues like vlL-6 (viral interleukin 6 
homologue), vIRF (viral interferon responsive factor) and vFUP  (viral FLICE 
inhibitory protein) (Moore et al., 1996; Russo et al., 1996). The remainder are 
common to gammaherpesviruses, and often represent critical components of 
the life cycle or are involved in establishing latent infection (such as LANA, 
the latency associated nuclear antigen, which is functionally related to EBNA- 
1). The viral genes are divided in terms of their expression. They can be 
divided into latent and lytic, depending on which phase of the life cycle they 
are expressed in, or immediate early, early, late-early, and late depending on 
when they are expressed after infection (Jenner et al., 2001). The latent 
genes are suspected to be involved in tumourigenesis.
The lytic phase is characterised by the release of new viral progeny and the 
latent phase by limited gene expression. KSHV encodes a number of cellular 
homologues, and it is thought that these genes determine the pathogenicity of 
KSHV (Neipel et al., 1997).
Initial infection involves lytic replication, followed by establishment of latency 
in some cells. During latency, only a handful of genes are expressed, and 
only three are detectable in all latent infections (Sarid et al., 1999). 
Reactivation from latency into lytic replication can be stimulated with sodium 
butyrate or 12-o-tetradecoylphorbol 133-acetate (TPA) (Yu et al., 1999) or 
induction of the lytic cycle promoter ORF-50 (Rta) (Lukac et al., 1998).
The association of the latent life cycle with oncogenesis stems from the 
transcription pattern in KSHV-related tumours and the fact that acute infection 
does not induce tumours. The interactions and cellular functions of the latent 
genes are also evidence for their role in oncogenesis. Although no single
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KSHV gene is sufficient for oncogenesis - like HTLV-1 tax, the biological roles 
of the latent genes together have these abilities (Table 1.4.2).
LANA has many roles in the pathogenesis of KSHV and has been functionally 
linked to EBNA-1 in EBV. It binds to p53, downregulating its activity and 
preventing it from driving cells into apoptosis (Friborg, Jr. et al., 1999). LANA 
binds to and inactivates pRb (Radkov et al., 2000). LANA also associates 
with a whole range of other cellular factors involved in cell cycle dysregulation 
(Komatsu et al., 2001). After its interaction with p53 and pRb, perhaps it’s 
most important role is its ability to tether the viral episome to cellular DNA, 
allowing latent infection (Ballestas et al., 1999). It also seems to allow the 
latent life cycle by inhibiting lytic replication, and exists antagonistically with 
Rta (the major promoter in the lytic life cycle) (Lan et al., 2004).
The viral cyclin (vcyclin) is a cellular cyclin D homologue. Its sequence shows 
around 50% sequence similarity with cyclin D2 (Li et al., 1997) and it can bind 
to and activate Cdk4 and Cdk6 and direct their kinase activity towards Rb 
(Chang et al., 1996). There is evidence that vcyclin binds preferentially with 
Cdk6 (Godden-Kent et al., 1997). The vcyclin is also much less susceptible to 
inactivation by cellular factors which normally govern the cell cycle, including 
pRb and p21 (Direkze and Laman, 2004; Verschuren et al., 2004). These 
factors give the viral cyclin a key role in oncogenesis.
vlL-6, vBcl-2 and vFLIP all act on apoptosis and cellular transcription factors 
such as I KappaB kinase (IKK) leading to NF-kB activation (Field et al., 2003; 
Weiss et al., 1998). These abilities together allow KSHV to cause malignant 
cell proliferation.
Recent evidence that disruption of the latent genes leads to senescence, 
apoptosis or interference in cell pathway interaction in latently infected PEL 
cells (Guasparri et al., 2004; An et al., 2004) offer the potential to treat KSHV- 
driven malignancies. Methods to inhibit gene expression which are feasible in 
a clinical setting are now needed.
- 8 0 -
Table 1.4.2 Latent genes and their main biological roles
Gene name Gene location Gene
classification
Life cycle Major function
A N A -1 ORF 73 1 Latent Binds p53 and pRB
vcyclin ORF 72 1 Latent Cell cycle progression
vFUP ORF 71 1 Latent Inhibition of Fas-induced apoptosis. 
Activation of NFkB
Kaposin A K-121 TO.7 2 Latent Unknown
vlRF1 K 9 2 2 Latent in KS Inhibits interferon-induced gene expression,
A N A -2 /
vlRF3
ORF 10.5 3 Latent in 
PEL, MCD
MYC activation interacts with p53 
Interacts with p53
LANA, latency associated nuclear antigen; v-FLIP, viral Fas-associated death domain-like interleukin 1 (3 converting 
enzyme; vIRF, viral interferon regulatory factor; vGPCR, viral G-protein-coupled receptor; vlL-6, viral interleukin 6; vMIP, 
viral macrophage inflammatory protein; ORF, open reading frame; K, genes unique to KSHV/HHV-8; KS, Kaposi’s 
sarcoma; PEL, primary effusion lymphoma; MCD, multicentric Castleman’s disease. Gene classification as determined by 
Sarid et al, 1998. Data for table taken from Cathomas, 2003.
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Figure 1.4.2 Structure of the KSHV Episome. (Sharp and Boshoff, 2000)
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Figure 1.4.2 Numbers outside of episome represent nucleotide base pairs in 
kilobases (kb). Numbers within the episome indicate KSHV-encoded ORFs. 
Novel ORFs not present in other herpesviruses were designated K1 to K15. 
Blue arrows indicate ORFs encoded in a 5’ to 3’ positive polarity. Red arrows 
indicate ORFs encoded in a 3’ to 5’ negative polarity. Green arrows indicate 
ORFs encoding proteins expressed during latent infection. Annotations 
outside the episome indicate putative function of each ORF. ORFs 71 to 73 
are transcribed from the same promoter on a polycistronic transcript and the 
splice site for the intron indicated. (A) Results of an immunofluorescence 
assay (IFA) on the PEL cell line BCP-1, using a specific anti-LANA 
monoclonal antibody. The distinctive nuclear stippling pattern can be seen. 
K15 gene structure shows the highly spliced message with the exons 1-8  
(E1-E8) indicated. (B) IFA results for the PEL cell line BCP-1, using a specific 
anti-K15 human patient sera. The pattern of fluorescence for this K15-specific 
serum is patches throughout the cytoplasm, some associated with the plasma 
membrane. TR, terminal repeat DNA domains (pink stripes); CBP, 
complement-binding protein; ssDBP, single-stranded DNA binding protein; 
gB, glycoprotein B; DNA Pol, DNA polymerase; vlL-6, viral interleukin-6 
homolog; DHFR, dihydrofolate reductase; vMIP, macrophage inflammatory 
protein; nut-1, nuclear tRNA-like transcript; vBcl-2, B-cell 
leukemia/lymphoma-2; TK, thymidine kinase; TS, thymidylate synthase; gH, 
glycoprotein H; gM, glycoprotein M; UDG, uracil DNA glucosidase; gL, 
glycoprotein L; vFLIP, viral FLIP; vcyc, viral cyclin; vGPCR, viral G-protein 
coupled receptor; (P), predominant form of K15; aa, amino acids; IRES, 
internal ribosomal entry site.
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1.4.4 Targets for therapeutic intervention
There are currently no good therapies against KSHV. Although the antivirals 
ganciclovir, cidofovir and foscarnet effectively inhibit the lytic life cycle (Kedes 
and Ganem, 1997), the transforming properties of KSHV involve latent gene 
expression and these antiviral drugs do not have any effect. Treatment for KS 
often involves surgical removal, radiotherapy or chemotherapy. Topical 
treatment with 10% docosanol cream is effective in some KS lesions, and 
treatment of underlying immunosuppression either with HAART or regulation 
of immunosuppressant drugs is important.
The latent genes LANA, vFUP  and vcyclin are obvious targets when 
considering the oncogenic potential of KSHV (Staudt and Dittmer, 2003). 
They are the only three genes expressed in all latently infected cells. 
Disrupting LANA should theoretically cause expulsion of the virus. Inhibition 
of LANA may be an effective therapeutic, however LANA has other roles, and 
reducing LANA expression may reactivate the lytic life cycle. In KS, where the 
copy number of the virus is small this may be desirable, however in PEL and 
MCD this could cause major complications.
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2.1 Standard Methods
2.1.1 Plasmid preparation
Plasmid preparation was performed broadly according to the Qiagen 
guidelines for use of miniprep, maxiprep or endotoxin free maxiprep. 
Endotoxin free maxipreps were performed to produce viral packaging 
plasmids which require high transfection efficiency.
Minipreps were performed for routine screening for inserts or to test plasmids 
for production of virus. Colonies grown on an LBantib,ot,c plate (usually 
ampicillin or kanamycin) were taken and inoculated into 5 mis of |_Bamp or 
LBkan for overnight culture. The number of colonies chosen for individual 
minicultures varied according to the ligation efficiency. Between 4 and 8 
colonies per reaction was usually sufficient.
The minicultures were grown overnight (16 hours) at 37°c shaken at 225 rpm.
1.5 mis of this culture was taken and placed into a 1.5 ml eppendorf, where it 
was spun at 6,000 rpm in a desktop centrifuge for one minute. The LB was 
removed, and the pellet resuspended, lysed and neutralized by alkaline lysis 
method in accordance with the guidelines in the kit. The cloudy liquid was 
then centrifuged at 13,000 rpm in a desktop centrifuge. This was decanted 
into the miniprep columns, spun at 13,000 rpm for one minute. The wash 
steps (endonuclease removal, PB; column wash, PE; column clean) were 
performed according to the kit guidelines.
Resuspension was in 50 pi of water and plasmids were then kept on ice 
during use or at -20°c for long term storage. DNA concentration and purity 
was assessed using a UV spectrophotometer measuring the A26o and 
A26o/A28o ratio.
Maxicultures for maxiprep were prepared by inoculating 500mls (for high copy 
plasmids) or 2000 mis (for low copy plasmids) of LBamp or LBkan with 1 ml of
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miniculture and growing overnight at 37°c shaken at 225 rpm. This broth was 
centrifuged at 4,000 rpm for 10 minutes using a JA10.5 rotor and 2x250 ml or 
6x350 ml centrifuge bottles. These mixtures were resuspended, lysed and 
neutralized according to the Qiagen kit guidelines. After centrifugation for 
20,000g for 30 minutes using a JA25.5 rotor, maxiprep/ endotoxin free 
maxiprep columns were equilibrated (15mls buffer QBT), and the clear 
supernatant added to the column. Washes were performed according to the 
Qiagen kit guidelines.
Resuspension was in 0.5 ml water, and plasmid concentration and purity was 
assessed using a UV spectrophotometer measuring the A260 and A260/A280 
ratio.
Where necessary, phenol/chloroform extraction precipitation was used to 
increase the purity of plasmid DNA. A volume equal to that of the sample of 
phenol/ chloroform/ iso-amyl alcohol in a ratio of 25:24:1 followed by vigorous 
mixing for 30 seconds and then phase separation by centrifugation at 
13,000g for 5 minutes. The aqueous phase was extracted. This procedure 
was repeated using chloroform/ iso-amyl alcohol at a ratio of 24:1. Ethanol 
precipitation, where necessary, was performed by adding 3.5 volumes of 
100% ethanol to the DNA mixture and 0.1 volumes of sodium acetate. This 
resulting mixture was incubated at -20°c for 1 hour and the precipitated DNA 
pelleted using a desktop centrifuge at 13,000g for 15 minutes. The 
supernatant was carefully discarded and the pellet resuspended in sterile 
nuclease free water or a suitable buffer.
2.1.2 Restriction digestion
Restriction digests were used to clone fragments of DNA, determine correct 
insertion, orientation of inserts and confirm plasmid integrity.
Restriction digestion was performed at 37°c unless otherwise indicated in the 
Promega notes (25°c for Sma I and 65°c for BstB I) in a total volume of 20 pi.
Incubation was normally for 1 hour, but overnight incubations were used for 
some polymerase chain reaction (PCR) products containing short overhangs 
(as advised by the New England Biolabs digestion handbook). The buffer 
used was determined by consulting the Promega enzyme buffer compatibility 
chart, when performing multiple digests the most appropriate buffer was 
chosen. 0.5 pi (generally 5-6 units of enzyme) was incubated with 1-2 pg 
plasmid DNA for each reaction, and a non-digested plasmid and positive 
control plasmid containing the target restriction site were always used. After 
restriction, 4 pi of 6x DNA loading buffer (see below) was added and the 
mixture stored at 4°c or -20°c until agarose gel analysis/ extraction.
2.1.3 Agarose gel analysis
1% weight/ volume (w/v) agarose in TAE (tris-acetate 0.4M, ethylene di­
amino tetraacetic acid (EDTA) 0.01 M) gels were standardly used for analysis 
throughout this thesis. Smaller fragments (such as PCR products <100bp) 
used higher w/v gels, usually 2% or 3.5%. Agarose gels were prepared by 
heating the agarose (AMRESCO) / 0.5x TAE mixture until the agarose fully 
dissolved. Between 50 and 100mls of the solution was poured into a gel cast, 
an appropriate comb added and left to cool for 5-10 minutes. Before the gel 
became solid, 2-4 pi of 10 mg/ml ethidium bromide (Sigma) was added and 
mixed gently into the liquid. Gels were placed in a tank containing 0.5x TAE. 
Samples were loaded with a Promega 1kb ladder in lane 1 and 
electrophoresed at 5-10 V/cm for 30 minutes-2 hours depending on the size 
of fragments and resolution required. If fragments were to be used for DNA 
ligation, gel extraction was performed using a Qiagen gel extraction kit in 
accordance with the manufacturers guidelines. Up to 100 mg of gel was 
placed in an eppendorf and 300 pi buffer QG added. Mixture was incubated 
at 65°C for 10 minutes and purified using supplied column, centrifugation at 
13,000g and washing using buffer QG and PE. Elution was in 50 pi (or 30 pi if 
quantity of DNA was low or high concentration required) sterile water.
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2.1.4 Ligation
Ligation reactions were performed using New England Biolabs T4 DNA ligase 
and NEB T4 DNA ligase buffer in a total volume of 10 pi. 100-400ng of 
backbone DNA was mixed in a 1:3 vector:insert ratio with 20 units (1 pi) of 
enzyme per ligation reaction. The mixture was incubated for 30 minutes at 
room temperature (sticky ends), 1 hour at room temperature (blunt ends) or 
overnight at 4°c. 1 pi of reaction mixture was used for transformation.
2.1.5 Competent cell preparation
Electrically competent cells were prepared by inoculating a 50 pi aliquot of 
appropriate cells (HB101 or DH5a) into 250 mis of LB under sterile 
conditions. After 6-8 hours at 37°c shaken at 225 rpm, when the cells reached 
an Aeoo of 0.5-0.8 using a UV spectrophotometer, the bacteria are in 
logarithmic growth phase and are ready for harvest.
The bacteria, 375 mis of distilled autoclaved water and 5.5 mis of 10% 
glycerol were placed at 4°c. After 1 hr, the medium was centrifuged at 4,000g 
at 4°c for 15 minutes using a JA10.5 rotor to pellet the bacteria. The pellet 
was resuspended gently in 250mls of cold distilled water, and then 
centrifuged at 4,000g at 4°c for 15 minutes. The pellet was resuspended in 
125 mis distilled, autoclaved water. This mixture was centrifuged at 4,000g at 
4°c for 15 minutes and resuspended in 5 mis glycerol. The mixture was 
transferred to a 15 ml falcon. This mixture was centrifuged at 4,000g at 4°c for 
10 minutes and resuspended in 500 pi cold glycerol. 50 pi aliquots were snap 
frozen in a dry ice-ethanol bath and kept at -80°c for up to 6 months. 
Chemically competent cells were purchased as Top 10’s from Invitrogen BV, 
Groningen.
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2.1.6 Bacterial transformation
Chemical transformation (heat shock) was performed by placing the 
competent cells (individual aliquots) on ice for 30 minutes, and then adding 1 
pi of the ligation mixture or 100 ng of intact plasmid. This mixture was heated 
to 42°c in a water bath for 35 seconds, and then 1 ml of LB (no antibiotic) 
added and incubated at 37°c for 1 hour. 100 pi was then plated onto an LB 
plate containing suitable antibiotic (usually ampicillin or kanamycin).
Electrical transformation was performed when increased efficiency was 
required, such as for blunt end or low yield ligations. Aliquots of electrically 
competent bacteria were placed at 4°c for 15 minutes prior to electroporation. 
After 15 minutes, the cells (50 pi) were placed in a chilled 1 mm cuvette. 1 pi 
of the ligation reaction was added to the cells and mixed by gentle agitation. 
Electroporation was performed in a BioRad 100 electroporator, using 200 
ohms, 2.5 pF and 1.25 kV. Time constants for successful electroporation 
were between 4 and 5 ms.
2.1.7 Blunting sticky DNA fragments
Two methods were used to blunt sticky DNA fragments when compatible 
sticky ends could not be found in the vector and insert. Fill-in reactions, to 
preserve the restriction sites were performed using T4 DNA polymerase 
Large (Klenow) fragment, and exonuclease reactions to destroy the restriction 
site and generate flush DNA ends were performed using Mung Bean 
Nuclease. In both cases, DNA was extracted (see section 2.1.1) and eluted in 
30 pi water.
For Klenow treatment, the DNA was mixed with 5 pi 10x DNA polymerase 
buffer (Promega), a final concentration of 1 mM dNTPs, 1 unit/ pg DNA of 
Klenow (Promega) and water to a total volume of 50 pi. This was incubated at 
37°c for 30 minutes and then 65°c for 30 minutes.
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Mung Bean nuclease treatment was performed in a total volume of 100 pi, 
using 10 pi of 10x Mung Bean buffer and 50-70 units of Mung Bean nuclease. 
Water was used to make up the final volume. This was incubated at 37°c for 2 
minutes, or room temperature for 15 minutes.
Enzyme was removed by agarose gel analysis and extraction or Qiagen PCR 
clean-up kit (used according to the manufacturers guidelines). After blunting, 
alkaline phosphatase treatment is required to prevent backbone self-ligation. 
5 units of Shrimp Alkaline phosphatase (Promega) was added to the DNA 
and 5 pi of SAP 10x buffer. Final volume was made up to 50 pi with water. 
This mixture was incubated at 37 °c for 15 minutes and enzyme removed by 
phenol/ chloroform extraction.
2.1.8 PCR diagnosis/ cloning
Polymerase chain reaction (PCR) was carried out either to amplify fragments 
for cloning or to detect presence of DNA inserts. PCR was performed on a 
Primus 96-plus thermocycler (MWG Biotech). Reaction conditions were 
optimized based upon the Tm of the primers, the GC content and length of 
the amplified fragment. Typically, reaction volume was 50 pi. 5 pi of complete 
PCR buffer (Roche), 1 pi Taq DNA polymerase (Roche) or Expand high 
fidelity polymerase for cloning (Roche), 1 pi 10 mM dNTP’s and 100 ng of 
each primer were added to the target DNA and the volume made up by UV 
Stratalinker treated water. 10 ng (plasmid) -  1 pg (whole cellular) DNA was 
used depending on the quality of the sample. Typical amplification conditions 
were 35-40 cycles of 95°c for 1 minute, 55°c for 1 min, 72°c for 2 minutes, 
followed by a further 1 minute at 72°c. Controls included a no polymerase 
reaction, no template reaction and if appropriate, internal controls for the p- 
actin gene. If no product was seen, the annealing step (55°c) temperature 
was lowered, if multiple nonspecific products were seen, this temperature was 
increased. If the product was large (>1 kb), the length of the extension step
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(72°c) was increased to 4 or 6 minutes. After cycling, the product was mixed 
with 4x DNA loading buffer and placed on agarose gel for analysis.
2.1.9 Site directed mutagenesis
Site directed mutagenesis was performed using a Stratagene QuickChange 
Site Directed Mutagenesis kit in accordance with the manufacturers 
guidelines.
PCR primers overlapping the region containing the new mutation were 
designed as indicated by the manufacturer. 1, 10 and 100 ng of original 
plasmid were incubated in parallel with 1 unit of high fidelity Taq polymerase, 
the primers and 1 pi of 10 mM dNTPs. 40 rounds of PCR amplification were 
used with an annealing temperature of 55°c and an extension time of 2-5 
minutes (20 seconds per kilobase). After PCR, the original plasmid was 
enzyme digested and resulting mixture transformed into electrocompetent 
bacteria. 10-1000 colonies were seen after overnight incubation at 37°c.
2.1.10 Nucleic acid extraction
Nucleic acid extraction was required to analyse DNA (or RNA) from cells in 
tissue culture or for samples from mice in in vivo experiments.
DNA extraction was carried out using a Qiagen Blood and Cell Culture Mini kit 
in accordance with the manufacturer’s guidelines. Tissue samples were 
suspended in tissue lysis buffer: 50 mM KCI, 10 mM Tris pH 8.3, 2.5 mM 
MgCb, 0.01% gelatin, 1% tween and 200 pg/ml proteinase K (Sigma). 
Samples were incubated at 55°c for 24 hours and then at 94°c for 10 minutes 
to inactivate the proteinase K. Phenol chloroform precipitation was performed.
Cells from tissue culture or ascitic samples were centrifuged at 1200g for 5 
minutes and resuspended in DNA lysis buffer: 100 mM NaCI, 10 mM Tris-
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HCL pH 8.0 and 10 mM EDTA. Solution was mixed thoroughly and incubated 
at room temperature for 10 minutes. DNAse free RNAse A was added to a 
final concentration of 100pg/ml. This mixture was incubated at room 
temperature for 2 hours. Proteinase K was added and the mixture incubated 
for 14-18 hours at 56°C. Phenol chloroform extraction was then performed 
(see section 2.1.1).
RNA for RT-PCR (reverse transcriptase polymerase chain reaction) and qRT- 
PCR (quantitative RT-PCR) was extracted from tissue samples and cells from 
tissue culture. Whenever RNA extraction was performed, all work surfaces, 
gloves and containers were treated with RNAseZAP (Ambion) to remove 
RNAse from the environment. RNA purification was performed using the 
RNEasy kit (Qiagen) in accordance with the manufacturers guidelines. 
Briefly, up to 5 x 106 cells were used for each extraction. Cells were 
centrifuged at 3000 rpm in a desktop centrifuge and then resuspended in 350 
pi of buffer RLT and vortexed until no clumps were visible. This lysate was 
placed in a QiaShredder column to homogenize and centrifuged at 13000 
rpm for 2minutes. 350pl of 70% ethanol was added to the flowthrough and 
this mixture passed over an RNEasy column. The column was washed with 
both buffer RW1 and buffer RPE and the RNA eluted in 30 pi of sterile RNAse 
free water.
2.1.11 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
RT-PCR was performed on RNA extracted from cells as a two stage process 
consisting of cDNA synthesis (RT step) and PCR. RNA was diluted to a final 
concentration of 0.1 mg/ml in sterile, nuclease free water. 10 pi of this 
solution was mixed with 1 pi RNAse inhibitor (Promega) by gentle tapping. A 
positive control (RNA known to contain gene of interest) and a negative 
control (nuclease free water) were added at this step. An internal control 
(primers to p-actin) was used if results were poor. 2 tubes for each sample, 
each containing 2 pi of this solution was mixed with 0.5mM dNTP and 10mM
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DTT and diluted to a final volume of 19pl with sterile nuclease free water were 
prepared. 1pl of Superscript RT II (Invitrogen) diluted to 40 U/pl was added 
(final concentration 2 U/pl) to one tube and 1 pi of nuclease free water to the 
other for each sample (no RT control for each sample). These mixtures were 
incubated on a Primus 96-plus thermocycler (MWG Biotech) at 42°C for 5 
minutes, 50°C for 50 minutes and then 70°C for 15 minutes. Mixtures were 
kept on ice if for immediate use and at -20°C if for use later.
PCR was performed using primers for the gene of interest and any further 
appropriate controls (see section 2.1.8)
2.1.12 TaqMan quantitative PCR / quantitative RT-PCR
Quantitative PCR and RT-PCR was performed using an ABI TaqMan Prism 
7000 machine. Primers used for detection of lentiviral packaging cDNA and 
latent gene mRNA and DNA are listed in section 2.6.4. All reactions were 
performed using SYBR green at the concentrations indicated unless a probe 
is specified (for LANA). These conditions were shown through optimisation 
according to the manufacturers guidelines to be sensitive, specific and with 
no primer-dimer formation. Standard TaqMan cycling conditions were used 
throughout. Negative controls (no template and water only) and positive 
controls (known positive samples) were included in every reaction plate.
2.1.13 Western blotting (SDS-PAGE)
Protein was prepared by lysing 104 to 106 cells in Radio immunoprecipitation 
assay (RIPA) buffer (20 mM Tris pH 7.5, 50 mM NaCI, 1% SDS) and samples 
were quantified and equalized using a BCA assay. A BCA kit was purchased 
from Pierce and used to determine protein concentration. Standard protein 
concentrations of 1, 2.5, 5, 10 and 20 mg/ml protein were prepared using 
BSA (Promega) diluting the protein in RIPA buffer. 1 pi (representing total of 
1, 2.5, 5, 10 or 20 pg protein) was used for each standard. Mixtures A and B 
were mixed at a 1:50 ratio and 1 ml of this mixture incubated with 1 pi of
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standard or 5 pi of protein sample and incubated at 37°c for 30 minutes. The 
A540 of the resulting mixture was used to create a standard line and thus 
determine the absolute protein concentration in the samples. Equalised 
samples were then mixed with 4X SDS loading buffer (see below), boiled for 
2  minutes and centrifuged at 13,000 rpm in a desktop centrifuge for 1 minute.
Gels were prepared as 6 % (LANA), 12% (eGFP) or 15% (vcyclin, vFLIP, p- 
actin) w/v polyacrylamide solution with 0.1% w/v SDS (sodium dodecyl 
sulphate) and 0.1% w/v APS (ammonium persulphate) buffered in pH 8 .8  
Tris HCI. Water was used to dilute to final volume and NNN’N’- 
Tetramethylethylenediamine (TEMED) was added at 0.05% final volume. 
Gels were poured with a 5% w/v acrylamide gel in Tris-HCI pH 6 .8  buffer 
stacking layer for protein loading. 10 pi of Rainbow colour protein molecular 
weight ladder (BioRad) was loaded in lane 1 and 10 pg sample in lanes 2 
onwards. Gels were electrophoresed at 100 volts until the marker/dye layer 
reached the bottom of the gel.
Protein was transferred to a HyBond-P (Amersham) membrane using semi­
dry transfer for 30 minutes (small proteins) or 90 minutes (LANA) per 
membrane in standard transfer buffer (see below). After transfer, membrane 
was blocked with milk (Marvel) resuspended in PBS containing 0.05% v/v 
Tween 20 (PBS-Tween) for 1-2 hours. Membrane was incubated with primary 
antibody overnight at 4°c at concentrations recommended by the 
manufacturer. Membranes were washed 4x for 15 minutes with PBS-Tween 
and then incubated for 30-60 minutes with secondary antibody used in 
accordance with the manufacturers guidelines. After incubation, a further 4x 
15 minutes washes were performed and mixture incubated with ECL+ 
(Amersham) according to the manufacturers guidelines. 10 second, 1 minute 
and if necessary 1 0  minute exposures were taken and developed.
Where appropriate to ensure equal loading, the membrane was reprobed with 
p-actin antibody overnight and washed and developed as above.
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2.2 Tissue Culture
2.2.1 Adherent cell line culture
Adherent cell lines were cultured in Dulbecco’s Modified Eagles Medium 
(DMEM) supplemented with 10% fetal calf serum (FCS). Antibiotics were not 
routinely used for tissue culture unless cryptic contamination was suspected. 
Eradication of suspected contamination was only carried out if the cell line 
was irreplaceable, and involved a two week culture period in penicillin and 
streptomycin or ciprofloxacin. Cells were ensured mycoplasma negative by 
culture testing every 3 months carried out by Mycoplasma Experience. When 
cells became > 70% confluent, or every three days (whichever was the 
sooner) cultures were passaged (‘split’). Medium from plates was carefully 
poured into suitable disinfectant. Each 10 cm plate was washed 2x with 10 
mis of pre-warmed PBS (Phosphate Buffered Saline) and then incubated for 
2-5 minutes at 37°c with 1 ml of Trypsin-EDTA diluted in 4 mis of pre-warmed 
PBS. After this time, cultures were vigorously agitated. Cells would normally 
separate from the plate easily after this time. If cells did not separate from the 
culture dish, a longer incubation or using undiluted Trypsin-EDTA was 
sometimes necessary. The supernatant containing the cells was then 
centrifuged at 1200 rpm for 5 minutes in a 15 ml falcon. The resulting pellet 
was resuspended in 10 mis pre-warmed DMEM + 10% FCS. The cell density 
of this mixture was established using a haematocytometer and cells reseeded 
into new plates at an appropriate density. Trypan blue was used to determine 
live cell number once a week. This involved mixing an equal volume of trypan 
blue stain and cells. Cells were then counted using a haematocytometer, but 
strongly stained cells were considered to be dead or dying.
Frozen cell stocks were produced every month. 4 plates of cells were 
trypsinised as above, collected, centrifuged at 1200g for 5 minutes and the 
pellet resuspended in 1ml 90% FCS and 10% di-methyl sulphoxide (DMSO) 
and placed in cryotubes. These tubes were placed at -80°C overnight in
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polystyrene containers to slow the freezing process. The morning after, cells 
were moved to storage in liquid nitrogen.
When counting cells for seeding experiments, a haematocytometer was used. 
Cells were diluted with an equal volume of trypan blue. Cells which were 
healthy excluded the dye from their membranes. Unhealthy or dead cells 
appeared blue under microscopy and were not counted. If large number of 
dead cells were seen in a culture, it was discarded.
Tissue culture microscopy was performed using a Nikon Eclipse E600 
inverted microscope with Nikon fluorescent lamp. The aperture was 10, 20, 
60 or 80x with total final magnification 100 -  800x. Unless otherwise stated in 
figures, magnification was 100x. Images were taken using a Zeiss Axiocam 
Camera and software.
2.2.2 Suspension cell line culture
All PEL cell lines used (BC-3, JSC-1, HBL-6, BCP-1) and the KSHV negative 
B cell line Ramos were suspension cells and were cultured as follows. This 
method also applies to the T cell lines H9 SF2 and H9 MN9. Cells were 
cultured in Royal Park Memorial Institute medium (RPMI 1640) supplemented 
with 10% (most lines) or 20% (BCP-1) FCS. See Table 1.4.1 for details of 
PEL cell lines used. Antibiotics were not routinely used for culture and cells 
were ensured mycoplasma negative by testing every 3 months by 
Mycoplasma Experience. Cells were split every three days by dilution into 
fresh medium to a cell density of 1x106 cells/ml with 10mls of media in a T-25 
flask and 25 mis of medium in a T-75 flask. BCP-1 cells were seeded at 2x106 
cells/ml. 30 mis of cells were centrifuged at 1200g for 5 minutes and the pellet 
resuspended in 1 ml 90% FCS and 10% DMSO and placed in cryotubes. 
These tubes were placed at -80°C overnight in polystyrene containers to slow 
the freezing process. The morning after, cells were moved to storage in liquid 
nitrogen.
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2.2.3 Puromycin/ neomycin selection
For cells to be grown in puromycin or neomycin selection, fresh bottles of 
appropriate medium were supplemented with appropriate growth factors and 
serum and puromycin (Clontech) added to a final concentration of 3 pg/ml for 
selection and 2 pg/ml for continuing culture made from a stock solution of 2 
mg/ml which was stored at -20°C. Neomycin (as G418 from Gibco) was used 
at a final concentration of 1 mg/ml for selection and 500 pg/ml for 
maintenance of resistant clones.
2.2.4 Ficoll gradient
Ficoll solution (Amersham) was used to separate live from dead cells in 
suspension cell culture. This is possible because the density of the Ficoll 
solution is carefully designed to allow dense dead cells to pellet at the bottom 
of the tube and less dense live cells to remain as a layer between the medium 
and the Ficoll solution. A Ficoll gradient separation was performed every two 
weeks prior to seeding suspension cells in culture, and for PEL cells was 
performed as cells were seeded the day before any experiment. Ficoll 
gradient separation was not routinely used on PEL cells for in vivo 
experiments as this would involve these cells remaining outside of a tissue 
culture situation for extended periods of time.
A Ficoll gradient was established by placing 15mls Ficoll solution (Amersham) 
into a 50ml tissue culture tube. 35mls of medium containing cells was added 
slowly to prevent mixing of the two liquids. A clear interface was visible 
between the two liquids. This container was carefully centrifuged at 1200g for 
15 minutes with the centrifuge brake disengaged. After centrifugation, the 
white layer of cells between the medium (above) and the Ficoll solution 
(below) was carefully removed and resuspended in fresh medium for cell 
counting. The used Ficoll, dead cells and old medium were discarded.
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2.2.5 Primary endothelial cell culture
Human dermal microvascular endothelial cells (DMVEC) were purchased in 
dry ice (Clonetics) at passage 2. If cells were not to be used immediately, 
they were placed in liquid nitrogen for storage. Endothelial cell growth 
medium 2 (microvascular) (EGM2-MV, Clonetics) was prepared in 
accordance with the manufacturers guidelines. This medium contained hEGF 
(human epidermal growth factor, final concentration 5 ng/ml), hydrocortisone 
(final concentration 200 ng/ml), gentamicin (final concentration 50 pg/ml), 
amphotericin B (final concentration 50 ng/ml), serum (FCS) 10 ml (2%), 
VEGF (vascular endothelial growth factor, final concentration 0.5 ng/ml), 
rhbFGF (recombinant human basic fibroblastic growth factor, final 
concentration 10 ng/ml), IGF-1 (insulin like growth factor, final concentration 
20 ng/ml) and ascorbic acid (final concentration 1 pg/ml) as supplied by the 
manufacturer. For thawing cells, cells were warmed slowly in a water bath 
until almost completely thawed. Cells were added to 10mls of prewarmed 
DMEM + 10% FCS. Cells were centrifuged at 1200g for 5 minutes and 
supernatant discarded. Cells were then placed in 10 mis of prewarmed 
EGM2-MV (Clonetics) and into a 10 cm2 dish or T-75 flask. The passage 
number was noted on the tissue culture vessel. After 48 hours, the medium 
was changed for fresh EGM2-MV to remove any dead cells and cell debris. 
Cells were examined using phase microscopy to determine if they required 
passaging. Cells which were > 75% confluent required passage. Cells were 
tested for the presence of mycoplasma every 3 months by Mycoplasma 
Experience.
Cells were passaged every 3 days. For passaging, medium was removed and 
cells washed with pre warmed (37°c) PBS. 5 mis pre warmed trypsin-EDTA 
was placed on the cells and incubated for 5 minutes at 37°c. Vigorous 
agitation was often necessary to remove cells completely from the plate, 
especially as cells became later passage. The trypsin-cell mixture was 
centrifuged at 1200g for 5 minutes and the trypsin then discarded. The pellet 
was resuspended in 1ml of fresh pre warmed EGM2-MV. Cell number was
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estimated using trypan blue and a haematocytometer as for other cells, and 
the cells plated at a final density of 2-5 x 103 cells/ cm2 (3x105 cells in a T-75 
flask or 10 cm plate).
2.2.6 MSC/ HSC isolation
MSC and HSC were isolated from fresh bone marrow (bone marrow obtained 
from the molecular haematology unit, University College Hospital (UCH) in 
accordance with local ethical guidelines). This bone marrow was purified 
immediately after extraction and was not stored or frozen before purification. 
Purification was performed using the Magnet-assisted cell sorting (MACS) 
system (Miltenyi Biotech) in accordance with the manufacturers guidelines. 
The bone marrow was diluted into 5 mis of PBS (if the volume was less than 
5 mis) and incubated with a MACS hapten anti-CD34 beads 30 minutes at 
4°c. All steps were carried out with strict aseptic technique in tissue culture 
facilities. This solution was centrifuged at 1200g for 5 minutes and then pellet 
resuspended in magnetic anti-hapten beads for 15 minutes at 4°c. The MACS 
column was placed in the MACS magnetic separator and column equilibrated 
with 500 pi of wash buffer. Labeled cell solution was placed in the MACS 
column and the flow through collected. The column was rinsed three times 
with 500 pi wash buffer and the flow through collected in the same container. 
This flowthrough was collected and stored and was assumed to be the CD34 
-ve  fraction. The MACS column was removed from the magnetic separator, 
rinsed three times with 500 pi wash buffer and flow through collected. This 
flow through was treated for 10 minutes at 4°c with 20 pi of MACS multisort 
release buffer. A new MACS column was placed in the MACS magnetic 
separator and the cell/release buffer mixture passed through the column. The 
flow through was collected. The column was rinsed three times with 500 pi 
wash buffer and the flow through collected in the same container. This 
fraction was the CD34 +ve bone marrow fraction. The CD34 +ve and CD34 - 
ve fractions were centrifuged at 1200g for 15 minutes and the pellet 
resuspended in 90% F C S /10% DMSO for freezing in liquid nitrogen or plated
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in appropriate medium. CD34 expression was not checked by fluorescence 
activated cell sorting (FACS) at this stage.
2.2.7 Mesenchymal stem cell culture
Frozen CD34-ve cells were thawed as described for endothelial cells (see 
section 2.2.5) or fresh cells used. All cells collected from a bone marrow 
sample were used at once. The cells were placed on a 10 cm dish in 10 mis 
of MesenCult (StemCell Technologies) and incubated at 37°c and 5% CO2 . 
After 48 hours cells were assessed by light microscopy. Some cells have 
adhered to the plate by this time, and there are numerous non-attached cells 
in the medium. The plate was washed gently with PBS and then 10mls 
MesenCult added. After 14 days, MSC should be clearly visible on the plate. 
After a further 14 days, the cells were checked for cell surface profile and if 
confirmed as being consistent with MSC were marked passage 2 and used as 
MSC for further experiments. If at any point the cells ceased to retain 
expression of SH2 or SH4 (see section 3.1) or became morphologically 
distinct from the expected picture of MSC the culture was assumed to have 
begun differentiation and was discarded.
Passaging and seeding density was as for endothelial cells, except 
MesenCult was used instead of EGM2-MV. MSC were passaged twice per 
week and the medium changed for fresh every day. Cells were tested for the 
presence of mycoplasma every 3 months by Mycoplasma Experience.
2.2.8 Differentiation of MSC and HSC
Differentiation of MSC was accomplished by seeding cells at high density (5 x 
104 cells/cm2) and replacing MesenCult with medium supplemented to 
stimulate differentiation into a particular lineage. The medium for adipogenic 
differentiation contained: 50 pg/ml ascorbic acid, 1 mM dexamethasone 
(Sigma), and 50 pg/ml indomethacin (Sigma). The medium for osteogenic 
differentiation contained: 200 pg/ml ascorbic acid, 0.1 mM dexamethasone
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(Sigma), and 10 mM R-glycerophosphate (Sigma). Cells were cultured in this 
medium for 28 days, changing the medium every second day. Differentiation 
usually became morphologically obvious by day 7-10. Oil Red O and alkaline 
phosphatase staining were performed as previously described (Pittenger et 
al., 1999).
HSC cannot be cultured in vitro without differentiation. Differentiation of 
CD34+ve cells into endothelial lineage was carried out by growing cells in 
EGM2-MV medium (see section 2.2.5 for information on EGM2-MV 
supplements) for 28 days. Were assessed for the presence of surface 
markers at 0, 14 and 28 days.
2.2.9 Cell doubling time measurement
Cell doubling time was measured by seeding 1x105 cells (1 x 104 primary or 
stem cells) into 1 ml of appropriate medium in a 24 well plate and culturing for 
24 hours. After this time, the number of cells in the well was estimated using a 
haemocytometer. The cell doubling time in days was calculated according to 
the formula
Doubling time (days)= Iogio2 / logio(a)-logio(b) 
where a=number of cells after 24 hours and b= 1x105
This process was performed in triplicate and repeated to allow the cell 
doubling time to be calculated over the course of the experiment.
2.2.10 Antibody staining for cell surface markers
Cells for antibody staining were trypsinised (if necessary) and washed twice 
in PBS + 1% FCS after pelleting by centrifugation at 1200g for 5 minutes. 
Infected cells or cell from medium potentially containing virus were fixed in 
4% paraformaldehyde for 15 minutes before staining. Primary antibody was 
diluted to the working concentration in PBS + 1% FCS and the pellet
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resuspended and incubated for 1 hour at 37°c. Cells were centrifuged at 
1200g for 5 minutes and washed twice with PBS + 1% FCS. Secondary 
antibody was diluted to the working concentration in PBS + 1% FCS and 
incubated for 30 minutes at 37°c. If the secondary antibody was conjugated to 
a fluorescent tag, the tube was wrapped in foil to keep the mixture in the dark. 
Secondary antibody was removed by washing twice with PBS + 1% FCS and 
appropriate analysis (eg FACS) then performed.
2.2.11 Cell cycle FACS (PI staining)
Cells were trypsinised (if appropriate) and washed twice in PBS + 1% FCS. 
Approximately 1 x 106 cells were resuspended in PBS + 1% FCS and were 
fixed in 4% paraformaldehyde for 1 hour at 4°c. Cells were washed twice in 
PBS and resuspended in 1 ml of PI staining solution (3.8 mM sodium citrate, 
50 pg/ml PI (Sigma)) and 50 pi of RNAse A 10 pg/ml solution (Promega). 
Cells were incubated in this solution for 3 hours at 4°c, washed twice in PBS 
and stored at 4°c until analysis by FACS. FACS analysis showed the position 
in the cell cycle according to FL2-H fluorescence. See figure 5.5d for details 
of cell gating to determine stage of cell cycle.
2.2.12 BrdU / MTT assay for cell proliferation
MTT assay (Roche) was performed in accordance with the manufacturers 
guidelines. Cells were seeded into a 96 well multiplate format. When 
adhered, cells were incubated for 4 hours with MTT (3-(4,5-dimethylthiazol-2- 
yl)-diphenyl-tetrazolium bromide). Cells were then incubated with formazen 
dye for 1 hour to solubilise and the colour density at A570 measured on a plate 
colorimeter.
BrdU Cell Proliferation ELISA (Roche) was performed according to the 
manufacturer’s guidelines. Cells were cultured in a 96 well format, and when 
adhered were labelled with BrdU (bromodeoxyuridine) for 16 hours. FixDenat 
solution was added for 30 minutes, and then anti-BrdU peroxidase added.
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After 1 hour, TMB (peroxidase substrate) was added and the colour density at 
A370-A492 measured on a plate colorimeter.
2.2.13 Annexin V staining for apoptosis
Percentage of cells in apoptosis was determined by annexin-V FITC and PI 
staining using the Apoptosis Detection Kit (Molecular Probes) in accordance 
with the manufacturers guidelines. Cells were washed in PBS and then 
resuspended in 100 pi annexin binding buffer. 5 pi Annexin V-FITC antibody 
was added to the mixture and incubated in the dark for 30 minutes. 1 pi of 1 
mg/ml PI solution was added and cells incubated on ice for 10 minutes. Cells 
were washed twice in PBS. FACS analysis for green and red fluorescence 
was performed. Live healthy cells showed low levels of fluorescence. 
Apoptotic cells showed green (Annexin positive) and dead cells showed both 
red and green fluorescence.
2.2.14 Immunofluorescence
IFA (Immunofluorescence assay) was performed on cells as follows. Cells 
were fixed for 15 minutes at room temperature in 4% PFA (paraformaldehyde, 
SERVA) then washed 3x with PBS + 3% FCS. Cells were permeabilised in 
PBS+ 0.2% TRITON-X (Sigma). Cells were spotted on glass slides and 
allowed to dry before being kept at -20°c until use. IFA for LANA was 
performed by incubating cells with LANA antibody (Kellam et al., 1999) 
diluted 1:120 or negative control (PBS) for 1 hour at 37°c. Cells were washed 
in PBS+ 3% FCS 3 times. Cells were then incubated with anti-rat FITC 
antibody (Dako) for 30 minutes at 37°c and then washed in PBS+ 3% FCS 3 
times. 50% glycerol was dropped onto the slide and a cover slip added. Cells 
were then visualised using a Nikon Eclipse E600 inverted microscope with 
Nikon fluorescent lamp. The aperture was 10, 20, 60 or 80x with total final 
magnification 100 -  800x. Unless otherwise stated in the figures the 
magnification used was 100x. Images were taken using a Zeiss Axiocam 
Camera and software.
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2.2.15 FACScalibur software
FACScalibur software (Beckton Dickinson) was used to gate, interpret and 
correct fluorescence analysis according to the manufacturers guidelines. 
Fluorescence overlap seen as bleed through to FL2-H of strongly eGFP 
expressing cells and expression in FL1-H of immature dsRed proteins (Baird 
et al., 2000) was corrected using samples expressing varying levels of one 
fluorescent protein and calibrating the software to compensate the readings 
appropriately. This was repeated with a sample expressing the other 
fluorescent protein, and the compensation stored and applied to all 
subsequent samples.
2.2.16 Generation of single cell clones
To make single cell lines, 293t and HeLa cells were infected with pSIN- 
deGFP at an MOI of 2 to maximise infection rates while minimising multiple 
insertions. Several 293t and HeLa cell lines were produced from an infected 
population by serial dilution of cells and plating in 96 well plates in 
conditioned medium. The mixture was diluted 1 in 20,000 such that each well 
should contain <1 cell. Conditioned medium was found to improve the speed 
and success with which colonies were established. The colonies were split 
into 24 well plates when large enough. When confluent, each colony was 
screened by FACS and those which displayed a defined eGFP expression 
assumed to be genuine single cells. These clones were then tested to 
determine whether they were still amenable to transfection by introducing a 
LacZ-FLAG plasmid.
2.3 Virus production
2.3.1 293t cell transfection for virus production
Three methods were used to transfect 293t cells. 293t cells were seeded at 
4x106 cells in a T-75 flask or 10 cm dish in 10 mis medium the night before 
transfection. 16 hours later, the medium on the cells was changed prior to 
transfection for 6 mis of fresh medium.
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PEI (polyethyleneimine) transfection was carried out as previously published 
(Naldini et al., 1996b). 2 eppendorfs were labeled T  and ‘2’. Mix ‘1’ contained 
10 pg of p8.91 or p8.2 (where experiments called for the HIV-1 accessory 
genes), 15 pg pHR or pSIN plasmid and 5 pg pVSVg. This mixture was 
made to a final volume of 1400 pi with 150 mM NaCI. Mix ‘2 ‘ contained 200 pi 
10 mM PEI (Sigma) and 1200 pi NaCI. The two mixes were incubated at 
room temperature for 15 minutes and then added dropwise to the tissue 
culture medium and placed at 37°c. The medium was changed for 10mls 
fresh medium after 4 hours.
For calcium phosphate transfection, the quantities of DNA (as for PEI 
transfection) were diluted in 220 ml in TE buffer (1 mM Tris-HCI, pH 8.0, 0.1 
mM EDTA). 250 pl HEPES buffer (280 mM NaCI , 50 mM HEPES, 1.5 mM 
NaP04, pH 7.1) was added and the mixture vortexed briefly. 30 pl 2 M CaCb 
was then added slowly over a 30 second windows to the DNA solution. This 
mixture was incubated at room temperature for 30 minutes. This mixture was 
then added to the cells and placed at 37°c overnight. Medium was changed in 
the morning for 10 mis fresh medium.
For FuGene (Roche Applied) transfection the manufacturers guidelines were 
followed. 1.5 pg pHR or pSIN vector, 1 pg p8.91 or p8.2 and 1 pg pVSVg 
were added to 200 pl serum free medium. 10 pl FuGene 6 (a FuGene:DNA 
ratio of 3:1) was added to this mixture without touching the sides of the 
eppendorf. This mixture was mixed gently and incubated at room temperature 
for 15 minutes. This mixture was then added dropwise to cells and placed at 
37°c. There was no need to change the medium after transfection.
2.3.2 Harvesting virus
Virus was harvested three times after transfection. 48 hours after the medium 
change (60-65 hours after transfection), supernatant was removed and 
filtered with a 45 micron (0.45 pm filter). This medium was kept at 4°c if it was
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to be used in an experiment within 24 hours, or stored at -80°c in 1 ml 
aliquots for longer periods. Fresh medium (10 mis) was placed on the cells 
after harvest. This procedure was repeated 24 and 48 hours later if the cells 
remained adherent to the plate. If there were large numbers of cells which 
had detached from the plate that harvest was destroyed. Viral stocks left over 
after each experiment were discarded once thawed.
2.3.3 Assaying titre
2.3.3.1 p24 ELISA
p24 ELISA was carried out using a kit supplied by Aalto Bio Reagents 
according to the manufacturers protocol. 24 hours prior to assay, high bind 
white plates were coated wit 100 ml per well of 5 mg/ml D7320 anti-p24 
antibody in 0.1 M NaHCC>3. Wells were washed with LBS and blocked with 
LBS + 2% milk powder w/v for 1 hr at room temperature. 20 pl of PBS 
containing 5% Empigen BB detergent (Surfachem UK Ltd) was added to 80 pl 
of virus supernatant. This was diluted 1 in 20 or 1 in 200 in PBS + 5% 
Empigen BB. A dilution series of p24 standard protein (in LBS + 0.05% 
Empigen was included on the plate. After blocking, plates were washed in 
LBS and 100 pl of each sample added. Plates were incubated for 4 hours at 
room temperature and then washed twice with LBS. Secondary anti p24 
antibody- alkaline phosphatase (EH12E1-AP) was diluted to 0.5 pg/ml in 4% 
w/v milk powder + 20% FBS + 0.5% Tween-20 in LBS and incubated on the 
plates for 1 hour. Plates were washed five times with LBS + 0.5% Tween 20 
and then exposed to 100 pl alkaline phosphatase substrate Lumi-Phos Plus 
(Aureon Biosystems). Plates were incubated in the dark for 30 minutes at 
37°c. Plates were read using Stingray software (Dazdaq, UK) and a Lucy 1 
Luminometer (Athos-Labtech). The p24 standard was used to calculate the 
quantity of p24 in each sample and the number of infectious virions.
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2.3.3.2 293t infectious units (GFP)
293t cells were seeded at 1 x 105 cells per well in a 6 well plate 24 hours 
before infection. Serial 1:10 dilution of viral supernatant of unknown titre was 
performed. The final volume of virus that was added to each well was 1 ml. 
The equivalent amounts of virus added was usually 10 pl, 1 pl, 0.1 pl, and 
0.01 pl. If the infection rate in the lowest concentration was above 1%, the 
experiment was repeated using more dilute concentrations. The infection was 
assumed to be on 2 x 105 cells as these cells double roughly every 24 hours. 
After 48 hours, the expression of eGFP was assessed by FACS analysis in 
terms of percent of cells eGFP positive. These values were plotted on a 
logarithmic graph and the line of best fit through the linear region of infection 
determined. This region was when infection was below 30% to minimize 
multiple insertions (see Fig 3.2c for example). The titre could be calculated by 
finding two points on the graph (points (x1,y1) and (x2,y2) are any two points 
on the line of best fit through the linear region of a plot of percent of cells 
infected against MOI) and using the formula
293tlu/ml = (No. of cells infected x (y2-y1)) /100  x (x2-x1)
This formula was derived as follows:
m = (y2-y1)/(x2-x1)
(% infection x No. of cells infected) /100  = Titre x volume of virus added *
volume of virus added = x2-x1 
% infection = y2-y1 
Titre x volume of virus added = (No. of cells infected x (y2-y1)) /100  
Titre = (No. of cells infected x (y2-y1)) /100  x (x2-x1)
Note that for the assumption marked * to be true, infection must be low to 
minimize multiple insertions (< 30%).
2.3.3.3 TaqMan qPCR estimation of titre
293t cells were seeded and infected as for assaying of titre by 293tlU (GFP). 
48 hours after infection, the cells were trypsinised and DNA extracted as
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shown in section 2.1.10. This DNA was analysed using TaqMan qPCR (see 
section 2.1.12) for the presence of both lentiviral insert and for GAPDH (see 
section 2.6.4 for primer details and optimum reaction conditions).
The number of lentiviral inserts per cell was calculated. Using this information, 
the number of cells which were infected and the volume of virus added to the 
cells, the titre of the virus in terms of copy number per 293t cell was 
estimated.
2.3.4 Infection of cell lines
For infection of cell lines, an appropriate volume of virus was placed on ice or 
at 4°c until the virus had almost completely thawed. Medium on cells was 
changed before infection. Virus was diluted (if necessary) and added to the 
cells dropwise. The vessel was gently agitated to disperse virus and placed at 
37°c for 4 hours. After 4 hours, medium was changed for fresh. All medium 
containing virus was placed in Virkon (or other suitable disinfectant approved 
to kill HIV-1) before being discarded. Pipettes used to handle medium 
containing lentivirions were also placed in Virkon for 4 hours before being 
discarded.
2.3.5 Ultracentrifugation to concentrate virus
Virus was concentrated by ultracentrifugation in a refrigerated BeckMan 
Coulter ultracentrifuge with a swinging bucket rotor (SW27) at 48,000 g 
(25,000 RPM), 4°c overnight (12-16 hours). Ultracentrifugation was performed 
in disposable, sterile tubes rated to 100,000 g (BeckMan Coulter) and the 
buckets for the rotors were washed thoroughly in Virkon before and after 
ultracentrifugation. Typically, 20-25 mis supernatant was used in each 
centrifuge tube. After ultracentrifugation, the supernatant from the tubes was 
gently decanted into Virkon. A clear or slightly brown (due to the presence of 
serum) pellet was usually visible in the tube. 1-2 mis of medium appropriate to 
the target cell (e.g. DMEM, MesenCult or EGM2-MV) was added to this tube 
and placed on ice for 1 hour. After this time, the medium was pipetted 
vigorously and the pellet examined to ensure it had completely dissolved.
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Further incubation on ice was sometimes necessary for this. The titre of this 
concentrated stock was determined and it was stored in 100 or 250 pl 
aliquots at -80°c.
2.3.6 Centricon units to concentrate virus
Centricon 80 or Centricon 20 units (Millipore) with a 100 kDa molecular 
weight cut-off were used to concentrate virus through a principle of 
ultrafiltration. The units were used as described by the manufacturer. 
Centricon 80 units could concentrate 80 mis of supernatant, centricon 20 
units up to 20 mis. The centricon units were equilibrated using equilibration 
buffer (Millipore). Viral supernatant was added to the units and centrifuged at 
1200 rpm for 30 minutes. The flow through was discarded into Virkon. The 
Centricon units were inverted, 2 mis of elution buffer added and the units 
centrifuged at 1200 rpm for 15 minutes. The titre of this eluate was 
determined and it was stored at 4°c for immediate use or at -80°c for later 
use.
2.4 RNA interference
2.4.1 Ambion in-vitro RNA transcription kit
The Ambion Silencer siRNA in vitro transcription kit (Cat # 1620) was used in 
accordance with the manufacturers guidelines. Briefly, 21 nt target DNA 
templates were synthesized (MWG Biotech) with the sequence 5’- 
CCTGTCTC-3’ at the end. This sequence is complimentary to the T7 
promoter primer sequence provided in the kit. 2 pl of DNA template (100 pM) 
was added to 6 pl DNA hybridisation buffer and 2 pl T7 promoter primer. One 
tube for each template oligo (one sense and one antisense) was prepared 
and incubated at 70°c for 5 minutes and then left to cool to room temperature. 
2 pl Klenow buffer, 2 pl dNTP mix, 4 pl nuclease free water and 2 pl Exo- 
Klenow were added to the reaction (all buffers and enzymes supplied with the
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kit). These mixtures were incubated at 37°c for 30 minutes. 2 pl of these 
solutions were placed in new tubes (one tube for sense, one for antisense) 
with 4 pl nuclease free water, 10 pl NTP mix, 2 pl 10x Reaction buffer and 2 
pl T7 enzyme mix. These mixtures were incubated for 2 hours at 37°c, mixed 
together and then incubated overnight at 37°c. The resulting mixture was 
digested with DNAse and filtered using columns provided, quantified by 
measurement of the A260 of the mixture using a spectrophotometer and stored 
at -80°c.
2.4.2 Transfection of dsRNA into cell lines
dsRNA molecules were either synthesized (section 2.5.1) or purchased 
prepared from Dharmacon. Cells for transfection were seeded at 70%  
confluence.
Transfection was performed using FuGene 6 (Roche), Oligofectamine 
(Invitrogen), Transit (Mirus), or Effectene (Qiagen). These reagents have 
been recommended by the manufacturers as being RNAse free and therefore 
suitable for transfection of dsRNA. They were each used as directed by the 
manufacturer.
Medium on cells was changed before transfection. FuGene transfection was 
performed by preparing an eppendorf containing 200 pl of serum free medium 
containing the DNA or dsRNA. FuGene 6 was added to the mixture at a 
FuGene:DNA or dsRNA ratio of 3:1. dsRNA was used so as to make a final 
concentration of 100, 200 or 400 nM. 0.5pg DNA was used per well of a 6 well 
plate. FuGene was added carefully without touching the sides of the 
eppendorf. Mixture was incubated for 15-30 minutes at room temperature and 
then added dropwise to cells.
The Oligofectamine (Invitrogen) protocol involved producing two mixes. For a 
6-well plate, one mix contained dsRNA to a final working concentration of 
100,200 or 400 nM or 1 pg DNA diluted to 38 pl with serum free DMEM and
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the other mix contained 8 pl serum free DMEM and 4 pl oligofectamine. Mix 2 
was added to mix 1 and incubated at room temperature for 15 minutes. This 
mixture was added dropwise to cells which were gently agitated. For larger or 
smaller wells, the quantities were altered appropriately.
For Transit (Mirus) transfection, 4 pl Transit per pg DNA or RNA was added 
to 250 pl serum free medium. This medium was incubated for 15 minutes.
DNA (1-2 pg per well for a 6 well plate) or dsRNA to a final concentration of
100, 200 or 400 nM was added to the mixture and incubated for 30 minutes. 
This mixture was added dropwise to cells in tissue culture.
The Effectene (Qiagen) protocol involved preparation of 0.5 pg DNA or 
dsRNA to a final working concentration of 100, 200 or 400 nM in 50 pl buffer 
EC (Qiagen). 3 pl enhancer was added, vortexed for 1 second and incubated 
at room temperature for 2 minutes. 10 pl Effectene was added to the mixture, 
vortexed for 10 seconds and incubated at room temperature for 5-10 minutes. 
This mixture was added dropwise to cells in tissue culture.
2.4.3 RNAi target selection
Targets for RNAi were selected based upon the criteria thought to be 
important for efficient gene knockdown. These criteria were based upon 
recommendations from Ambion and Dharmacon, and included:
• At least 50 bp from the end of the gene
• At least 19 but no more than 25 bp
• Roughly 50/50 GC content
• Avoid long strings of G’s and C ’s
•  Avoid strings of 3-4 A’s or T ’s
• Sequences should start with AA
• Sequences starting with a G may be more efficient for the U6 promoter
• Choose two or three targets from different sections of the gene
• BLAST the sequenced to ensure it has no homology to cellular genes
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An alternative was using one of several internet websites for automatic target 
selection (e.g. www.ambion.com/rnairesource). The target sequence was 
designed as a short hairpin in the format:
5’ -  Target sequence -  TTCG -  complementary sequence -  TTTTT -  3’ and 
the complementary oligo with a CTAG placed on the 5’ end. For examples of 
oligos ordered for shRNA see section 2.7.2
2.4.4 Short hairpin oligo annealing conditions
10 pl of a 100 pmol/ml solution of each oligo was placed in 280 pl annealing 
buffer (100 mM Tris-HCL pH 7.5, 1 M NaCI, 10 mM EDTA). This mixture was 
heated in a water bath to 95°c for 3 minutes and then allowed to cool to room 
temperature slowly. Phenol/chloroform extraction was performed (see section 
2.1.1) and precipitated DNA resuspended in 50 pl sterile water.
2.4.5 T4 polynucleotide kinase (PNK) treatment of oligos
Unless oligos were ordered 5’ phosphorylated, the annealed oligos require T4 
PNK treatment before cloning into pGEM-U6. T4 PNK (Promega) was used in 
accordance with the manufacturers guidelines. 6 pl of 10x T4 PNK buffer, 2 pl 
of ATP (1 M) and 2 pl of T4 PNK were added to the 50 pl of annealed oligos 
(section 2.5.4). This mixture was incubated at 37°c for 1 hour and reaction 
stopped by phenol/chloroform extraction. Precipitated DNA was resuspended 
in 50 pl sterile water.
2.4.6 Cloning procedure for lentiviral shRNA production
3 mg pGEM-U6M was digested using Sma I (Promega) (section 2.1.1). After 
2 hours, Xba I and shrimp alkaline phosphatase were added to the mixture 
and incubated at 65°c (Xba I is not efficient at 37°c) for 2 hours. This 
backbone was purified by agarose gel extraction (section 2.1.3). Backbone 
and oligos were ligated (section 2.1.4). Ligation was usually sufficient for 1 
hour at room temperature, although occasionally overnight incubation at 4°c 
was required.
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For oligo insertion into pGEM-U6L, the backbone was digested with Sal I 
(section 2.1.1) and blunted with Mung Bean nuclease (Promega, section 
2.1.7). Phenol/ chloroform extraction was performed and then digestion with 
Xba I performed. The backbone was extracted and oligos inserted as above.
Successful insertion of the oligonucleotides and accurate sequence was 
confirmed by DNA sequencing. 1 pg of confirmed pGEM plasmid was 
digested with EcoR1 (section 2.1.1) and the 300 bp insert extracted after 
agarose gel analysis (section 2.1.3.). Appropriate lentiviral backbone (pSIN 
vector) was digested with EcoR1 and shrimp alkaline phosphatase (SAP, 
Promega). SAP dephosphorylates the vector backbone to prevent self ligation 
and is added directly to the digest reaction mixture to a final concentration of 
1 U/pl. SAP is compatible with almost all Promega 4-core buffers (except D 
and J).
The insert and lentiviral backbone were ligated (section 2.1.4) and insert 
confirmed by digestion with Xba I, where the gel reveals a fragment only if 
insertion was successful. Orientation could be checked by sequencing, 
although knockdown was found to be independent of orientation and this was 
not routinely performed.
2.4.7 Formulae for calculating knockdown efficiency
Knockdown efficiency for cells expressing eGFP was calculated based on 
mean fluorescence intensity (MFI). Two formulae were used to calculate the 
knockdown efficiency depending on the nature of the experiment performed.
If cells were infected or transiently transfected and the knockdown performed 
at the same time, the knockdown was assessed in percent as:
100 -  ((MFI with sh-eGFP -  MFI untreated cells) / (MFI with sh-LacZ -  MFI 
untreated cells) * 100)
If cells were a stable line expressing eGFP, the knockdown was calculated as
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100- ((MFI with sh-eGFP) / (MFI with sh-LacZ) *100)
The calculation of knockdown therefore does not include the fact that even 
with 100% knockdown cells would still have some autofluorescence, and 
therefore underestimates the knockdown. This effect was assumed to be 
negligible.
2.5 in vivo studies
2.5.1 Immunodeficient mice for in vivo PEL model
immunodeficient mice for experiments were bred by Adrian Thrasher, Institute 
of Child Health (ICH) and used with his permission. Their genotype was RAG 
(recombination activating genes) -/-, C3 -/- and common gamma chain -/-. 
Mice were cared for at the ICH by scientific support staff.
Mice were culled in accordance with the ATCC defined criteria for humane 
conditions. A weight gain of more than 6 grams above the mean in the weight 
control group was taken as the cut-off for severe ascites and mice were 
culled. A palpable solid tumour mass exceeding 1 cm was taken as solid 
tumour development and mice were culled.
2.5.2 Injections of PEL cells and lentiviral vector
PEL cells were injected intraperitoneally into mice in the midline of the 
abdomen. A short needle and a transverse angle was used and the mice 
positioned such as to maximize the chances of a peritoneal rather than 
subcutaneous or bowel injection was performed. Lentiviral vector injections 
were performed on the lateral side of the abdomen at a different injection site 
from the PEL cells.
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2.5.3 Statistical analysis of in vivo experiments 
Outliers in experiments were included in any statistical analysis. On bar 
charts where error bars are indicated the bars indicate the standard error of 
the mean unless otherwise indicated in the figure legends. The standard error 
of the mean (aM) is calculated by:
where a is the standard deviation of the group and N is the number of
samples
The standard deviation (a) was calculated by finding the square root of the 
variance (a2)
2 ztx - m2 I 
q - n |
Comparison of two weight groups was performed using a t test to determine 
the significant difference between two means. The calculations were 
performed using GraphPad Prism version 3.1.
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2.6 Information regarding methods
2.6.1 Primers used for PCR cloning
Name Target Cone F Cone R
eGFP F 5’-CCACAAGTTCAGCGTG-3’ 100ng 100ng
eGFP R 5’-CAGGACCATGTATC-3’
dsRED F 5’-GTAATGCAGAAGAAGACT-3’ 75ng 75ng
dsRed R 5’-ATGTCCAGCTTGGAGTCCACG-3’
EF1a F 5’-CACAACACCTGAAATGGAAGAA-3’ 100ng 100ng
EF1a R 5’-TTTTATGCGATGGAGTTTCCCCACA-3’
CMVF 5’-AAGACCCCACCTGTAGGTTTGGC-3’ 100ng 100ng
CMV R 5-AAATGAAAGACCCCCGCTG-3’
BactinF 5'-GTTCCATGTCCTTATATGGAC-3’ 100ng 100ng
B actin R 5-TTGGACGGGCGGCGGATCGGCAAA-3’
SFFVF 5-ATAAAAGATT TTATTTAGT-3’ 50ng 50ng
SFFV R 5-GCAGAAGCGCGCGAACAGAA-3’
cPPTF 5’-CGCCAAATGGCAGTATTCATCC-3’ 100ng 100ng
cPPT R 5’TCCAAACTGGATCTCTGC-3’
WPREF 5-GAATGTCAATAAAACAAAATGGTGG-3’ 100ng 100ng
WPRE R 5’-CGGTATCGATCAGGCGGGGAGGC-3’
Cycling conditions
35 cycles of 95°c for 1 minute, 50°c for 2 minutes 
72°c for 1 minute
35 cycles of 95°c for 1 minute, 55°c for 2 minutes 
72°c for 1 minute
35 cycles of 95°c for 1 minute, 55°c for 1 minute 
72°c for 1 minute
35 cycles of 95°c for 1 minute, 50°c for 1 minute 
72°c for 1 minute
35 cycles of 95°c for 1 minute, 58°c for 2 minutes 
72°c for 1 minute
35 cycles of 95°c for 1 minute, 55°c for 1 minute 
72°c for 1 minute
35 cycles of 95°c for 1 minute, 50°c for 1 minute 
72°c for 1 minute
35 cycles of 95°c for 1 minute, 55°c for 1 minute 
72°c for 1 minute
Sequences for cloning chosen by personal communication (eGFP, dsRed and CMV - personal communication Dr. Hsei- 
Wei Wang) or using NetPrimer (http://www.premierbiosoft.com/netprimer/)
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2.6.2 RNAi short hairpin primers
Target Name Target sequence
eGFP GTTCATCTGCACCACCGGCAAGC
LacZ GCT GT GATT GCGTCT GGGTTT GC
SURVIVIN GGACCACCGC AT CT CT AC ATT C
dsRed TAATGCAGAAGAGACCATGG
vCYCLIN C GTT CCT GCCAACGTCATT C
vCYCLIN N GTCGCGTT GGCCCTT AAT C
vFLIP C GT GCTCGT CAGGTT CT CC
vFLIP N GT AAC AAG AAG G AAGTT AC
LANAC GCT AGGCCAC AACACAT CT
LANAN GT CCCACAGT GTT CACAT C
vFLIP 5 AAGCTT AAT AG CTGT CC AG AAT G
vFLIP 444 AAT AGGCGT GAGGCTT CT GAGCT
vFLIP 967 AAGT GCGGAGCGGCGACGGT GGCT
vCYCLIN 6 AACT GCCAAT AACCCGCCCT CGG
vCYCLIN 316 AAGCT CAGAAGCCT CACGCCT AT
vCYCLIN 675 AAG CATATT G G GAT GC GAT GTTT
LANA 623 AAGGTCCCTCTACACTAAACCCA
LANA 1278 AAGTT CACAACAGCAGCAGGAGC
LANA 2369 AAGT GGATT ACCCT GTT GTT AGC
Primer template (eGFP used as example):
S 5’ - GTTCATCTGCACCACCGGCAAGC TTCG GCTTGCCGGTGGTGCAGATGAAC TTTTT -3’
( 5 '- TARGET SEQUENCE HAIRPIN COMPLEMENTARY TARGET POLY-T-3')
AS 5’ -  AAAAA GTTCATCTGCACCACCGGCAAGC CGAA GCTT GCCGGT GGT GCAGAT GAAC -3’
The as primer is the complementary sequence to the s primer (to allow annealing) with a 5’ Xba I cloning site (CTAG)
- 1 2 0 -
2.6.3 PCR primers for analysis
Name 
U6 Distal
(for confirming sequence of inserted 
hairpins
SFFVF
W PRER
(for confirming insertion of genes after 
SFFV promoter)
T arget Cone F Cone R
5’ -  CCCATGATTCCTTCATATTTGC -  3' 250nm
5’ -CAAGAACAGATGGTCACCGCA -3' 
5’ - C CT G AACTAGT AACACAT A -  3’
500nm
300nm
Cycling
conditions
Standard
PCR
(2.1.8), and
sequencing
30 cycles: 
94°C 15s 
47°C 1min 
72°C 45s
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2.6.4 TaqMan qPCR/qRT-PCR primers, probes and conditions
Name
Lentiviral packaging cDNA
vCyclin
vFLIP
LANA
Human GAPDH
Mouse GAPDH
Target / Probe
F 5'-ACTTGAAAGCGAAAGGGAAACCA-3’ 300pmoles 
R 5'-GTGCGCGCTTCAGCAA-3’ 300pmoles 
F 5’-CATTGCCCGCCTCTATTATCA-3’ 300pmoles 
R 5’-ATGACGTTGGCAGGAACCA-3’ 300pmoles 
Forward 5’-TTTCCCCTGTTAGCGGAATGT-3’ 300pmoles 
Reverse 5’-CTAAGTGAAGCAGGTCGCGC-3’ 300pmoles 
F 5-TTGCCACCCACGCAGTCT-3’ 500pmoles 
R 5’-GGACGCATAGGTGTTGAAGAGTCT-3’ 500pmoles 
Probe 5’-TCTTCTCAAAGGCCACCGCTTTCAAGTC-3’
Forward 5’-GGAGTCAACGGATTTGGTCGTA-3’ 300pmoles 
Reverse 5’-GGCAACAATATCCACTTTACCAGAGT-3’ 300pmol 
Probe 5’-CGCCTGGTCACCAGGGCTGC-3’
Forward 5’-GGCATGGCCTTCCGTGT-3’ 300pmoles 
Reverse 5’-GGTTT CT CC AGGCGGCA-3’ 900pmoles
qPCR/RT-PCR
qPCR
qPCR/ qRT-PCR
qPCR/qRT-PCR
qRT-PCR 
(700pm/ 700pm 
used for qPCR) 
qRT-PCR 
(700pm/ 700pm 
used for qPCR) 
qPCR
SYBR green used for all reactions except LANA and human GAPDH, where probes significantly improved the accuracy of 
the assay. Standard TaqMan cycling conditions for an ABI Prism 7000 machine were used throughout.
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2.6.5 Antibodies and reaction conditions
Antibody Manufacturer Western Blot 
concentration
Secondary Antibody Manufacturer Staining
concentration
Secondary
antibody
LN53 (rat anti- n/a 1/1000 Mouse anti-rat CD31 Research Diagnostics 1/500 (1)
LANA) (1/120 for IFA) HRP
(Immunological CD34-FITC Research Diagnostics 1/120 n/a
Direct), 1/5000
Sheep anti- Exalpha 1/1000 Goat anti-sheep
vcyclin biological HRP (Santa 
Cruz), 1/5000
CD38 Santa Cruz 1/120 (1)
Rat anti-vFLIP Gift from Mary 
Collins
1/200 Mouse anti-rat 
HRP
CD45 Research Diagnostics 1/500 (2)
(Immunological CD49b Santa Cruz 1/120 (1)
Direct), 1/5000
Mouse anti p- Oncogene 1/5000 Rat anti-mouse CD133 Santa Cruz 1/120 (1)
actin (Santa Cruz),
1/10000 SH2-FITC StemCell Technologies 1/1000 n/a
Mouse anti- BD Biosciences 1/8000 Rat anti-mouse
eGFP (Santa Cruz), 
1/10000
SH4-FITC StemCell Technologies 1/1000 n/a
Mouse anti- Santa Cruz Rat anti-mouse HLA-DR Research Diagnostics 1/200 (3)
FLAG (Santa Cruz),
1/10000 Thy1 (CD90) Research Diagnostics 1/500 (3)
Mouse anti- Cell Signalling Rat anti-mouse
survivin Technology (Santa Cruz), 
1/10000
Lin
Rat anti-murine 
MHC-PE
ZyMed
StemCell Technologies
1/1000
1/500
(2)
n/a
Secondary antibodies: (1) rat anti-mouse-FITC (Santa Cruz) used 1/120 ; (2) goat anti-rat-FITC (Santa Cruz) 1/120 ; (3) goat anti-rabbit-FITC
(Immunologicals Direct) 1/500
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2.6.6 Cell line information
Cell line Cell type Special Features ATCC number
293t Human embryonic kidney Derived from 293 cells 
Large T antigen positive
Not in ATCC database
HeLa Human cervical epithelial 
adenocarcinoma
HPV positive ATCC CCL 2
MOLT-4 Human acute T 
lymphoblastic leukaemia (T 
cell)
ATCC CRL 1582
Ramos Human Burkitts lymphoma 
derivative (B cell)
EBV positive ATCC CRL 1596
BC-3 B-Cell (see table 1.4.1) KSHV positive Not in ATCC database
JSC-1 B-Cell (see table 1.4.1) KSHV positive Not in ATCC database
HBL-6 B-Cell (see table 1.4.1) KSHV positive Not in ATCC database
- 1 2 4 -
Chapter 3:
Lentiviral vectors to infect human primary and stem cells 
Chapter aims:
The aims of this chapter were to isolate and culture human primary and adult 
stem cells and show that a lentiviral system can transfer genes into these 
cells. Production and quantification of virus was optimized and elements of 
the viral backbone which may be required for gene transfer were identified. 
The effect of infection on the ability of these cells to differentiate was also 
determined.
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3.1 Isolation and culture of primary and stem cells
Primary cells are cultured from tissue without direct genetic modification. Cell 
lines have genes introduced allowing them to replicate indefinitely, or have 
been derived from cancerous tissue which already contains mutations 
allowing this. Primary cells have a limited lifespan in culture and eventually 
reach senescence. This limit varies between cell types. Primary cells are 
more useful for some in vitro studies because of the altered gene expression 
in cell lines. Primary cells are not as easy to handle as cell lines as they tend 
to be refractory to both chemical and electrical transfection. Viral vectors can 
be used to transduce these cells (Akkina et al., 1996; Dilloo et al., 1997; 
Drexler et al., 2004; Gruber et al., 1985; Lebkowski et al., 1988).
Cell cultures of primary and stem cells were established to allow investigation 
of growth characteristics and cell surface marker profiles. Human dermal 
microvascular endothelial cells (DMVEC) were purchased and were 
maintained in EGM2-MV (both from Clonetics). The manufacturer’s guidelines 
suggested supplementing medium with epidermal growth factor (EGF), 
vascular endothelial growth factor (VEGF) and basic fibroblastic growth factor 
(bFGF) (see materials and methods). The cells maintained a ‘cobble-stone’ 
appearance (Fig 3.1a) and stained positive (see section 2.2.5) for markers of 
endothelial lineage such as CD34 and CD31 (Fig 3.1b).
To determine the expansion potential of these cells, the cell doubling time 
over serial passage was investigated. The cells maintained a cell doubling 
time of around 3 days until passage 14. The population became completely 
senescent by passage 16-18 (Fig 3.1c). To avoid potential experimental bias 
from using senescent cells, all experiments conducted using DMVEC were 
therefore performed between passage 4 and 10.
Human mesenchymal stem cells (MSC) and haematopoietic stem cells (HSC) 
were isolated from fresh human bone marrow (supplied by the Molecular
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Haematology Unit, UCH). Briefly, bone marrow was diluted in Mesencult 
(Stem Cell Technologies) and placed in 10 cm dishes. After 48 hours, the 
supernatant was then removed and fresh medium replaced. After 10-14 days, 
cells were clearly visible, and by day 28 morphologically resembled MSC (Fig
3.1 d) (For details of this protocol, please see materials and methods section 
2.2.6). Analysis of these cells showed that they displayed a cell surface 
marker profile consistent with undifferentiated MSCs (Pittenger et al., 1999) 
(Fig 3.1e).
There is not currently any known method of culturing HSC without stimulating 
them to differentiate. Growth in EGM2-MV stimulates HSC to differentiate into 
endothelial cells (personal communication, Hsei-Wei Wang). The other CD34 
+ve cells present in the supernatant are presumed not to proliferate in EGM2- 
MV and therefore the remaining cells were treated as a pure population of 
HSC. Staining of supernatant before culture in EGM2-MV did show a large 
population with a cell surface phenotype consistent with HSC (Fig 3.1f).
As MSCs can spontaneously begin to differentiate, MSCs were stained for 
SH2 and SH4 before experiments. These markers are associated with the 
undifferentiated state in MSCs and indicative that these cells have not begun 
differentiation (Pittenger et al., 2000).
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Figure 3.1 Isolation and culture of primary and stem cells
Details of the antibodies and staining concentrations for these experiments 
can be found in the materials and methods section (2.7.5)
(a) Light microscopy of human DMVEC at passage 4 grown in EGM2-MV 
(Clonetics)
(b) FACS analysis of human DMVEC at passage 4 stained for CD34 (top) and 
CD31 (bottom). Purple populations represent stained cells, green overlay 
represents cells with secondary but no primary antibody (see materials and 
methods section 2.2.10 for details of protocol).
(c) Graph showing the cell doubling time (in days) of DMVEC from passage 3 
- 1 8 .  Cell doubling time was estimated by counting cells and calculating the 
time required for a population to double (see materials and methods 2.2.9).
(d) Light microscopy of human MSC at passage 3 grown in Mesencult 
(StemCell technologies).
(e) FACS analysis of cell surface profile of MSC at passage 3. Cells were 
stained with antibodies to SH2, SH4, CD49b, CD13, CD45, HLA-DR, CD34 
andCD133. Stained populations are shown in purple, negative controls with 
secondary antibodies only shown in green.
(f) FACS analysis of cell surface profile of HSC at passage 4. Cells were 
stained with antibodies to CD34, CD38, Thy 1 and Lin. Stained populations 
are shown in purple, negative controls with secondary antibodies only shown 
in green.
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3.2 Accurate determination of viral titre
In order to make results of experiments involving lentiviral vectors valid both 
between experiments and to other reports, accurate determination of viral titre 
is required.
In the current literature, several methods have been described to assess viral 
titre. The most common and perhaps easiest method of assessing viral titre 
involves measuring the quantity of virus required to infect one cell, commonly 
the 293t HEK cell (the 293t infectious unit, or 293tlU) (Naldini et al., 1996b). 
Measurement of the quantity of HIV-1 core antigen (p24) is popular for 
viruses which do not express markers. Recently, TaqMan quantitative PCR 
(qPCR) on infected cells or qRT-PCR on viral supernatant have been used 
(Klein et al., 2003).
These methods each hold advantages and disadvantages. Measurement of 
293tlU is convenient but difficult when using viruses which do not express a 
marker such as eGFP or puromycin resistance. Measuring p24 is prone to 
error as it does not measure infectious virions. The gag protein (p24) 
measures particle production but not delivery of the transgene. Assessment 
of titre by qPCR has the advantage of being both accurate and reproducible 
however is technically much more difficult than the other methods.
To optimize a reliable method of determining titre, a pHR (second generation) 
vector containing eGFP expressed from the CMV promoter (gift from Didier 
Trono, University of Geneva, Switzerland) and a pSIN (self-inactivating) 
vector expressing eGFP from the CMV promoter (produced from pCSGW, a 
gift from Adrian Thrasher, Institute of Child Health, London) were used (Fig 
3.2a). pSIN vectors are theoretically safer due to deletions in the LTR. Three 
batches of virus were produced, and the titre then analysed by measuring 
p24 concentration and 293tlU by expression and qPCR detection of the 
lentiviral insert. Titre in 293tlU/ml was determined by choosing a linear region 
on a logarithmic representation of the infection rates at increasing quantity of
- 1 3 2 -
virus (Fig 3.2b). These data indicate that there is considerable variation in titre 
depending on the method of assessment. (Fig 3.2c).
The considerable variation in the p24 titres between batches with comparable 
expression levels in terms of 293tlU may be because of the detection of non- 
infectious virions in the supernatant. Although p24 has the advantage of 
being fast and easy, it was unreliable and was not a good indicator of 
infectivity. This method was therefore only used when other methods proved 
to be unsuitable.
qPCR analysis of infected cells showed some surprising results. These data 
indicate that several copies of the packaging signal are present in cells to 
achieve expression. One copy should be sufficient for expression. To 
determine whether this result was an experimental error, the relationship 
between viral dose and copy number of the packaging signal was assessed 
(Fig 3.2d). These data indicate that any error in this method is consistent.
The standard used was prepared by serial dilution of a plasmid. An accurate 
concentration was determined using a spectrometer and the molecular mass 
of the plasmid determined by pDRAW32 software. These data were used to 
calculate the molar concentration of the plasmid, and dilutions to 
concentrations of 1 x 107 copies per pi made. Serial dilutions of this standard 
were used to calibrate the TaqMan qPCR machine in accordance with 
guidelines from ABI.
To test whether my standard was at fault, a second standard was prepared 
(to rule out error in manufacture). This new standard gave results very similar 
to the old (data not shown). It was decided that, although the results were 
high, they were within an order of magnitude of other published results. The 
results were also reproducible and consistent.
Published literature (Woods et al., 2003) indicate that several integrated 
copies of the lentiviral vector may be present in transduced cells even when
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there are low expression levels, and therefore the ‘infectious unit’ simply 
means the average number of virions required for detectable expression. This 
clearly implies that a single copy is sufficient to express the transgene, if the 
integration is in an appropriate genomic location however the average 
number of integrations for an infectious unit may actually be higher.
It was decided to use 293tlU as a method of expressing titre wherever 
possible. This number can be directly correlated with the percent of cells 
which will be infected. Where it is not possible to use 293tlU (such as viruses 
which do not contain a marker), qPCR would be used to assess the 
integrated copies per cell, and this would be converted into 293tlU by dividing 
by 4.71. This number was chosen from the line of best fit on figure 3.2d. 
These data also imply that although MOI is a useful indicator of dosing, it 
should not be used to accurately indicate copy number.
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Figure 3.2 Accurate determination of viral titre
(a) Diagram of the pHR (second generation) and pSIN (self inactivating) 
backbones used in this chapter. LTR -  long terminal repeat; CMV -  
cytomegalovirus immediate early promoter; eGFP -  enhanced green 
fluorescent protein.
(b) Table showing the titres of 3 batches of virus produced using a published 
protocol ((Naldini et al., 1996b), materials and methods 2.3.1) with a pHR 
(top) or pSIN (bottom) backbone. These batches were assessed by 
performing p24 ELISA on viral supernatant (p24), or infecting 293t cells and 
determining the quantity required to infect one cell by eGFP expression 
(293tlU) or TaqMan qPCR for the lentiviral insert (qPCR) (materials and 
methods section 2.3.3).
(c) Graph illustrating the determination of viral titre by expression in 293t cells. 
The percent of cells eGFP positive (determined by FACS analysis) was 
measured after infection of 2 x 105 293t cells with serial 10-fold dilutions of 
viral vector. The dilution was performed such that all wells had 1ml of medium 
added and the equivalent amount of lentiviral vector ranged from 0.01 to 10 
pi. The titre was determined by the formula (see materials and methods
2.3.3.2 for derivation)
293tlu/ml = (No. of cells infected x (y2-y1)) /100  x (x2-x1)
where (x1 ,y1) and (x2,y2) are any two points on the line of best fit through the 
linear region of infection (blue line on Fig 3.2c)
(d) Graph representing the absolute copy number of the lentiviral vector per 
cell determined by qPCR and percent of cells eGFP positive by FACS 
analysis 48 hours after infection of 1 x 105 293t cells with MOI of lentiviral 
vector ranging from 1 to 20.
- 1 3 7 -
3.3 Production of lentiviral vectors
Production of virus involves transfection, production and harvest. To produce 
the highest titre virus, all 3 factors were optimized. The optimum transfection 
method, quantity of medium for production and length of time before harvest 
was investigated.
Calcium phosphate, PEI and lipid based reagents are popular methods of 
transfecting cells. These methods were assessed in terms of their efficiency 
at infecting a population of 293t cells. It was found that FuGene gave higher 
transfection efficiency in 293t cells than calcium phosphate or PEI (Fig 3.3a). 
FuGene also required less plasmid.
Production and packaging of virions involves production of viral proteins in 
the appropriate quantities. A single rate limiting step could decrease the 
optimum titre. Production of virus requires expression of proteins from 3 
plasmids. These plasmids encode the HIV-1 genome (p8.91 or p8.2), the 
VSVG envelope (pVSVG) or the gene of interest (pSIN- or pHR-). The 
optimum ratio of plasmids for virion production was determined (Fig 3.3b). 2 
micrograms p8.91, 2 micrograms pVSVg and 3 micrograms of pSIN vector 
using a 3:1 ratio of FuGene:DNA was chosen for future experiments.
Virions in the medium are constantly being produced and degraded. The half 
life for pseudotyped virions at 37°C is low (Strang et al., 2004). The rate of 
production has been optimized, and the rate of breakdown cannot readily be 
altered. As with all equilibria, the final concentration will be a balance 
between synthesis, degradation, and the volume of the medium. Decreasing 
the volume of the medium while keeping the rate of synthesis and 
degradation constant should increase the concentration of the virus 
produced.
Most experiments culture 293t cells in 10 to 20 mis of medium for harvesting. 
The effect of using smaller volumes for virus production was investigated. It
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was found that 8mls of culture medium gave the optimum titre while 
preserving the health of the 293t cells (Fig 3.3c).
Protocols described in previous reports indicate that the culture should be left 
for 60 to 96 hours between transfection and harvest. No rationale for this was 
found, however. The optimum and maximum length of time between 
transfection and harvest of virus was therefore determined. These data 
indicate that virus can be harvested as early as 36 hours after transfection, 
although 48 hours gives the optimum titre. Virus production can remain stable 
for 96 hours after transfection, and so a harvest anywhere within these time 
limits (48-96 hours) will give acceptable yields (Fig 3.3d).
These data indicate that optimization of protocols for viral production can 
yield titres of up to 2 x 108 293tlU per ml. This is significantly higher than 
many published reports, which require concentration of supernatant to 
achieve titres of this order of magnitude.
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Figure 3.3 Production of lentiviral vectors
(a) Graph assessing transfection efficiency of FuGene, Calcium phosphate 
and PEI on 293t cells. pSIN-CMV-eGFP was transfected into 5 x 106 293t 
cells in a 10cm plate format in quantities from 1 to 10 pg. The protocols for 
transfection were in accordance with the manufacturers recommendations 
(FuGene) or published protocols (see materials and methods 2.3.1). The 
percent of cells eGFP positive was determined by FACS analysis 24 hours 
after transfection. Experiments were performed in triplicate and error bars 
indicate the standard error of the mean of this experiment.
(b) Graph showing the final titre produced by altering the ratio of plasmids for 
viral production. 5 x 106 293t cells were transfected with FuGene, pVSVg, 
p8.91 and pSIN-CMV-eGFP as in (a). Virus was harvested after 60 hours and 
the titre estimated by eGFP expression in 293t cells (Chapter 3.2).
(c) Table indicating the final titre of virus (in 293tlU) after transfection of 5 x 
106 293t cells in a 10cm plate with FuGene, 3 pg pSIN-CMV-eGFP, 2 pg 
pVSVg and 2 pg p8.91. 4 hours after transfection, the medium was changed 
and the amount of DMEM (in mis) shown added to the cells. After a further 48 
hours, the health of 293t cells was assessed visually according to the 
presence of cells or cell debris floating in the medium. indicates > 50 cells 
in medium not adhered to the plate visible in each 200x magnification view.
indicates between ten and fifty cells in medium not adhered to plate visible 
in each 200x view, and V s  ‘ indicates less than ten cells in medium not 
adhered to plate were visible.
(d) Graph showing the final titre (in 293tlU) of lentiviral vector produced as in
(c) with 8mls of DMEM. Medium was changed after 4 hours, and virus was 
harvested after the time indicated on the x axis. After harvesting, virus was 
frozen at -80°C until the end of the experiment when the titration was
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performed. Experiment was performed in duplicate and the error bars indicate 
the standard error of the mean.
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3.4 Elements enhancing transgene expression in primary and stem cells
Many primary and stem cells are refractory to transfection. There have been 
reports however that these cells can be transduced by viral vectors, and there 
is evidence that lentiviral vectors may be particularly suited to this task 
(Demaison et al., 2002). Additional elements may however be required to 
achieve efficient infection (see section 1.3.2.4).
The ability of lentiviral vectors based on the pHR or pSIN backbones to infect 
primary and stem cells was tested. Vectors encoding the enhanced green 
fluorescent protein (eGFP) expressed from the CMV promoter were chosen 
(Fig 3.2a). An MOI of 5 293tlU/cell was chosen for this experiment as Chapter 
3.2 showed this was sufficient to saturate infection in 293t cells. These 
vectors were capable of transducing primary cells and some adult stem cells 
(Fig 3.4a and b), with no significant difference between the two vectors. Fig 
3.4b indicates that HSC are not easily infected with the lentiviral vectors. 
Since self inactivating vectors have been proposed to be safer the pSIN 
backbone was used for further experiments.
The CMV promoter expresses well in adherent cells, but not in suspension 
cells. The lack of expression in HSC could be due to low infection rates in 
addition to the inability of the CMV promoter to express.
A more suitable promoter which would express in HSC was required. To 
investigate this, different promoters were cloned into a pSIN backbone. The 
EF1a (Ma et al., 2003) and SFFV promoter (Demaison et al., 2002) have both 
been used in stem cells and so were chosen here.
The expression of these vectors (pSIN-EF1a-eGFP and pSIN-SFFV-eGFP, 
Fig 3.4c) in HSC, MSC and DMVECs was determined. As these vectors may 
show promoter dependent eGFP expression in 293t cells, the titres of the 
samples were equalized by TaqMan qPCR before infection. Expression in
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HSC was low with all promoters, although these results are difficult to 
interpret given the low infection rate of the lentiviral vector (Fig3.4d). The 
SFFV promoter was the most versatile, showing expression in all tested cells 
and was therefore used for further experiments.
Several elements to enhance infection or expression have been used in both 
primary and stem cells (Demaison et al., 2002; Gropp et al., 2003; Ma et al., 
2003). To show the benefits of these elements in this lentiviral system, the 
cPPT or WPRE (cloned by PCR from pCSGW) were added either together or 
individually to a pSIN-SFFV-eGFP backbone. The infection and expression of 
these vectors in MSC, HSC and DMVEC was assessed by qPCR (Fig 3.4e) 
and FACS (Fig 3.4f).
It was found that the cPPT marginally enhanced infection but not expression 
levels, the WPRE enhanced expression but not infection in primary and stem 
cells. This confirms previous reports regarding these elements (Demaison et 
al., 2002; Ma et al., 2003), and for further experiments a pSIN-SFFV vector 
containing both the cPPT and the WPRE was used.
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Figure 3.4 Elements enhancing transgene expression in primary and stem
cells
Unless otherwise stated in this experiment, all viruses were produced with the 
FuGene protocol (see section 2.3.1 and Chapter 3.3).
(a) Graph indicating the percent of DMVEC, MSC or HSC eGFP positive by 
FACS analysis after infection of 1 x 104 cells with an MOI of 5 293tlU/cell of 
pHR-CMV-eGFP or pSIN-CMV-eGFP. FACS analysis was performed 72 
hours after infection.
(b) Graph of qPCR analysis for the lentiviral insert of experiment performed in
(a) showing the lentiviral copy number per cell.
(c) Diagram of pSIN-EF1a-eGFP (top) and pSIN-SFFV-eGFP (bottom) 
showing the change in promoter from pSIN-CMV-eGFP
(d) Table showing the mean fluorescence intensity determined by FACS 
analysis of 293t cells, DMVEC, MSC and HSC infected with pSIN vectors 
expressing from the CMV, EF1a or SFFV promoters at an MOI equivalent to 
5 293tlU/cell (as the titre was determined by qPCR, this figure is an 
approximate equivalent only). FACS analysis was performed 72 hours after 
infection.
(e) Graph indicating the effect of adding the cPPT, WPRE or both to the 
pSIN-SFFV-eGFP backbone. Lentiviral copy number per cell was determined 
by TaqMan qPCR for the lentiviral insert 72 hours after infection of DMVEC, 
MSC or HSC with an MOI of 5 293tlU/cell of the virus indicated in the legend. 
The experiment was performed in triplicate and the error bars indicate the 
standard error of the mean.
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(f) Graph showing the mean fluorescence intensity of the cells from the 
experiment performed in (e).
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3.5 Enhancing infection
Infection rates in MSC and HSC are significantly lower than those achieved 
with 293t cells. Methods to enhance infection were investigated. In some 
cells, cell cycle progression is necessary for infection (Korin and Zack, 1998). 
These cells may benefit from a longer incubation with virus. Infection rates 
can also be enhanced with polybrene. Infecting cells in ‘suspension’ has also 
been tried (Clements et al., 2006). A lower MOI was used here than in the
previous experiment to allow the effects of any enhancement to infection to
be seen more clearly.
The effects of incubation with polybrene at 1, 4 and 10 pg/ ml on infection 
rates in DMVEC, MSC and HSC was investigated. Polybrene has a positive 
effect on infection in HSC, but a more marginal effect on MSC and DMVEC 
(Fig 3.5a).
To determine whether those cells which do not show a shift in fluorescence 
are uninfected or are not expressing, the infected populations of HSC, MSC 
and DMVEC were sorted by FACS and tested for the presence of the 
lentiviral insert by qPCR. These data indicate that even at high MOI, cells not 
expressing are not infected (Fig 3.5b).
HSC are slowly dividing and any given population will also contain a
proportion of quiescent cells. They might therefore benefit from an incubation 
longer than 4 hours. The incubation time was determined as the time 
between addition of virus to medium and changing the medium. 293t, MSC, 
HSC and DMVEC were incubated for between 1 hour and 24 hours with viral 
vector. Medium on stem cells needs to be changed every day, so longer 
incubations were not feasible. The length of incubation was found to be 
critical in some cells, but not in others. 293t cells could efficiently be infected 
with incubations as short as 1 hour, whereas primary and stem cells required 
8-16 hours for optimum infection. Overnight incubation only enhanced
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infection rates for stem cells (Fig 3.5c). All further infection for stem cells were 
therefore carried out overnight.
Infecting adherent cells directly after trypsinisation and before plating was 
found to provide high infection rates. Infections performed in this manner 
showed that at an MOI of 5, 95% of DMVEC and 92% of MSC could be 
infected (Fig 3.5d).
It was noted from experiments involving high MOI that cellular morphology 
changed and cell doubling time increased. The effect on cell doubling time 
and BrdU uptake after infection was assessed in 293t cells, MSC, HSC and 
DMVEC. An increase in cell doubling time and decrease in BrdU uptake was 
seen with MOI above 10 in all cell types (Fig 3.5e-f). These results were not 
easily explained. Viral infection should not cause such a dramatic increase in 
cell doubling time after 7 days. It is possible that these cells are showing this 
decrease in cell doubling time because of the effects of handling and 
trypsinisation, although this would not explain why there was no effect in 
control cells (uninfected). These data may also be counting apoptosing or 
dead cells. RT-PCR for interferon responsive genes or a gene expression 
microarray would be useful in these cells to determine whether this is an 
interferon response, an apoptotic process or a previously undescribd effect of 
viral infection.
These data therefore indicate that care needs to be taken to ensure that the 
minimum amount of virus required to reach the desired expression level is 
used.
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Figure 3.5 Enhancing Infection
(a) Graph showing the lentiviral copy number per cell determined by TaqMan 
qPCR analysis of 1 x 104 DMVEC, MSC or HSC in a 6 well plate incubated 
with pSIN-SFFV-eGFP at an MOI of 2 293tlU/cell and the concentration of 
polybrene indicated in the legend. Medium was changed after 4 hours, and 
analysis performed after 72 hours. Experiment was performed in triplicate and 
the error bars indicate the standard error of the mean.
(b) Graph showing the lentiviral copy number per cell of 1 x 104 DMVEC, 
MSC and HSC infected with an MOI of 2 293tlU/cell of pSIN-SFFV-eGFP. 
Cells were infected for 4 hours, the medium changed and after 72 hours were 
sorted using Mo-Flo FACS for fluorescence intensity. Sorted (+ve) indicates 
those cells which fluoresced significantly above the background level 
(determined by uninfected cells). Sorted (-ve) indicates the population which 
fluoresced at levels comparable to uninfected cells. Experiment was 
performed in triplicate and the error bars indicate the standard error of the 
mean.
(c) Graph showing the lentiviral copy number per cell determined by TaqMan 
qPCR analysis of 1 x 105 293t cells, and 1 x 104 DMVEC, MSC and HSC 
infected at an MOI of 2 293tlU/cell of pSIN-SFFV-eGFP and incubated with 
virus for the time indicated in the legend. After this time, medium was 
changed and analysis was performed after a further 72 hours. Experiment 
was performed in triplicate and the error bars indicate the standard error of 
the mean.
(d) Graph showing the lentiviral copy number per cell determined by TaqMan 
qPCR analysis of 1 x 104 DMVEC, MSC and HSC infected at the MOI 
indicated in the legend of pSIN-SFFV-eGFP. Cells were incubated with virus 
for 4 hours, medium was changed and analysis performed after a further 72 
hours. Experiment was performed in triplicate and the error bars indicate the 
standard error of the mean.
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(e) Graph showing the cell doubling time in days of 1 x 105 293t cells, and 1 x 
104 DMVEC, HSC and MSC infected with the MOI indicated on x axis of 
pSIN-SFFV-eGFP. Cells were incubated with virus for 4 hours and then the 
medium changed. Analysis of cell doubling time (see materials and methods 
2.2.9) was performed 7 days after infection.
(f) Graphs of BrdU uptake (see materials and methods 2.2.12) of cells from 
experiment performed in (e).
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3.6 Stable transgene expression
MSCs have the ability to differentiate into many cell types, notably adipocytes, 
chondrocytes and osteocytes. Conditions that stimulate the differentiation of 
rat, mouse and human MSCs into these lineages have been established. 
Differentiation of HSC is possible in the laboratory, although little is known 
about these pathways. It is not currently possible to grow human HSC in an 
undifferentiated state.
The ability of MSC’s cultured in our laboratory to differentiate into adipocytes 
and osteocytes was assessed. Conditions previously shown to be efficient at 
inducing differentiation were used (Pittenger et al., 1999). After differentiation, 
oil red O or alkaline phosphatase staining was performed. Oil red O staining 
indicates lipid deposition within cells and is considered to be a marker of 
adipocytic lineage. Alkaline phosphatase activity is considered to be a 
specific marker of osteocytic lineage. After culture for 28 days in medium 
stimulating differentiation, MSCs showed efficient differentiation (Fig 3.6a).
HSC derived by CD34 selection from bone marrow (Chapter 3.1) formed 
adherent cells which morphologically resembled endothelial cells after 14 
days in culture in EGM2-MV medium (Fig 3.6b). It was not possible to prove 
these cells to be endothelial cells as antibodies to markers which are present 
on endothelial cells but not HSC were not available at the time.
The ability of human MSC to differentiate after infection was determined. 
After differentiation of MSC into either adipocytes or osteocytes, these cells 
are difficult to remove from plates in culture for FACS analysis. Osteocytic 
differentiation was therefore chosen as it is possible to quantify the 
differentiation through colorimetric assessment of the cells at 405nm. Cells 
showed impaired ability to differentiate into osteocytes when the infectious 
MOI was above 20 293tlU/cell (Fig 3.6c). Reduction in adipocytic 
differentiation potential was also seen, although this effect proved difficult to 
quantify (data not shown). For further experiments an MOI of 5 293tlU/cell
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was chosen as this value has no significant effect on cell doubling time (Fig 
3.5e) or BrdU uptake (Fig 3.5f).
HSC infected with a lentiviral vector retained the ability to form cells which 
were morphologically consistent with endothelial cells. This ability was 
compromised by infection with high MOI (data not shown), however it is again 
not possible to assess this quantitatively.
It has been documented that in stem cells (most notably embryonic stem 
cells) a degree of silencing occurs when these stem cells are stimulated to 
differentiate after infection with viral vectors. Lentiviral integrations have been 
reported to be resistant to silencing, even in ES cells (Gropp et al., 2003). To 
investigate whether this was true of the lentiviral system employed in our 
hands, MSCs were infected with pSIN-SFFV-eGFP and stimulated to 
differentiate towards adipocytes and osteocytes. The expression of eGFP 
was analysed by fluorescence microscopy 28 days after stimulation (Fig 
3.6d). Oil Red O and alkaline phosphatase staining confirmed the lineage of 
these differentiated cells. HSC infected with the lentiviral vector and then 
cultured in EGM2-MV for 28 days also showed stable expression of eGFP by 
FACS analysis after differentiation (Fig 3.6e).
Long term expression without differentiation in MSCs was assessed. MSCs 
were infected with pSIN-eGFP and cultured until the cells entered 
senescence. The cells continued to express eGFP throughout their entire 
lifespan (15 passages, Fig 3.6f). HSC cannot be cultured without 
differentiation, and so this assay could not be performed with HSC.
These data indicate the robustness of expression from this lentiviral system. 
Stem cells can be efficiently infected, and they maintain this expression both 
in the undifferentiated state and when stimulated to differentiate. Using 
optimized infection protocols, over 90% of cells can be infected without 
compromising differentiation potential.
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Figure 3.6 Stable transgene expression
Unless otherwise stated, the lentiviral vector for these experiments was pSIN- 
cPPT-SFFV-eGFP-WPRE and the cells were incubated overnight with the 
vector.
(a) Light microscopy of MSCs stimulated to differentiate into adipocytes (top), 
osteocytes (middle) or unstimulated (bottom). No staining was performed in 
the left hand column, an oil red O stain for lipid droplets (a marker of 
adipocytic lineage) in the middle column and alkaline phosphatase activity 
assay (marker for osteocytic lineage) in the right hand column. See materials 
and methods section 2.2.8 for differentiation conditions.
(b) Light microscopy of HSCs selected from human bone marrow by CD34 
expression and grown in EGM2-MV for 14 days. Cells were diluted into 
EGM2-MV at a density of 1 x 105 live CD34 +ve cells per ml in 4 mis of 
medium in a 6 well plate. Live cells were determined by trypan blue staining 
(see materials and methods 2.2.1).
(c) Graph indicating the absorbance at 405 nm (A405) determined by 
colorimetry. The absorbance at 405 nm indicates the expression of alkaline 
phosphatase and therefore is a quantitative measurement of the amount of 
osteogenic differentiation. MSC were infected with the MOI shown. Medium 
was changed the morning after infection for one stimulating differentiation into 
osteocytes. A405 was measured after 28 days.
(d) Phase (left), green fluorescence (middle) and stain (oil red O, top right and 
alkaline phosphatase, bottom right) microscopy of MSC infected at an MOI of 
5 293tlU/cell and cultured for 28 days in conditions promoting adipocytic (top) 
or osteocytic (bottom) differentiation.
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(e) FACS analysis of human CD34 +ve HSC infected with an MOI of 5 
293tlU/cell of lentiviral vector in the presence of 4 pg/ml polybrene 48 hours 
after infection (top) and after 14 days in culture in EGM-2MV (bottom).
(f) FACS analysis of MSC infected with an MOI of 5 293tlU/cell of lentiviral 
vector at passage 4 and cultured until cell senescence (around passage 15). 
FACS analysis was performed at passage 6 (7 days after infection, top) and 
at passage 15 (8 weeks after infection, bottom).
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3.7 Bicistronic expression in stem cells
Many applications for lentiviral systems call for the expression of more than 
one transgene, or the expression of an additional marker gene. Methods for 
this include the use of dual promoter and IRES expression systems. My 
previous results with different promoters in stem cells (Chapter 3.4) imply that 
it might be difficult to find two different promoters which would reliably express 
in stem cells. It was therefore decided to investigate the production of both a 
generic IRES expression system for multiple transgene expression and an 
IRES expressing an antibiotic resistance cassette for selection.
The EMCV IRES was chosen as this IRES has previously been shown to 
require fewer cellular cofactors than early IRES (Borman et al., 1994) and 
offer strong expression (Jang and Wimmer, 1990), however this IRES still 
requires some cellular factors. Initial assessment was performed with a 
construct expressing both dsRed and eGFP (Fig 3.7a). The expression levels 
of both these proteins can be measured by FACS analysis as eGFP 
represented on FL1-H, and dsRed on FL2-H.
The expression in 293t, DMVEC, HSC and MSC with pSIN-RIG was 
assessed. Infection at an MOI of 2 showed expression of both dsRed and 
eGFP in 293t cells and DMVEC, although dsRed expression levels in stem 
cells was found to be low (Fig 3.7b). An MOI of 2 293tlU/cell was chosen to 
allow small differences in the expression between 293t and stem cells to be 
more clearly visible. Strong bleed of FL1-H levels into FL2-H was found 
during calibration of the FACS machine. All measurements of FL2-H have 
therefore been compensated to allow for FL1-H bleed. This was performed 
using a filter plug-in for the FACSCalibur software.
Expression of the 3’ gene (eGFP) is controlled by ribosomal entry at the site 
of the IRES. This is the cofactor dependent step, and so the lack of 
expression of the 5’ gene (dsRed) could not be readily explained by a lack of
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these factors. There is little indication in literature as to why this may be, 
although a report (Baird et al., 2000) suggested that premature termination of 
translation of dsRed prevents tetramer formation and may yield a non- 
fluorescent protein. A 50 base pair linker sequence was added to the 3’ end 
of the dsRed gene in case premature termination of transcription was 
occurring (Fig 3.7c). Infection of stem cells with this construct significantly 
enhanced expression of dsRed (Fig 3.7d).
To determine whether the expression of the 3’ gene (eGFP) could be used as 
an indicator of the strength of expression of the 5’ gene (dsRed) in MSC, 
FACS analysis was used to link expression after infection with pSIN-RIG+. In 
an infected population, cells expressing eGFP also expressed dsRed, and 
these data imply that the strength of expression of the two genes is directly 
proportional (Fig 3.7e).
In order to facilitate production of pure populations expressing a protein at low 
MOI, a resistance cassette can be used. Selection after infection is 
particularly desirable since adverse effects of infection with high MOI has 
already been shown (Fig 3.5). A commercially available neomycin resistance 
cassette (Clontech, California, USA) was cloned by PCR into the 3’ transgene 
location and eGFP into the 5’ transgene location to create pSIN-eGFP-IRES- 
Neo (Fig 3.7f). Infection of both 293t cells and MSC with a low MOI of this 
vector yielded a population which initially expressed low levels of eGFP, 
however after 7 days in culture with neomycin showed almost 100% of the 
cells to be eGFP positive (Fig 3.7g).
These data indicate that IRES systems can offer a simple method of 
expressing multiple genes from a single lentiviral vector. This can be used for 
complex gene expression or production of a pure population of cells 
expressing a transgene through the use of a resistance cassette. These data 
also indicate that the strength of expression of the 3’ gene is an indicator of 
the strength of expression of the 5’ gene.
- 1 6 5 -
HS
C 
MS
C 
DM
VE
C 
29
3t
Figure 3.7 Bicistronic expression in stem cells
5 ’- LTR cPPT SFFV clsRed [RES eGFP LTR -3 ’
Uninfected Infected
i o* 10
FL1-H FL1-H
MFI
FL1-H
MFI
FL2-H
Before 3.3 4.2
After 334.2 221.6
FL1-HFL1-H
MFI
FL1-H
MFI
FL2-H
Before 2.3 3.5
After 211.5 196.1
mtt- - . rTT-n.,
10* 1 r
FL1-HFL1-H
MFI
FL1-H
MFI
FL2-H
Before 4.1 3.7
After 81.4 10.1
FL1-HFL1-H
MFI
FL1-H
MFI
FL2-H
Before 3.24 4.16
After 57.2 9.6
-166-
HS
C 
MS
C 
DM
VE
C 
29
3t
Figure 3.7 Bicistronic expression in stem cells
5 ’- cPPT SFFV dsRed 1 IRES eGFP - 3 ’
Uninfected Infected
o
CO
o
CM Oa! ~R2
o
ao
FL1-HFL1-H
MFI
FL1-H
MFI
FL2-H
Before 4.11 4.27
After 351.3 268.4
R2
FL1-HFI1-H
MFI
FL1-H
MFI
FL2-H
Before 3.41 2.96
After 302.7 254.1
R2
■mff
FLJ-HFL1-H
MFI
FL1-H
MFI
FL2-H
Before 3.5 4.01
After 195.2 152.8
FL1-H FL1-H
MFI
FL1-H
MFI
FL2-H
Before 4.28 3.88
After 110.1 96.4
-167-
Figure 3.7 Bicistronic expression in stem cells
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Figure 3.7 Bicistronic expression in stem cells
Figure 3.7 Bicistronic expression in stem cells
Unless otherwise stated, infection was performed by incubating cells with 
virus overnight and changing medium in the morning. HSC were infected in 
the presence of polybrene at a concentration of 4 pg/ml. Analysis was 
performed 72 hours after infection.
(a) Diagram of the lentiviral vector pSIN-cPPT-SFFV-Red-IRES-eGFP-WPRE 
(pSIN-RIG). LTR - long terminal repeat; cPPT- central polypurine tract; SFFV- 
spleen focus forming virus; IRES- internal ribosomal entry site; eGFP- 
enhanced green fluorescent protein
(b) FACS analysis as x-y plots and table of mean fluorescence intensity (MFI) 
of 293t cells, DMVEC, MSC and HSC infected at an MOI of 2 293tlU/cell with 
pSIN-RIG. The xy plots indicate FL1-H (green fluorescence) and FL2-H (red 
fluorescence, compensated for green fluorescent bleed, see materials and 
methods 2.2.15). The left hand column indicates uninfected cells, and the 
middle column infected cells. The tables (right hand column) show the MFI of 
FL1-H (green) in the left hand column and FL2-H (red) in the right hand 
column, before (top row) and after (bottom row) infection. Results indicate 
that dsRed is not being expressed strongly in MSC and HSC.
(c) Diagram of the lentiviral vector pSIN-cPPT-SFFV-Red-linker-IRES-eGFP- 
WPRE (pSIN-RIG+). The 50 bp linker is indicated as a black box.
(d) FACS analysis as x-y plots and table of mean fluorescence intensity (MFI) 
of 293t cells, DMVEC, MSC and HSC infected at an MOI of 2 293tlU/cell with 
pSIN-RIG+. The xy plots indicate FL1-H (green fluorescence) and FL2-H (red 
fluorescence, compensated for green fluorescent bleed, see materials and 
methods 2.2.15). The left hand column indicates uninfected cells, and the 
middle column infected cells. The tables (right hand column) show the MFI of 
FL1-H (green) in the left hand column and FL2-H (red) in the right hand 
column, before (top row) and after (bottom row) infection. The MFI of FL2-H
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indicate that fluorescence on both axes is detectable in both 293t and stem 
cells after inclusion of the 50bp linker.
(e) FACS analysis of MSC after infection with an MOI of 5 293tlU/cell of pSIN- 
RIG+. The top two plots indicate eGFP expression in these cells (top 
uninfected, bottom infected) and show the four gates for fluorescence on FL1- 
H (G1-4). The fluorescence on FL2-H (dsRed expression compensated for 
eGFP bleed) for cells within gates G1-4 are shown in the bottom four graphs. 
These data indicate that the strength of expression of eGFP can be used as 
an indicator of the strength of expression of dsRed, an vice-versa.
(f) Diagram of pSIN-cPPT-SFFV-eGFP-linker-IREs-Neo-WPRE (pSIN-eGFP- 
Neo)
(g) FACS analysis of 293t cells (top) and MSC (bottom) infected with pSIN- 
eGFP-Neo at an MOI of 1 293tlU/cell. Cells were then cultured for 7 days 
either normally, or in medium containing 10 pg/ml neomycin sulphate. FACS 
analysis after this time indicated that the population of cells grown in 
neomycin (green line) showed a shift in fluorescence to the right when 
compared to cells grown in normal medium (red line). This shows a selection 
pressure favouring eGFP expression through the presence of the neomycin 
resistance cassette.
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3.8 Vector safety for in vivo use
Stem cells have wide ranging applications both in vitro and in vivo (Clements 
et al., 2006). Lentiviral vectors broaden the scope of these cells, however 
before these vectors can be used in vivo, there needs to be significant 
advances in both the technology and the availability of data regarding the 
safety and long term effects of these vectors.
The in vivo safety of these vectors involves key issues surrounding the fact 
that they contain genetic information from HIV-1. The production of replication 
competent lentiviruses (RCL) would lead to replication in the host. This may 
potentially cause immunodeficiency, and represents the construction and 
release of a new human pathogen. Recombination or release of integrated 
transgenes because of coinfection with wild type virus is a concern. This 
could allow the production of a transmissible viral progeny containing 
genetically modified components. The possibility of insertional mutagenesis 
from the action of reverse transcriptase and integrase in these vectors has 
recently been raised (Themis et al., 2005). Finally, germ line mutations are of 
concern. In order to develop a ‘cure’ for a genetic disease, this is a necessary 
step however the effects on future generations is not well understood.
It is possible to test some of the concerns regarding the safety of these 
vectors. The experiments here are based upon previous investigations into 
lentiviral safety (Bukovsky et al., 1999).
The presence of RCL can be determined by infecting large numbers of cells 
with virus and determining their ability to pass on the expression of 
transgene. RCL would make cells produce new virions, so the medium in 
which cells infected with RCL are cultured in would also contain virions.
100 plates of 293t cells were infected at an MOI of 10 with pSIN-cPPT-SFFV- 
eGFP-WPRE (a total of 1010 293tlU). After 48 hours, the medium was 
changed to remove any residual virus and then after a further 48 hours the
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medium harvested and placed in culture with uninfected 293t cells. Any RCL 
in the first batch of virus would result in virions in the medium, which would 
give expression in the second batch of cells.
FACS analysis of these cells after 48 hours showed no expression of eGFP 
(Fig 3.8a). These data indicate that there was no production of RCL, and 
therefore that the rate of RCL production is < 1 per 1 x 1010 293tlU.
The release of transgenes from both the pHR’ and pSIN vectors was also 
assessed by coinfection of MOLT-4 cells with wild type HIV-1 (Fig 3.8b).
The results imply that transgenes delivered by the pHR vector are capable of 
mobilization by wild type HIV-1. The pHR backbone was much more subject 
to recombination than the pSIN backbone as determined by the mobilization 
of infectious virions encoding eGFP. Much larger scale experiments would be 
required to assess this accurately (Fig 3.8c). The release of a single GFP 
positive event from the pSIN backbone could be a lentivirion remaining in 
culture after medium change.
These data indicate that 3-plasmid production systems produce safe vectors 
with very low RCL rates. This would be expected due to the absence of much 
of the HIV-1 genome from the plasmids. It is also shown here that lentiviral 
vectors can be mobilized after infection, but that deletions in the LTRs of 
pSIN vectors make them safer than pHR vectors in the presence of wild type 
HIV-1.
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Figure 3.8 Vector safety for in vivo use
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Figure 3.8 Vector safety for in vivo use
(a) Experiment to demonstrate that pSIN vectors in 3-plasmid transfection 
systems produce undetectable quantities of RCL. 100 plates of 1 x 107 293t 
cells were infected at an MOI of 10 of pSIN-SFFV-eGFP (a total of 1010 
293tlU). After 48 hours, the medium was changed to remove any residual 
virus and then after a further 48 hours the medium harvested and placed in 
culture on 100 plates of uninfected 293t cells (1 x 107 cells/plate). After 72 
hours, FACS analysis of uninfected 293t cells (top), 293t cells from the first 
infection (infected with vector) (middle) and of 293t cells infected with 
supernatant harvested from infected cells (bottom) showed that infected 293t 
cells produced no further infectious virion. FACS analysis was performed by 
trypsinising all 100 plates and analyzing 107 cells from each batch.
(b) Diagram of the protocol employed to demonstrate the ability of wild type 
virus to mobilize the lentiviral vector. SF2 and MN9 cells are HIV-1 positive T 
cell lines which produce infectious HIV-1 in the medium. MOLT4 cells are a 
HIV negative T cell line.
(c) Results for experiment detailed in (b). Medium from MOLT4, SF2 or MN9 
cells was harvested (1st cell). MOLT4 cells were either infected with an MOI of 
5 293tlU/cell of pHR-CMV-eGFP, pSIN-CMV-eGFP or left untreated (2nd cell). 
72 hours after the 2nd cells were infected with lentiviral vector, medium from 
the 1st cell (HIV-1 +ve SF2, HIV-1 +ve MN9 or HIV-) was added to uninfected 
or infected MOLT4 cells. After a further 72 hours, medium from these second 
cells was harvested and used to infect new MOLT4 cells (3rd cell). After 72 
hours, these cells were fixed and analysed for eGFP expression by FACS 
analysis (right hand column). These results indicate that superinfection of wild 
type HIV-1 on cells already infected with a lentiviral vector can result in 
mobilization of the transgene. These data also show that the pSIN backbone 
is far more difficult to mobilize than the pHR backbone.
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3.9 Discussion and conclusions
In this chapter, I show that human adult stem cells can be isolated from 
human bone marrow using a simple protocol and that MSC can remain 
undifferentiated in culture. Conditions which maintain HSC in culture without 
differentiating are not currently known, however cells which match the 
immunophenotype of human HSC could be isolated from bone marrow 
samples.
Quantification of virions was a major concern in this chapter. Although the 
293tlU is an established method for quantification of virus, this cannot be 
used for viruses which do not express a marker. Viruses which express eGFP 
under the strength of different promoters can yield different figures based on 
the strength of expression. There is also the possibility that the vector 
passively transfers eGFP protein, resulting in a high measured titre (Nash and 
Lever, 2004). Waiting 96 hours instead of 48 hours after infection to measure 
eGFP titre would minimize this effect.
The use of p24 concentration to determine titre is also widespread, however 
this method was shown to be unreliable in my hands. The p24 assay is reliant 
on a standard curve to estimate the number of virions. It does not indicate the 
infectious ability of the virions, just the presence of p24. TaqMan qPCR is a 
relatively novel technology for quantification of copy number of DNA. This 
makes the technology ideal for the purposes of assessing viral titre. 
Unfortunately, my results indicated that several copies of the viral DNA were 
present in every expressing cell.
One possible explanation for overestimation of the titre is the measurement of 
non-integrated DNA present after the RT step but not integrated into the host. 
This would be detected by qPCR but not by p24 or by measuring eGFP 
expression. This effect could be reduced by leaving cells for longer than 72 
hours after infection, by which time free DNA would be degraded. Although
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this is a possible source of error, I do not think that this effect would be 
significant enough to account for my results.
Although it is possible that not every copy of the virus expresses, that several 
copies are required to represent 1 293tlU, or that non-integrated DNA is 
being measured it is more likely that my standards were incorrect or that my 
PCR reaction conditions were not fully optimized.
As I was chiefly using this method to convert viral titres into equivalent 
293tlU, it was not necessary for me to determine the absolute number of viral 
copies per cell. Controls within my experiments indicated that my results were 
reproducible and that my standard appeared to be correct. I would like to 
have investigated this further, perhaps by producing a cell line which was 
known by fluorescence in-situ hybridization (FISH) or genomic Southern blot 
to contain 1 or 2 copies of the lentiviral vector and recalibrating my assay 
using this cell line as a standard.
The production of high titre lentiviral vectors remains an obstacle to 
overcome. The protocol for producing vector is still based upon early 
references (Naldini et al., 1996b). These publications do not indicate the 
rationale for the protocols chosen. These conditions were therefore 
investigated, and it was found that optimization of harvest time, quantity of 
medium and ratio of packaging plasmids would regularly yield high titre (>108 
293tlU/ml) virus. This is considerably higher than most publications using 
lentiviral vectors, and demonstrates the necessity for optimization of systems 
in individual hands rather than blind use of conditions from previous 
publications.
Both adult stem and primary endothelial cells could be infected with a 
lentiviral vector. Chapter 3.4 shows evidence for the use of additional 
elements such as the cPPT and WPRE to enhance infection and expression 
in primary and stem cells.
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An important observation of the effect of lentiviral infection on stem cells was 
made. The disturbance of the growth rate of these cells from infection even 
with a low MOI of virus was marked. This effect is not often reported in 
publications involving lentiviral vectors, and most experiments using these 
vectors do not consider the potential for the vectors to disturb cell growth.
Although the disturbance at low MOI is slight in cell lines, it is greater in stem 
cells and therefore the possibility of greater implications for experiments using 
these methods needs further investigation. Microarray analysis of infected 
cells may yield more information about which genes and cellular pathways 
may be responsible for this. It is possible that this effect is either due to 
overexpression of a foreign gene or a transient antiviral response, or it may 
be a longer lasting effect of integration of foreign genetic material.
The data presented here indicate stem cells can continue to differentiate 
normally after infection with low MOI. This would seem to support a more 
transient response to infection, although the detrimental effects on 
differentiation after infection with MOI above 20 293tlU/cell would indicate 
permanent damage from the infection process. These data warrant much 
more detailed investigation of the pathways which are disrupted, however this 
is beyond the scope of this thesis. It was sufficient for me to demonstrate that 
at low MOI these cells can behave essentially normal.
Investigation of bicistronic expression shows that the lentiviral system can be 
used with an IRES to express two genes driven by the same promoter in stem 
cells. Although the data presented here show that stem cells can coexpress 
two fluorescent proteins, the requirement for compensation of eGFP bleed 
into FL2-H means that these data cannot be regarded as conclusive. It was 
very difficult, even with the assistance of the FACScalibur software, to 
separate these variables and this represents a weakness in my experiment. 
These data could be strengthened through the use of an alternative 
fluorescent protein such as the newer dsRed derivatives which have more 
defined excitation-emission spectra. Alternatively, quantitative analysis of
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protein expression through ELISA or quantitative Western blot analysis could 
have been performed. It was sufficient for my purposes to demonstrate that a 
resistance cassette could be used to establish a pure population expressing a 
transgene, however further investigation and conclusive evidence that the 
expression levels of these proteins are linked is something I would like to 
have performed as it adds to the value and utility of the vector.
The last results presented here show that the pSIN vector is much safer than 
the pHR based vectors. The pSIN vector is much less likely to recombine with 
and be mobilized by wild type HIV-1, although these vectors are equally 
unlikely to form RCL. This result was expected from the deletions in the LTR 
which make the vectors self-inactivating and confirm previous reports 
(Bukovsky et al., 1999).
Lentiviral vectors offer considerable advantages over other in vitro and in vivo 
systems. For expression systems in in vitro experiments, they offer 
transduction of cells which are difficult or impossible to transfect, and offer 
stable expression. Lentiviral vectors are more robust than retroviruses, 
especially in stem cells, and are as easy to produce as both adenoviral and 
retroviral vectors.
These data support the use of lentiviral vectors for future in vitro and in vivo 
work in our hands. We show that we can use these vectors with minimal 
disturbance to target cells. Recent gene therapy trials with retroviruses have 
revealed potential preferential integration sites for MoMLV in vivo, which 
raises the potential for lentiviral vectors to suffer from the same problems. I 
could have determined the frequency and sites of integration with the vectors 
I had produced using FISH and linear amplification-mediated PCR (LAM- 
PCR). This would have been a more complete extension of this work. I could 
also have confirmed via measure of the interferon responsive genes whether 
the interferon response was permanently upregulated in these cells. These 
data would be useful for clinical applications with these vectors.
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Despite the demonstration in published literature of the efficacy and ease of 
use that lentiviral systems allow, their use in vivo is underrepresented in 
scientific research. It is possible that lentiviral systems based on other viruses 
such as the feline immunodeficiency virus (FIV) or equine infectious anemia 
virus (EIAV) may be considered more suitable for in vivo applications since 
they are non pathogenic to humans, however these vectors show many of the 
same problems as HIV-1 based vectors. HIV-1 based vectors can be made 
more appealing for therapeutic applications by more thorough 
characterization of their effects in cells and more mainstream acceptance that 
HIV-1-based vectors are not HIV-1.
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Chapter 4:
Lentiviral delivery of RNA Interference 
Chapter Aims:
The aims of this chapter were to knockdown gene expression of endogenous 
and exogenous genes by expressing short hairpin RNA from a polymerase III 
promoter in a self inactivating lentiviral backbone (pSIN). It was also shown 
that this lentiviral expression system can deliver effective RNAi to cell types 
refractory to transfection and therefore not amenable to synthesized dsRNA.
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4.1 Evaluation of RNAi in cell lines using dsRNA
To assess a lentiviral system for delivery of shRNA, a validated target 
sequence and a cell line in which RNAi functions well is required. First, the 
efficacy of commercially available transfection reagents to transduce both 
adherent and suspension cell lines with a plasmid expressing eGFP was 
evaluated. The manufacturer’s guidelines were used (see materials and 
methods 2.4.2) and the percentage of cells which were eGFP positive 16 
hours after transfection was assessed by FACS analysis. All four tested 
reagents performed well in 293t and HeLa cells, however they all performed 
significantly worse in suspension and primary cells (Fig 4.1a). Oligofectamine 
was chosen for future transfections with dsRNA, as it transfected both 293t 
and HeLa cells and showed some ability to transfect human umbilical vein 
endothelial cells (HUVEC) and dermal microvascular endothelial cells 
(DMVEC).
A target sequence for eGFP was chosen to test the efficacy of RNAi based 
on criteria available from www.ambion.com (5’-GTTCATCTGCACCACCGGCAAGC- 
3’). dsRNA targeting this sequence was synthesised by Dharmacon. One of 
the problems with knocking down the expression of eGFP is the long protein 
half life in cells. To avoid this, a commercially available destabilized form of 
eGFP (deGFP) which has a significantly reduced half life in cells (< 6 hours, 
http://www.clontech.com/clontech/techinfo/vectors dis/pd2EGFP.shtml) when 
compared to wild type eGFP (half life of 26 hours (Corish and Tyler-Smith, 
1999)) was used to create a lentiviral construct (pSIN-deGFP). The sequence 
of deGFP was analysed to ensure the target sequence was present. Accurate 
assessment of the efficacy of RNAi is difficult to perform when infected cells 
demonstrate a broad range of expression levels, as happens during lentiviral 
infection. To avoid this, and hopefully detect a more readily visible shift, a cell 
population with a uniform expression level of deGFP was required. This could 
be achieved by cell sorting, or single cell cloning to develop a cell line. Cell 
sorting proved unreliable, and because of problems such as contamination of 
sorted cells and impure populations, it was decided that the best standard
- 183-
would be to generate a cell line expressing a uniform level of eGFP by a 
limiting dilution method.
293t and HeLa cells were infected with pSIN-deGFP at an MOI of 2. Several 
293t and HeLa cell lines were produced from an infected population by serial 
dilution of cells and plating in 96 well plates in conditioned medium. 
Conditioned medium was used as it was found that single 293t cells grew into 
colonies much faster in conditioned medium than when in DMEM (data not 
shown). The mixture was diluted such that each well should contain £1 cell. 
The colonies were split into 24 well plates when confluent. After a further 7 
days each colony was screened by FACS and those which displayed a 
defined homogenous eGFP expression were assumed to have originated 
from single cells. These clones were then tested to determine whether they 
were still amenable to transfection by introducing a LacZ-FLAG plasmid. Only 
2 293t lines (293t-D1 and 293t-D12) and 1 HeLa line (HeLa-D7) showed 
suitable FACS profiles and maintained transfection ability (Fig 4.1b) and were 
used for further investigation.
To determine the copy number of the lentiviral vector in these cells each 
clone was analysed using TaqMan qPCR for both the lentiviral insert and 
GAPDH (see materials and methods). This allowed the estimation of the 
number of copies of the insert per cell (Fig 4.1c). These data indicate that 
despite the low MOI, several copies of the lentiviral vector are present in each 
cell, however the number is sufficiently low it is unlikely to have any adverse 
affect on the cell.
Initial transfection of commercially synthesised dsRNA targeting eGFP into 
D12 293t cells, under conditions shown above to be effective, showed no 
significant silencing effect. The eGFP dsRNA did function in D7 HeLa cells 
producing a measurable silencing effect after 48 hours (Fig 4.1 d).
To determine whether eGFP dsRNA was failing to enter the 293t cells or 
whether the cells were not processing the dsRNA, FACS analysis of 293t
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cells after transfection with fluorescein tagged dsRNA molecules with the 
same sequence (gift from Sam Wilson, Windeyer Institute) showed that 
oligofectamine was able to deliver the dsRNA into 293t-D12 cells and 
therefore that delivery was not the cause of lack of function (Fig 4.1e). It was 
therefore concluded that in our hands 293t cells do not process dsRNA well 
for RNAi.
Several other groups have used 293t cells for research involving dsRNA and 
have found it to be functional. Other members of my laboratory confirm my 
results regarding 293t cells (Heike Laman, personal communication). I can 
offer no explanation of why this may be. For all further investigation of 
dsRNA, HeLa-D7 cells were chosen as they are both easy to culture and 
amenable to the effects of dsRNA.
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Figure 4.1 Evaluation of RNAi in cell lines using dsRNA
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Figure 4.1 Evaluation of RNAi in cell lines using dsRNA
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Figure 4.1 Evaluation of RNAi in cell lines using dsRNA
(a) Table showing the efficiency of 4 different commercially available 
transfection reagents (FuGene (Roche), Oligofectamine (Invitrogen), Transit 
(Mirus), and Effectine (Qiagen)) in different cell lines. Each reagent was 
tested as suggested by the manufacturer (See materials and methods section 
2.4.2 for details). 105 cells were transfected with 0.5 ng pCSGW (a plasmid 
expressing eGFP under the control of the SFFV promoter) under appropriate 
conditions. The medium was not changed after transfection. The next 
morning, each well was examined using FACS analysis to show the percent 
of cells which were eGFP positive. Each experiment was performed in 
duplicate and both sets of data shown.
(b) FACS analysis and Western blot analysis of cell lines assumed to 
originate from a single cell. For details of the method used to generate and 
test these single cell clones, see materials and methods section 2.2.16. Three 
clones 293t-D1, 293t-D12 and HeLa-D7 maintained transfection ability after 
single cell cloning. The narrow, defined band of eGFP expression (top) 
implies the presence of a population of cells which expressed a roughly equal 
level of eGFP and will allow more accurate quantification of knockdown.
(c) TaqMan qPCR for the lentiviral insert and GAPDH (see materials and 
methods) showing the number of copies of the insert per cell in cell lines 
produced in (b) compared to wild type 293t and HeLa cells. The analysis was 
performed in triplicate and the error bars indicate the standard error of the 
mean.
(d) Transfection of 400 nM of dsRNA targeting eGFP (Dharmacon) with 
oligofectamine (according to the manufacturers guidelines, see materials and 
methods) into 1 x 105 293t-D12 and HeLa-D7 cells. The purple population 
indicates the cells before transfection and the green overlay the cells 48 
hours after transfection. The mean fluorescence intensity (MFI) of each 
population is marked on the side of the FACS plot and indicates no significant
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knockdown in 293t-D12 cells and a significant knockdown of eGFP  
expression in HeLa-D7 cells.
(e) FACS analysis 24 hours after transfection of 400 nM of fluorescein tagged 
dsRNA targeting eGFP into 293t-D12 cells using oligofectamine in 
accordance with the manufacturers guidelines. The purple population indicate 
293t-D12 cells transfected with 400 nM of dsRNA targeting eGFP and no 
fluorescent tag. The green overlay represents 293t cells transfected with 
dsRNA with the fluorescein tag, and show a significant increase in mean 
fluorescent intensity (MFI).
- 189-
4.2 Comparison of polymerase III promoters for RNAi
Short hairpin designs transcribed from a polymerase III promoter have been 
shown to induce functional RNAi (Brummelkamp et al., 2002b; Sui et al., 
2002). These promoters have different cell type specificities and silencing 
requirements. As with all polymerase III promoters, they have motif 
dependent initiation of transcription. An example of this is the human U6 
promoter which begins RNA transcription faithfully after the sequence 
“GACCG”. The final guanine base pair is said to be the +1 base, and it is 
believed that altering this base pair abolishes RNA transcription. Polymerase 
II promoters generally lack such faithful initiation of transcription and because 
of the highly sequence dependent nature of RNAi were thought until recently 
to be unsuitable for RNAi (Zhou et al., 2005).
Several polymerase III promoters have been considered for use in RNAi. To 
determine the most functional promoter in human B cell lines and primary 
cells, I compared a human U6 promoter (cloned by PCR from BC-3 cells), a 
mouse U6 promoter (from the pSILENCER vector, Ambion) and the H1 
promoter (from the pSUPER vector, gift from Bryan Cullen). The human U6 
and murine U6 promoters have a similar size, around 300 base pairs, 
although the human H1 promoter is smaller, around 99 base pairs. The three 
promoters have little sequence homology. All three promoters were cloned by 
PCR into a pGEM backbone with a short hairpin based on the target 
sequence previously shown to be effective in reducing eGFP expression (Fig 
4.1 d). These vectors were called pGEM-hU6-sheGFP (human U6 promoter, 
with short hairpin targeting eGFP), pGEM-mU6-sheGFP (murine U6 
promoter) or pGEM-H1-sheGFP (H1 promoter). A short hairpin targeting a 
section of LacZ was chosen as a negative control and cloned into each 
vector. The naming convention was used again for this hairpin, e.g. pGEM- 
hU6-shLacZ (human U6 promoter, with short hairpin targeting LacZ) (Fig 
4.2a).
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After transfection into 293t-D12 and HeLa-D7 cells, all three pGEM vectors 
expressing a hairpin targeting eGFP induced a dose dependent silencing 
effect when compared to a LacZ hairpin. (Fig 4.2b).
A comparison of these vectors in a wider range of cell lines was performed. A 
low concentration of DNA (0.5 pg) was used to highlight small differences in 
promoter function. The results showed that the hU6 promoter was generally 
stronger than the mU6 promoter but was more limited in which cells it was 
functional in. The H1 promoter showed less cell type specificity but was 
broadly less efficient in terms of silencing efficiency (Fig 4.2c).
The human U6 promoter was chosen for further RNAi studies and for lentiviral 
short hairpin RNA expression, as it functions strongest in human cells such as 
BC-3 and primary endothelial cells.
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Figure 4.2 Comparison of polymerase III promoters for RNAi
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Figure 4.2 Comparison of polymerase III promoters for RNAi
50-
40-
% 30^
*  2 0 n
10 -
J .
0 - iU L i
COo>
CM
.3
a>
X
COO
CMD
i
COf—
CO
O
UJ
>
0
UJ
>31
COOm
pGEM-hU6
pGEM-mU6
pGEM-HI
-193-
Figure 4.2 Comparison of polymerase III promoters for RNAi
(a) Top; target sequence against eGFP (see section 4.1) and hairpin structure 
targeting eGFP. Bottom; target and hairpin structure targeting LacZ. Hairpin 
construction was aided by guidelines available on Ambion website
(www.ambion.com).
(b) Graphs indicating the effect of pGEM vectors with a human U6 (pGEM- 
hU6), murine U6 (pGEM-mU6) or human H1 (pGEM-H1) promoter and 
encoding a hairpin targeting eGFP (a). 1x105 293t-D12 (top) or HeLa-D7 
(bottom) cells seeded in a 6 well plate overnight were transfected with 0.5, 1 
or 2 pg of appropriate pGEM vector using oligofectamine in accordance with 
the manufacturers guidelines. 48 hours later, eGFP expression was 
measured by FACS analysis and the mean fluorescent intensity (MFI) 
assessed. Knockdown is expressed compared to infection with sh-LacZ (see 
materials and methods 2.4.7 for formula). Each experiment was performed in 
triplicate and the error bars indicate the standard error of the mean.
(c) Assessment of the function of the human U6 (pGEM-hU6), murine U6 
(pGEM-mU6) and human H1 (pGEM-H1) promoters in a wider variety of cell 
types. 1 x 105 293t, HeLa, U20S, and 3T3 cells and 1 x 104 HMVEC and 
DMVEC cells were transfected with oligofectamine according to the 
manufacturers guidelines. 1 x 105 BC-3 Cells were transfected with FuGene 
according to the manufacturer’s guidelines, as they were not transfectable 
with oligofectamine (Fig 4.1a). The DNA mixture included 0.5 pg of pd2-eGFP 
and 2 pg of pGEM vector and one control for each cell line transfected with 
0.5 pg pd2-eGFP and 2 pg pGEM vector containing a hairpin targeting LacZ. 
FACS analysis was performed 48 hours after transfection and the knockdown 
is expressed compared to infection with shLacZ. Each experiment was 
performed in triplicate and the error bars indicate the standard error of the 
mean.
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4.3 Requirements for effective silencing
Several factors were identified which might affect silencing efficiency. These 
include target sequence length, GC content, length and GC content of 
hairpin, potential secondary structure and specificity. This list was compiled 
from knowledge of the mechanism of RNAi and reports indicating that these 
factors may be important using dsRNA1. It was decided to investigate which 
of these, if any, were important in this system. For all experiments, the 
hairpins were transfected into HeLa-D7 cells and the knockdown effect 
observed as percent decrease in mean fluorescent intensity (MFI, see 
materials and methods section 2.4.7). A high knockdown therefore indicates a 
successful hairpin. All investigations were performed by synthesising 
oligonucleotides and creating pGEM-hU6 vectors containing hairpin 
structures (see materials and methods for cloning procedures). The eGFP 
hairpin (Fig 4.2a) was used as a template and variables investigated 
sequentially.
The size of the stem loop was determined to be largely irrelevant to silencing 
effect, although a 4-7 base pair length found to be optimum (Fig 4.3a). Four 
base pair stem loops were used for further studies as longer loops had little 
effect on silencing and cost was kept minimum by using shorter sequences. 
The GC content of the stem loop was also found to have little effect on 
silencing (Fig 4.3b). For further investigation, a 4 bp stem loop with a 50% GC 
content was used (TTCG).
The minimum length for silencing was investigated by progressively 
truncating or extending the sequence previously used. A target less than 19 
base pairs long was found to be non-functional, whilst there was no 
significant silencing difference between targets 21 and 29 base pairs long 
(Fig 4.3c). Sequences longer than 29 base pairs have been reported to
1 http://w ww .am bion com. tech lib /resources/R N A i/index html
- 195 -
induce a non specific silencing effect (Grant et al., 1995) and so were not 
investigated.
Point mutations were introduced into the hairpins to determine the specificity 
for the target sequence. It is important for the use of RNAi for us to be sure 
that any knockdown effects seen are as a result of the knockdown of the 
protein targeted, and not as a result of the dsRNA. It was found that a 1 bp 
mutation at the terminal ends of the sequence inhibited but not abolished 
knockdown. A 1 bp mutation in the middle or a 2 bp mutation at the terminal 
ends abolished the knockdown effect (Fig 4.3d). It was concluded therefore 
that shRNA is sequence specific, with the chances of off target knockdown 
small.
A 21 or 23 base pair target with a 4 base pair stem loop with 50% GC content 
was therefore shown to be both economical and effective for silencing.
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Figure 4.3 Requirements for effective silencing
Hairpin: Knockdown:
3 bp - TTC 28.2 ±3.1%
4 bp - TTCG 77.1 ±2.1%
5 bp - TATCG 74.5 ±1.9%
6 bp - TATCAG 76.4 ± 4.2%
7 bp - TAT AC AG 78.0 ± 0.3%
8 bp - TATACACG 71.9 ± 3.2%
9 bp - TGATACACG 70.5 ± 2.2%
10 bp - TGACTACACG 64.8 ±3.2%
11 bp - TGACGTACACG 52.2 ± 4.2%
12 bp - T GAC AGT AC ACG 22.0 ±1.1%
b GC content Knockdown
25 AGAT 72.6 ±4.8 %
25 TACT 71.1 ±3.9%
50 ACTG 75.3 ±5.1%
75 CGAG 70.8 ± 2.2%
75 GACG 73.2 ±6.7%
100 CGCG 75.6 ± 1.4%
100 GCCG 71.3 ±4.2%
Target Sequence Length Target Sequence Knockdown
15 ATCTGCACCACCGGC 0 ±0
17 CAT CT GCACCACCGGCA 8.3 ±7 .1%
19 T CAT CT GC ACC ACCGGCAA 58 7 ± 51 %
21 TTCATCTGCACCACCGGCAAG 75 4 ± 6.0 %
23 GTT CAT CT GCACCACCGGC AAGC 77.9 ±4.8%
25 AGTT CAT CT GCACCACCGGC AAGCT 71.3 ± 2.2 %
27 AAGTT CAT CT GCACCACCGGCAAGCT G 73.8 ± 5.2 %
29 GAAGTT CAT CT GCACCACCGGCAAGCT GC 78.6 ±4.1%
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Figure 4.3 Requirements for effective silencing
Mutant Number Mutation
1 GTTCAT GCACCACCGGCAAGC
2 G TCAACT CACCACCGGCAAGC
3 G ' T CA > CT GCACCACCGGCAAGC
4 GITCATCTGCACCACCGGCAAGC 
Original Target GTT CAT CT GCACCACCGGCAAGC
5 GTTCATCTGCACCACCGGCAA1C
6 GTTCATCTGCACCACCG CAA i C
7 GTT CAT CT GC AC C ACCG CAA S C
8 GTT CAT CT GCACCAC f GCAAGC
9 GTTCATCTGC ACCGGCAAGC
Mutant Number Knockdown
1 2 ± 0.9 %
2 1 ± 0.4 %
3 12 ± 1.2%
4 71 ± 3.1 %
Original Target 74 ± 0.8 %
5 72 ± 2.1 %
6 9 ± 1.0 %
7 1 ± 0.1 %
8 3 ± 0.3 %
9 0.02 ± 0.02 %
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Figure 4.3 Requirements for effective silencing
Tables showing the effect of target and hairpin variation on knockdown effect. 
pGEM-hU6 vectors targeting eGFP were created utilising the hairpin structure 
in Figure 4.2a as a template and the indicated component altered. All 
oligonucleotides were synthesised by Dharmacon and cloning performed as 
detailed in the materials and methods section. Throughout, knockdown is 
estimated by calculating the percent knockdown in MFI compared to a control 
hairpin (see materials and methods 2.4.7). MFI was determined by FACS 
analysis 48 hours after transfection. For transfection, 1 x 105 HeLa-D7 cells 
were transfected with 2 pg of pGEM-hU6 plasmid. Transfection was 
performed using oligofectamine in accordance with the manufacturer’s 
guidelines. Figures indicate the mean value (1st number) and range (2nd 
number) of experiments performed in duplicate. Rows highlighted in red 
signify the most efficient silencing conditions for each variable.
(a) Table showing the effect of altering hairpin length on knockdown in HeLa- 
D7 cells. Hairpins of 3-12 base pairs in length were cloned into pGEM vectors 
(left hand column) and knockdown assessed (right hand column).
(b) Table showing the effect of hairpin GC content on knockdown. The GC 
content (left column) and sequence (middle column) of hairpins cloned into 
the pGEM-U6 vector were assessed for knockdown efficiency (right hand 
column)
(c) Table showing the effect of length of target sequence on knockdown. 
Target sequences 15-29 base pairs long were introduced as hairpins into 
pGEM-U6 (left hand column) and the knockdown assessed (right hand 
column).
(d) The effect of point mutations on silencing effect. Nine oligonucleotide 
sequences containing 1,2 or 3 single base pair mutations were introduced as 
hairpins into pGEM-hU6 vectors to determine the ability of these mutations to
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abolish silencing effect (top). Characters highlighted in red show the base 
pairs which vary from that of original target. 48 hours after transfection of 2 pg 
of each mutant construct into 1 x 105 HeLa-D7 cells, the knockdown effect 
was measured (bottom).
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4.4 Cloning U6 promoter-driven shRNA into a lentiviral vector
To create a lentiviral vector expressing short hairpin RNA, a suitable cloning 
process was investigated. The only restriction site available for use to enable 
cloning of oligos into pGEM-hU6 is Sal I. A single mutation in the +1 base pair 
would allow the use of Sma I (Fig 4.4a). A mutation in the +1 base pair is 
believed to inhibit the efficiency of the U6 promoter (Alberts et al., 1994). Sma 
I would be a much more convenient enzyme to use for cloning oligos, so to 
test the extent of the inhibition, a point mutation was introduced into pGEM- 
hU6 to create pGEM-hU6M. This vector did show a slight reduction of 
silencing effect due to alteration of the +1 base pair, but this could be 
overcome by increasing the transfected quantity of vector (Fig 4.4b). This 
implies the decrease in efficacy is due to the U6 promoter function rather than 
alteration of the RNAi machinery.
Unfortunately both Sal I and Sma I are present within the pSIN backbone, so 
creation of a one-step cloning vector was prevented. pGEM-hU6M was used 
as a shuttle vector for future cloning since the Sma I site meant that cloning 
could be performed more easily. EcoRI sites in the pGEM-hU6 vector allowed 
easy removal of the promoter-hairpin sequence for insertion into the lentiviral 
vector (see materials and methods section 2.4.6).
The optimal location within the pSIN backbone of the U6 promoter (without 
the +1bp mutation) was assessed by the creation of 6 lentiviral vectors using 
the same short hairpin targeting deGFP (Fig 4.4c). The promoter was found 
to be most functional when present near the 5’ LTR. The knockdown effect 
was also found to be orientation independent (Fig 4.4d).
Lentiviral vectors based on pGEM-hU6 and pGEM-hU6M and encoding a 
hairpin against eGFP or LacZ were created. These vectors were called pSIN- 
U6-sheGFP or pSIN-U6M-shLacZ, and were tested in HeLa-D7 cells. hU6 
vectors proved to be slightly more efficient than hU6M vectors in terms of 
efficiency, however the saturation of the silencing effect was equal (Fig 4.4e).
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Since the knockdown level which could be achieved using the U6M promoter 
was so similar to that using hU6, and the cloning procedure involving hU6 
was considerably less efficient (see materials and methods), it was decided 
that U6M vectors would be used for further RNAi studies. The U6 promoter 
would be cloned into the 5’ position between the cPPT and the SFFV 
promoter. The orientation would be checked and documented in case further 
studies showed this to be relevant, although it was assumed at this stage not 
to affect silencing. The vector names were simplified to pSIN-sh(target). 
These vectors also express a puromycin resistance gene driven by the SFFV 
promoter (Fig 4.4c).
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Figure 4.4 Cloning U6 promoter driven shRNA into a lentiviral vector
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Figure 4.4 Cloning U6 promoter driven shRNA into a lentiviral vector
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Figure 4.4 Cloning the U6 promoter into the lentiviral backbone
(a) pGEM-hU6 sequence and pGEM-hU6M sequence including mutation to 
allow Sma I -  Xba I cloning to insert oligonucleotide sequences. The U6 
promoter sequence is underlined and restriction sites are highlighted in red.
(b) Graph showing the knockdown effect (see materials and methods 2.4.7) 
with increasing concentrations (0.25 -  2) pg of pGEM-hU6-sheGFP (left) and 
pGEM-hU6M-sheGFP (right). MFI was assessed by FACS analysis 48 hours 
after transfection of 1 x 105 HeLa-D7 cells with appropriate quantity of 
plasmid using oligofectamine in accordance with the manufacturer’s 
guidelines.
(c) Diagram representing the locations within the lentiviral backbone of the 
constructs created to test the function of the U6 promoter. The U6 promoter 
was either at the 5 ’ end (top two graphics), after the SFFV promoter (between 
the PAC and the WPRE; middle two graphics) or at the 3 ’ end (bottom two 
graphics). Orientation was either sense (upper graphic) and designated *+’ or 
antisense (lower graphic) and designated for each insert location. LTR- 
long terminal repeat; cPPT- central polypurine tract; SFFV- spleen focus 
forming virus promoter; PAC- Puromycin acyltransferase (resistance) 
cassette; W PRE- woodchuck hepatitis virus post transcriptional regulatory 
element.
(d) Graph comparing the knockdown effect of the lentiviral vectors shown in
(c). Each construct was used to create lentiviral stocks as detailed in the 
materials and methods section 2.3. 1 x 105 HeLa-D7 cells were infected at an 
MOI of 10 293tlU/cell of one of the six viruses and knockdown was assessed 
by FACS analysis after 96 hours (see materials and methods 2.2.15). A LacZ 
hairpin was not required as a control for this experiment as all comparisons 
are internal. The results show an orientation independent but 5’ optimum 
location for the U6 hairpin.
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(e) Graph to determine the MOI required for an efficient knockdown. Lentiviral 
stocks of pSIN-U6-sheGFP and pSIN-U6M-sheGFP were created as detailed 
in the materials and methods section 2.3. These vectors contained the U6 
hairpin in the 5’ location in the sense orientation. 1 x 105 HeLa-D7 cells were 
infected with the virus at increasing MOIs from 1 to 20 293tlU/cell (see 
legend) and knockdown was assessed by FACS analysis 96 hours after 
infection. Knockdown was determined as outlined in the materials and 
methods section 2.2.15. A LacZ hairpin was not required as a control for this 
experiment as all comparisons are internal.
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4.5 Evaluation of lentiviral RNA interference in cell lines
Knockdown of gene expression was first confirmed in 293t-D12 cells. The 
MOI and timecourse required for an effective knockdown was established (Fig 
4.5a). These data indicate that an MOI of 5 will reach optimum knockdown 
within 72 hours, and an MOI of 20 will reach optimum knockdown in 48 hours.
To show that the knockdown effect was related to the number of copies of the 
lentiviral inhibitor, 24 single cell clones were established from 293t-D12 cells 
infected with the lentiviral inhibitor at an MOI of 1. These populations had 
knockdowns of between 0 and 70%. It was found that there was a general 
correlation between the copy number of the lentiviral vector by qPCR and the 
efficiency of the silencing effect, although the relationship was not absolute 
(Fig 4.5b). This implies, as expected, that not all integrations of the lentiviral 
vector express equally, and that there may be several ‘silent’ integrations 
which do not express at all.
The expression of the hairpin caused a strong downregulation in eGFP at the 
mRNA level within 48 hours (Fig 4.5c, left). To ensure that this effect was not 
unique to 293t-D12 cells, the experiment was repeated in Hela-D7 and 293t- 
D1 cells (Fig 4.5c, right). Finally, to confirm in 293t-D12 cells that this 
knockdown resulted in decrease at the protein level, Western blots for eGFP 
showed that the protein level decreased after 48 hours, with maximum 
knockdown after 72 and 96 hours. This correlates with the 6 hour half life of 
destabilized eGFP(Fig 4.5d).
Since dsRNA did not function in 293t cells, it was theorised that the lentiviral 
vector may not be specifically targeting the eGFP mRNA. To confirm the 
RNAi was working in a sequence specific manner in 293t cells, the effect of 
silencing on bicistronic and coinfected monocistronic genes was established.
293t cells were infected with pSIN-RIG+ (construct expressing both dsRed 
and eGFP, see Chapter 3.7) or pSIN-dsRed and pSIN-deGFP and then
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infected 72 hours later with a short hairpin targeting eGFP or dsRed. In cells 
infected with the bicistronic vector, the shRNA both caused a strong 
downregulation of both genes. For the dual infection the protein knockdown 
was only the targeted gene (Fig 4.5e).
These data indicate that a target sequence leads to the entire mRNA strand 
being degraded. This result is both consistent with and adds experimental 
evidence to a sequence specific mRNA knockdown effect with RNAi but the 
evidence of 293t-D12 cells being resistant to dsRNA raises questions 
regarding the processing of shRNA to dsRNA .
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Figure 4.5 Evaluation of lentiviral RNA interference in cell lines
(a) Graph showing investigation of the MOI and time required for lentiviral 
mediated knockdown. 1 x 105 2 93t-D12 cells were seeded in 24 well plates 
and infected with a variety of MOIs from 1 to 50 293tlU/cell of pSIN-sheGFP 
or pSIN-shLacZ. After 24, 48, 72, 96 and 120 hours (see legend) the cells 
were analysed using FACS to determine the MFI. Knockdown was 
determined as outlined in the materials and methods section 2.4.7 . Each 
experiment was performed in triplicate and the error bars on the graph 
indicate the standard error of the mean.
(b) Graph showing the lentiviral copy number (x-axis) compared to 
knockdown (y- axis) of 24 single cell clones (see section 4.1 or materials and 
methods section 2.2.16) from 1 x 105 293t-D12 cells infected at an MOI of 5 
293tlU/cell with pSIN-sheGFP. Knockdown was determined as outlined in the 
materials and methods section 2.4.7. The lentiviral copy number per cell has 
been corrected for the presence of pSIN-deGFP by reducing the apparent 
copy number by 2 (Figure 4.1c). The solid line is the best fit linear regression 
and the dotted lines represent the 95% confidence intervals for that line.
(c) Graph to show mRNA levels for deGFP assessed by TaqMan qRT-PCR at 
intervals after infection. 1 x 105 293t-D12 cells were infected at an MOI of 5 
293tlU/cell with pSIN-sheGFP or pSIN-shLacZ and samples taken for 
analysis at 24, 48, 72, 96 and 120 hours (left). TaqMan qPCR of experiment 
repeated with 293t-D1 and HeLa-D7 cells analysed at 24, 48, 72 or 96 hours 
post infection (right). Results expressed as percent of mRNA relative to LacZ 
hairpin control. Each analysis was performed in triplicate and the error bars 
indicate the standard error of the mean. Primers sequences and reaction 
conditions can be found in the materials and methods section.
(d) Western blot of samples taken for (c). Samples were lysed and protein 
content equalised by Bradford assay. Results indicate the gradual reduction 
in eGFP protein levels consistent with the decrease in MFI (a).
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(e) Table showing knockdown of bicistronic and monocistronic genes in 293t 
cells. 293t cells were infected with an MOI of 10 293tlU/cell of pSIN-dsRed- 
IRES-eGFP or of pSIN-deGFP and pSIN-dsRed. After 72 hours cells were 
then infected with an MOI of 10 293tlU/cell of pSIN-shLacz, pSIN-sheGFP or 
pSIN-shdsRed. FACS analysis was performed 96 hours after infection and 
the mean fluorescence intensity (MFI) on FL1-H (green) and FL2-H (red) 
determined. Blue shading indicates control experiments, red shading 
indicates a detectable knockdown, and green shading indicates no significant 
knockdown.
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4.6 Functional inhibition of gene expression in primary and stem cells
The ability of RNAi to knockdown genes in primary cells which are refractory 
to transfection with dsRNA was assessed. DMVEC and MSCs have 
relevance to my thesis as models of KSHV infection, and so they were used 
as examples of primary cells. There have also been limited reports of the 
function of RNAi in these cells because they are not amenable to transfection.
Because of the limited life span of these cells, it was not possible to clone a 
DMVEC or MSC line expressing eGFP by limiting dilution. A reduction in 
average mean fluorescence intensity of the cells after infection with pSIN- 
deGFP was therefore used as a measure of the efficacy of RNAi. Cells were 
infected with pSIN-deGFP at an MOI of 10 293tlU/cell and then with either 
pSIN-sheGFP or pSIN-shLacZ 72 hours later. It was found that RNAi 
functions well in both DMVECs and MSCs (Fig 4.6a).
One application of RNAi is to produce knockout effects in stem cells both for 
in vitro and in vivo applications, however for this to be effective the U6 
promoter needs to be resistant to silencing. Many promoters and retroviral 
delivery systems experience inactivation (silencing) when stem cells 
differentiate (see Chapter 1.1 and Chapter 3).
The effects of silencing in MSC through differentiation was assessed. MSCs 
were infected with pSIN-deGFP and then pSIN-U6M-sheGFP or pSIN-U6M- 
shLacZ and placed in medium stimulating differentiation. The MSCs 
differentiated completely into both osteocytic and adipocytic lineages (Fig 
4.6b). These cells were therefore unaffected by the double infection and 
demonstrated stable reduction of eGFP expression throughout differentiation.
Vectors expressing lentiviral shRNA were used in hES cells in the laboratory 
and also demonstrated effective knockdown through differentiation into all 
three germ cell layers (Clements et al., 2006).
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The ability of these vectors to knockdown an endogenous gene rather than 
an artificially introduced one has not been shown. There is no reason to 
believe RNAi would behave differently for endogenous genes.
To show that these vectors are capable of both knocking down an 
endogenous gene and introducing a foreign gene throughout differentiation, it 
was decided to knockdown survivin expression and introduce eGFP, which is 
easier to detect and quantify than puromycin resistance. Survivin is an 
endogenous anti-apoptotic protein present in most cells and is not involved in 
differentiation (Caldas et al., 2005).
A vector based on pSIN-U6M which encoded a short hairpin targeting survivin 
and expressing eGFP instead of puromycin resistance was constructed - 
pSINeGFP-shsurvivin (Fig 4.6c). As a control, a vector expressing a short 
hairpin to LacZ- pSINeGFP-shLacZ- was also created. MSC were infected 
with these vectors, and then cultured in conditions designed to promote 
differentiation. The differentiated cells were checked to ensure appropriate 
expression of Oil Red O or alkaline phosphatase to confirm their adipocytic or 
osteocytic lineage (Fig 4.6d). A Western blot of the differentiated cells 
indicated that survivin levels were still knocked down (Fig 4.6e).
The results indicate that endogenous and exogenous genes are equally 
amenable to knockdown in these cells, both foreign gene expression and 
knockdown are stable throughout differentiation and that this does not affect 
the capability of these cells to differentiate.
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Figure 4.6 Functional inhibition of gene expression in primary and stem cells
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Figure 4.6 Functional inhibition of gene expression in primary and stem cells
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Figure 4.6 Functional inhibition of gene expression in primary and stem cells
(a) Graph showing functional knockdown in DMVEC (left) and MSC (right) 24, 
48, 72, 96 and 120 hours after infection (see legend). Cells were infected with 
pSIN-deGFP at an MOI of 10 293tlU/cell and then after 72 hours, when eGFP  
was visible under light microscopy, 1 x 104 cells were infected at an MOI of 10 
293tlU/cell with pSIN-sheGFP or pSIN-shLacZ. Knockdown was determined 
as outlined in the materials and methods section 2.4.7. Experiments were 
performed in triplicate and error bars indicate the standard error of the mean. 
The results indicate functional lentiviral shRNA in both primary endothelial cell 
types.
(b) Light and green fluorescence microscopy and oil red o (for adipocytic 
lineage) and alkaline phosphatase (for osteocytic lineage) staining of MSCs 
after differentiation. Cells were infected with pSIN-deGFP at an MOI of 10 
293tlU/cell and then after 72 hours, when eGFP was visible under light 
microscopy, 1 x 104 cells was infected at an MOI of 10 293tlU/cell with pSIN- 
sheGFP or pSIN-shLacZ. These cells were grown to confluence and placed in 
medium promoting differentiation into adipocytes (top two rows) or osteocytes 
(bottom two rows) for 28 days. Determining knockdown with FACS is not 
possible as these cells are difficult to trypsinise away from the plate. These 
results show efficient lentiviral knockdown of deGFP throughout differentiation 
and in mature adipocytes and osteocytes, and that MSCs are capable of 
differentiating after double infection.
(c) Diagram of the lentiviral vector pSINeGFP-shsurvivin (top) and sequence 
and hairpin (bottom) used to knockdown the expression of survivin.
(d) Light and green fluorescence microscopy and oil red o and alkaline 
phosphatase staining of differentiated MSCs. 1 x 104 MSCs were infected at 
an MOI of 10 with pSINeGFP-shsurvivin or pSINeGFP-shLacZ and allowed to 
grow until confluence. They were then placed in medium promoting 
differentiation into adipocytes or osteocytes and after 28 days were examined
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under light (left column) and fluorescence microscopy (middle column) and 
stained for oil red o (indicating adipocytic lineage) or alkaline phosphatase 
(indicating osteocytic lineage) (right column).
(e) Western blot of cells created in (d). Cells were placed in RIPA buffer in 
tissue culture plates for 5 minutes and then physically removed. Samples 
were equalised for protein concentration using the Bradford assay and SDS- 
PAGE performed using anti-survivin, anti-eGFP and anti-pactin antibodies. 
The results indicate that survivin inhibition and eGFP expression is stable 
throughout differentiation.
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4.7 Discussion and conclusions
In this chapter I confirm several published reports that lentiviral vectors are 
capable of delivering short hairpin RNA interference to cell lines and primary 
cells (Brummelkamp et al., 2002a; Abbas-Terki et al., 2002), and show for the 
first time that this effect can be delivered to MSC.
The experiments performed in this chapter provided data which, at the time, 
was unknown. Lentiviral shRNA was functional in our laboratory at around the 
time the first reports were published (Abbas-Terki et al., 2002) and the data 
available regarding optimum knockdown conditions and requirements was 
limited. This knowledge was however essential for us to knockdown genes 
reliably using this system. Literature reviews and systematic studies are now 
available which go into far more detail and provide valuable information for 
those involved in RNAi research (Overhoff et al., 2005).
Much new information regarding the mechanism of RNAi is also now known. 
Components of the RNA-induced silencing complex have been identified and 
characterised (Sontheimer, 2005). Interestingly, Argonaute 2, a component 
strongly implicated in RISC formation, is localised to mRNA decay centres 
known as cytoplasmic bodies (Sen and Blau, 2005). Studies of RNAi in 
c.elegans have identified over 90 genes which have a role in dsRNA 
mediated silencing (Kim et al., 2005). This further information does not 
currently offer any explanation for why 293t-D12 cells should be unable to 
reduce deGFP expression after transfection with dsRNA, but are able to do 
so with shRNA.
shRNA also allows stable silencing of gene expression. This ability increases 
the potential of the technology to include new approaches for investigation. 
Several reports of stability of expression with lentiviral vectors are confirmed 
here (Naldini et al., 1996a) including their stability during differentiation 
(Karlsson et al., 2002; Leurs et al., 2003). This has application to fields as far 
ranging as cell sources of metastatic disease to tissue engineering. Stable
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RNAi throughout differentiation is already yielding data regarding 
development in animal embryos (Chesnutt and Niswander, 2004).
Stable shRNA is dependent upon the choice of promoter. My investigation of 
promoter function (Figure 4.2 and Figure 4.4) shows that polymerase III 
promoters seem to function very broadly. This contrasts to their polymerase II 
counterparts which do not normally function so broadly across suspension, 
adherent and stem cells. This may in part be to their fairly conserved 
sequences and their essential roles within RNA production. Recent use of 
polymerase II promoters for RNAi (Zhou et al., 2005) and targeting 
polymerase II promoters specifically to certain tissues (De Palma et al., 2003) 
raises interesting possibilities for targeting this technology. Reports of 
inducible systems based around Cre-Lox (Ventura et al., 2004) or tetracycline 
(Lin et al., 2004) regulated U6 promoters show the true versatility of shRNA 
based systems.
My findings with regards to the +1 base pair of the hU6 promoter when 
attempting to create a vector more suitable for cloning are surprising. I was 
expecting the U6 promoter to have stricter initiation requirements. Since the 
polymerase III promoters function well in many cell lines, I would liked to have 
investigated the use of the other promoters and more variants of the U6 
promoter to create a more efficient and convenient system for general use. It 
was disappointing to find that RNA interference using these promoters cannot 
completely abolish expression of a protein. The most efficient knockdown I 
established reduced expression levels to around 10% of the levels in the 
control experiment. This concurs with current literature regarding RNAi, and is 
believed to be a result of the mechanism of RNAi. The dependence of RNAi 
on cellular factors which may not be abundant enough for a complete 
knockdown and the fundamental process of degrading an existing mRNA 
strand which may already have been translated means the knockdown 
cannot be 100%. Some studies may require complete silencing of gene 
expression, and as is shown in Chapter 5, low levels of transgene expression 
can cloud experimental results. My findings that with the lentiviral vector the
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U6 promoter functions well when placed near to the 5’ LTR but not elsewhere 
cannot be readily explained. My findings of orientation independence agree 
with published reports (Abbas-Terki et al., 2002).
A reflection on the novelty and variability of systems for RNA interference is 
shown here. This system proved less versatile for shorter and longer 
sequences than some reported vectors (Brummelkamp et al., 2002a), whilst 
is equally efficient when optimised. The ability of the vector to function with 
virtually any length of stem loop, and with no significant GC requirement was 
surprising but not contrary to published reports.
One important factor for the application of RNAi is the confirmation that only a 
single base pair mutation is required to diminish or abolish knockdown effect. 
It was perhaps predictable that mutations in the end of a 23 base pair target 
would diminish but not abolish effect given the results indicating a 19bp 
sequence is a requirement. The implications of this for RNAi based therapies 
has already been seen with the ability of rapidly mutating viruses such as 
HIV-1 to escape the effects of even multiple target RNA interference (Das et 
al., 2004). Related to this issue is off-target cellular effects of RNAi. It is 
possible that RNAi induces changes in non-targeted cellular proteins 
(Scacheri et al., 2004). Some groups have implicated the interferon response 
in this (Kim et al., 2004) or the effect of transitive RNAi. Transitive RNAi 
involves the extension of the target sequence intracellularly through an 
enzyme RdRP (RNA dependent RNA polymerase) leading to short fragments 
of off target dsRNA in the cell. There is evidence that this cannot occur in 
human cells, as they lack the appropriate RdRP (Chi et al., 2003). There is 
evidence also that no interferon response is invoked by RNAi (Heidel et al., 
2004). There is no good conclusion regarding the specificity or off target 
activity of RNAi. Microarray technology has yielded high profile publications 
with data showing both no and significant off target gene activity (Chi et al., 
2003; Jackson et al., 2003).
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One component of RNA interference which was too large to investigate within 
the scope of this thesis was the exact sequence requirements for targeting. 
Most major dsRNA synthesis companies now offer on-line utilities for 
sequence selection (www.dharmacon.com. www.ambion.com/techlib. 
http://www1.qiagen.com/Products/GeneSilencing/). The overall ‘hit’ rate for 
successful knockdown with this lentiviral system was around 50%. It would be 
interesting to know why some sequences silence much better than others, 
and more specifically when attempting to knockdown gene expression which 
targets will be effective.
This chapter describes the use of stable RNA interference knocking down 
expression of exogenous and endogenous gene expression in MSC and 
contributes to the study of RNAi in hES (Clements et al., 2006). A vector such 
as the one demonstrated here which can express and inhibit gene expression 
may be important for fields such as tissue engineering, where guiding the fate 
of these stem cells may require more complex manipulation of cellular 
pathways than offered using other expression systems. The demonstration 
that these vectors can function without affecting the ability of these cells to 
differentiate is important. It may be that retro- and lenti- viral vectors prove too 
dangerous to be ever used in a clinical setting but these findings regarding 
the polymerase III promoter apply to the use of other viral vectors, such as 
AAV, which have more defined integration patterns and may offer more of a 
hope in a clinical setting.
Overall, this chapter demonstrates stable RNA interference across a range of 
cell lines, primary and stem cells and investigates some of the requirements 
for optimum silencing whilst highlighting the novelty of this technology and the 
contradictions present across much of the literature. I show that human stem 
cells behave normally when transduced, and discuss the implications for this 
in both in vitro research and in vivo research.
- 2 2 2 -
Chapter 5:
In vitro knockdown of KSHV latent genes 
Chapter Aims:
The aim of this chapter was to utilise the lentiviral RNAi system (chapter 4) to 
knockdown genes within the KSHV oncogenic cluster. In order to achieve 
this, effective targets for each of the latent genes were isolated. The effects of 
the knockdown on latent models of KSHV infection (see Chapter 1.4) were 
determined in order to identify targets which might be suitable for potential 
therapeutics.
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5.1 Knockdown of the genes in the oncogenic cluster in 293t cells
In order to investigate further the potential of lentiviral shRNA (Chapter 4), 
KSHV was chosen as a target. The ultimate goal of these experiments was to 
investigate targets for potential therapeutics. As discussed in Chapter 1.4, the 
oncogenic cluster (LANA, vFLIP and vcyclin) are genes which are expressed 
in all latent KSHV infections. These genes offer appealing targets for 
knockdown, since they are known to dysregulate cell cycle components and 
have key roles in the latent life cycle (Chapter 1.4; Guasparri et al., 2004; 
Fujimuro and Hayward, 2003b). The knockdown of genes within the 
oncogenic cluster was therefore predicted to have adverse effects in PEL 
cells, which are models for the KSHV latent life cycle. We theorised that 
efficient knockdown of vFLIP and vcyclin would result in cell death, and that 
knockdown of LANA might have several effects. We expected to see the 
KSHV genome expelled from the cell as LANA was no longer present to 
tether the episome. We predict also that the reduction of inhibition of Orf-50/ 
Rta would cause activation of the lytic life cycle. The removal of LANA may 
also disrupt the p53/ pRb pathways and therefore result in cell death. To 
investigate the potential for a therapeutic involving knockdown of these latent 
genes, an in vitro knockdown was firstly demonstrated.
Since we predicted adverse effects in PEL cells from latent gene knockdown, 
it was thought that this might affect our ability to assess the knockdown effect 
accurately. 293t cell lines expressing one of the three genes in the oncogenic 
cluster were therefore created. These cells lines, 293t-LANA, 293t-vcyclin and 
293t-vFLIP were created using lentiviral vectors (pHR-CMV-LANA, created by 
Dan Hollyman; pHR-CMV-vFLIP-IRES-eGFP, created by Nigel Fields; pHR- 
CMV-vcyclin, see materials and methods). These cell lines continued to grow 
in culture and expressed the introduced genes 4 weeks after infection (Fig 
5.1a). BC-3 cells are PEL cells expressing all 3 KSHV genes from the 
oncogenic cluster and were used as a positive control. Ramos cells are a 
KSHV negative B cell line used as a negative control throughout these 
experiments.
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LANA was chosen first as there are published dsRNA sequences targeting 
LANA which are effective (Fujimuro and Hayward, 2003). Two targets within 
LANA were chosen, one at the N terminus and one at the C terminus (Fig 
5.1b). Short hairpins were designed according to the criteria found to be 
optimum in Chapter 4, and these hairpins were subcloned into lentiviral 
vectors expressing puromycin resistance as well as the short hairpin (Fig 
5.1b). The targets were assessed in terms of efficiency of knockdown in 293t- 
LANA cells. An MOI of 10 293tlU/cell was chosen based on previous 
experiments indicating that this MOI is sufficient and effective to produce a 
knockdown. Only one target (LANA-n) was found to be effective. Knockdown 
with a lentiviral vector was found to be dose dependent (Fig 5.1c), although 
because of the relatively long half life of LANA the knockdown took almost 
two weeks to reach maximum effect (Fig 5.1d).
To assess the efficacy of vFLIP and vcyclin knockdown, 2 short hairpins 
targeting each of the genes were chosen based on criteria from the Ambion 
(www.ambion.com) website and cloned into lentiviral vectors expressing the 
short hairpin and a puromycin resistance cassette (Fig 5.1b). It was found that 
all four targets induced some degree of silencing of the target gene (Fig 
5.1e).
The N terminus of all three latent genes were chosen for further studies 
based on silencing efficacy. These constructs were named pSIN-shl_ANA, 
pSIN-shvcyclin and pSIN-shvFLIP.
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Figure 5.1 Knockdown of the genes in the oncogenic cluster in 293t cells
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Figure 5.1 Knockdown of the genes in the oncogenic cluster in 293t cells
(a) Western blots showing expression of the latent genes in 293t cell lines. 
293t cells were infected with a lentiviral vector expressing a latent gene (pHR- 
CMV-LANA, pHR-CMV-vFLIP-IRES-GFP, pHR-CMV-vcyclin) at an MOI of 5 
and maintained in culture. Western blots show expression of the latent gene 
4 weeks after infection when compared to wild type 293t cells. Cell lines were 
named 293t-LANA (left), 293t-vcyclin (right) and 293t-vFLIP (bottom). BC-3 
cells are PEL cells expressing all 3 genes from the oncogenic cluster and are 
used as a positive control. Ramos cells represent a KSHV negative B cell line 
used as a negative control.
(b) The target sequences designed against the three genes in the oncogenic 
cluster (top) and map of the lentiviral vector expressing the shRNA. LTR- long 
terminal repeat; cPPT- central polypurine tract; SFFV- spleen focus forming 
virus promoter; PAC- puromycin n-acetyltransferase cassette; WPRE- 
woodchuck hepatitis virus posttranscriptional regulatory element.
(c) Western blot showing the effect of LANA knockdown on 293t-LANA cells 
and p-actin control. 1 x 105 293t-LANA cells were infected at the MOI 
indicated (1, 2, 5, 10 293tlU/cell) with pSIN-shLANA and cultured for 7 days. 
Cell lysates were equalised for protein concentration using the Bradford 
assay and Western blot for LANA performed.
(d) Western blot showing the timecourse of LANA knockdown in 293t-LANA 
cells. 1 x 105 293t-LANA cells were infected with an MOI of 10 293tlU/cell of 
pSIN-shLANA. Samples were taken for analysis on days 3, 5, 10 and 14. All 
samples were equalised for protein concentration by Bradford assay, and 
Western blot against LANA performed. The results show that LANA takes 5- 
10 days to reach maximum knockdown
(e) Western blot against vcyclin showing effective knockdown. 1 x 105 293t- 
vcyclin cells were infected with an MOI of 10 293tlU/cell of pSIN-shvcyclin-C
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and pSIN-shvcyclin-N and the knockdown effect assessed 7 days post 
infection. Protein samples were equalised using the Bradford assay and 
Western blot against vcyclin performed. Results indicate both the N and C 
terminus targets are effective at knocking down vcyclin expression.
(f) Western blot against vFLIP showing effective knockdown. 1 x 105 293t- 
vFLIP cells were infected with an MOI of 10 293tlU/cell of pSIN-shvFLIP-C 
and pSIN-shvFLIP-N and the knockdown effect assessed 7 days post 
infection. Protein samples were equalised using the Bradford assay and 
Western blot against vFLIP performed. Results indicate both the N and C 
terminus targets are effective at knocking down vFLIP expression.
- 2 2 9 -
5.2 Knockdown of genes in the oncogenic cluster in PEL lines
The efficacy of latent gene knockdown was established in BC-3 cells. BC-3 
cells are B cells latently infected with KSHV (Arvanitakis et al., 1996). All 3 
targets showed a knockdown effect in BC-3 cells (Fig 5.2a). Due to the long 
half life of the protein, the knockdown efficiency of LANA was confirmed by 
qRT-PCR 96 hours post infection (Fig 5.2b).
The structure of the mRNA responsible for LANA, vcyclin and vFLIP 
production predicts that multiple genes should be silenced since they are 
tricistronic or bicistronic. We know from Chapter 4.5 that concomitant 
silencing occurs when multiple genes are present on one transcript.
To investigate this, the effect of knockdown of one latent gene on the others 
was determined. Some reduction in all three genes from the knockdown of 
any single gene was expected. The results show surprisingly that despite 
coexisting on a tricistronic transcript, LANA targeted hairpins are independent 
in their knockdown effect, however hairpins targeting either the vFLIP or the 
vcyclin silence both genes simultaneously in BC-3 cells (Fig 5.2c).
The mechanism of RNAi predicts that the secondary structure of the mRNA is 
responsible for the degree of silencing seen. Further targets were chosen 
within the mRNA strand in order to determine if vcyclin and vFUP  could be 
silenced independently or whether all three genes could be knocked down 
with a single target (Fig 5.2d). The effect of these targets on all three 
members of the oncogenic cluster of BC-3 cells was assessed by Western 
blot, however no target which silenced the vcyclin or vFLIP individually or 
which silenced all three genes together was found (Fig 5.2e). Based on the 
proposed mechanism of RNAi, where the secondary structure of the mRNA is 
critical for the binding of the RISC, this structure may be responsible for lack 
of silencing.
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These data indicate that we can successfully target the latent genes of KSHV 
and that i(FLIP and vcyclin silencing is concomitant. The next step is to 
determine the efficacy of these knockdowns in KSHV models.
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Figure 5.2 Knockdown of genes in the oncogenic duster in PEL lines
(a) Western blots showing the knockdown of the latent genes in BC-3 cells. 1 
x 105 BC-3 cells were infected at an MOI of 10 293tlU/cell with pSIN-shLANA 
(left), pSIN-shvcyclin (bottom), pSIN-shvFLIP (right) or pSIN-shLacZ with 
polybrene at 1 pg/pl final concentration. Knockdown was assessed 5 days 
(for vcyclin and vFLIP) or 14 days (for LANA) after infection. Ramos cells 
indicate a KSHV negative B cell lines and BC-3 cells express wild type protein 
levels. Samples were equalised for protein concentration by Bradford assay.
(b) TaqMan qRT-PCR for LANA mRNA (see materials and methods for 
reaction conditions and primers). Analysis was performed on cells infected in
(a) 96 hours after infection to determine LANA knockdown. Results indicate 
effective LANA knockdown at the RNA level within 96 hours.
(c) Western blot panel showing the effect on all three latent genes when one 
is knocked down. 1 x 105 BC-3 cells were infected with pSIN-shLacz, pSIN- 
shvcyclin, pSIN-shvFLIP or pSIN-shLANA at an MOI of 10 293tlU/cell in the 
presence of 1 pg/pl polybrene. vcyclin and vFLIP protein levels were 
measured 5 days after infection, and LANA levels were measured 14 days 
after infection. Samples were equalised for protein concentration by Bradford 
assay. Western blots were performed for protein indicated on left hand side of 
the panel. Results indicate concomitant knockdown of vcyclin and vFLIP and 
independent knockdown of LANA.
(d) Graphic indicating targets against the latent genes chosen to investigate 
the possibility of independent silencing of vcyclin and vFLIP. Each target was 
given a name indicating the target gene and a number indicating the starting 
base pair of the target.
(e) Western blot to determine the efficacy of the nine sequences at silencing 
the latent genes individually. 1 x 105 BC-3 cells were infected with pSIN-
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shLacZ or virus produced against each of the nine targets indicated on the 
top row at an MOI of 10 293tlU/cell in the presence of 1 pg/pl polybrene. 
vcyclin and vFLIP protein levels were measured 5 days after infection, and 
LANA levels were measured 14 days after infection. Samples were equalised 
for protein concentration by Bradford assay. Western blots were performed 
against protein indicated on left hand side of the panel. No target was found 
which yielded silencing of the latent genes individually or which silenced all 
three genes using one target.
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5.3 Adverse effects of latent gene knockdown in PEL lines
To determine whether knockdown of the latent genes caused apoptosis in 
PEL lines, 4 PEL lines (JSC-1, BC-3, BCP-1 and HBL-6) were infected with 
pSIN-shLANA, pSIN-shvFLIP or pSIN-shvcyclin. Ramos cells (KSHV negative 
B cells) were used as a control to show that infection with the vector or 
expression of the shRNA do not have non specific adverse cellular effects. 
Annexin V staining used to assess cell viability by FACS (see materials and 
methods section 2.2.13).
After 14 days, all three knockdowns induced some apoptosis. LANA 
knockdown seemed to have a variable effect in PEL lines. With LANA 
knocked down, BC-3 and JSC-1 cells did not enter apoptosis as quickly as 
BCP-1 and HBL-6 cells. No PEL line was found to be resistant to apoptosis 
after vcyclin/vFLIP knockdown although some (JSC-1) responded faster than 
others (HBL-6) (Fig 5.3a).
To ensure that this effect was not due to differences in the infection rates 
within these cells, TaqMan qPCR for the lentiviral insert was used to 
determine the copy number present after infection. The results indicate that 
24 hours after infection the number of copies of the lentiviral insert was 
slightly less in HBL-6 than in other cells, although the presence of the vector 
was still significant (Fig 5.3b). Future infections with HBL-6 cells were 
performed with a higher MOI (1.6x) to compensate for this.
To show that the knockdown in different PEL lines is similar, TaqMan qRT- 
PCR was used 48 hours after infection to determine vcyclin, vFLIP and LANA 
mRNA levels. The results indicate a comparable, but not equal, knockdown of 
these genes in these cells (Fig 5.3c). The lower efficiency of RNAi in BC-3 
and JSC-1 cells does not seem to correlate with rates of apoptosis and 
therefore I propose that the knockdown is still sufficient to induce apoptosis.
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To determine whether vcyclin or vFLIP were more critical for cell survival, 
lentiviral vectors encoding vcyclin or vFLIP were used to rescue the 
expression levels of these genes after knockdown. These data indicate that 
inhibition of the viral FLIP is sufficient to induce apoptosis in both JSC-1 and 
BC-3 cells, as rescue of vcyclin proved insufficient to prevent cell death (Fig 
5.3d). Knockdown of vcyclin and restoration of vFLIP induces apoptosis but at 
a reduced rate in BC-3 and JSC-1 cells (Fig 5.3e). This suggests that 
although the knockdown of vcyclin has a role in inducing apoptosis, the key 
factor in the death of these cells is the loss of vFLIP.
These data show that RNAi is functional in these cells, and also confirms that 
different cells respond differently to RNAi. It was decided at this point that 
detailed investigation of the levels of mRNA, infection and knockdown 
required to cause apoptosis would yield little extra information in terms of 
potential therapeutics. It seems sufficient that knocking down vFLIP is enough 
to cause apoptosis, even if the knockdown is less than expected, and that 
knocking down LANA cannot reliably drive PEL cells into apoptosis. The 
resistance of PEL cells to LANA knockdown was of interest to us, as this does 
not fit with our predictions of the cellular role of LANA. This effect was 
therefore further investigated in the next section.
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Figure 5.3 Adverse effects of latent gene knockdown in PEL lines
(a) Graph showing percent of cells in apoptosis determined by Annexin-V 
FITC staining (see materials and methods). 1 x 105 Ramos, JSC-1, BC-3, 
BCP-1 or HBL-6 cells were infected with pSIN-shLacz, pSIN-shvcyclin, pSIN- 
shvFLIP or pSIN-shLANA at an MOI of 10 293tlU/cell in the presence of 1 
pg/pl polybrene. 7 days later, cells were stained with Annexin-V FITC 
antibody and the number of FITC positive cells measured and assumed to be 
cells in early or late apoptosis. Each analysis was performed in triplicate and 
error bars represent the standard error of the mean.
(b) TaqMan qPCR for the lentiviral packaging signal of 1 x 105 Ramos, BC-3, 
JSC-1, BCP-1 and HBL-6 cells infected with at an MOI of 1 293tlU/cell in the 
presence of 1 pg/pl polybrene. Each analysis was performed in triplicate and 
error bars represent the standard error of the mean. Results indicate that 
HBL-6 cells are more refractory to infection.
(c) Graph showing the relative vcyclin, vFLIP and LANA mRNA levels after 
knockdown determined by TaqMan qRT-PCR of 1 x 105 BC-3, JSC-1, BCP-1 
and HBL-6 cells 48 hours after infection with pSIN-shLacZ, pSIN-shvcyclin, 
pSIN-shvFLIP or pSIN-shLANA at an MOI of 10 293tlU/cell in the presence of 
1 pg/pl polybrene. ‘vcyclin’ represents the vcyclin mRNA levels after infection 
with pSIN-shvcyclin, ‘vFLIP’ represents the vFLIP mRNA levels after infection 
with pSIN-shvFLIP and ‘LANA’ represents the LANA mRNA levels after 
infection with pSIN-shLANA. All values are relative to that cell type after 
infection with pSIN-shLacZ.
(d) Graph showing the rescue from apoptosis of PEL cells after knockdown of 
vFLIP and vcyclin. Results are expressed as percent of cells remaining viable 
(determined by Annexin-V FITC staining) of 1 x 105 Ramos or BC-3 cells 7 
days after infection with pSIN-shLacZ (labels ‘Ramos’ and ‘BC-3’), pSIN- 
shvFLIP (labels ‘Ramos+shvFLIP’ and ‘BC-3+shvFLIP’) or pSIN-shvFLIP and
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pHR-vcyclin (‘BC-3+shvFLIP+vcyc) all at an MOI of 10 293tlU/cell in the 
presence of polybrene at 1 pg/pl. Results indicate that reintroduction of the 
viral cyclin is not sufficient to prevent apoptosis in cells where vFLIP is 
knocked down.
(e) Graph showing the rescue from apoptosis of PEL cells after knockdown of 
vFLIP and vcyclin. Results are expressed as percent of cells remaining viable 
(determined by Annexin-V FITC staining) of 1 x 105 Ramos or BC-3 cells 7 
days after infection with pSIN-shLacZ (labels ‘Ramos’ and ‘BC-3’), pSIN- 
shvcyclin (labels ‘Ramos+shvcyc’ and ‘BC-3+shvcyc’) or pSIN-shvcyc and 
pHR-vFLIP-IRES-GFP (‘BC-3+shvcyc+vFLIP) all at an MOI of 10 293tlU/cell 
in the presence of polybrene at 1 pg/pl. Results indicate that reintroduction of 
vFLIP is sufficient to protect cells from apoptosis in cells where vcyclin is 
knocked down.
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5.4 Long term culture of LANA knockdown cell lines
Since lentiviral vector infection is not uniform and some PEL cells could skew 
results by remaining uninfected, a pure population of LANA negative, KSHV 
positive cells were created for further investigation. pSIN-shLANA was used 
to infect BC-3 cells at an MOI of 10 293tlU/cell. This vector (Fig 5.1b) also 
encodes a puromycin resistance cassette, and after infection these cells 
(BC3-LN) were cultured in puromycin for 6 months. Analysis performed during 
and after this time in culture showed that these cells demonstrated a stable 
knockdown to around 10% of normal LANA levels by Western blot (Fig 5.4a) 
and 20% by qRT-PCR (Fig 5.4b). To determine whether this residual level of 
LANA was due to low levels of expression in all cells or some cells escaping 
knockdown, I FA was performed (Fig 5.4c). Cells were incubated with LN53 
antibody and then with an a-rat-FITC antibody. These cells were 
subsequently sorted, and the fluorescent (i.e. LANA expressing) and negative 
fraction compared for presence of lentiviral inserts by qPCR (5.4d). These 
data indicate that some cells, despite adequate infection with the vector 
continue to express high levels of LANA. Because of the mechanism of RNAi 
and of puromycin selection, it is likely that all cells have a low level of LANA 
which may be below the threshold for detection with this method.
The possibility of creating other PEL lines containing little or no LANA was 
assessed. Only BC-3 cells appeared to be completely resistant to LANA 
knockdown. Other cell lines such as JSC-1, BCP-1 and HBL-6 cells all show 
marked apoptosis after infection (Fig 5.4e).
Using a low MOI of shRNA vector, JSC-1 cells seemed to be able to survive 
with a LANA knockdown (Fig 5.4f). A JSC-1 cell line (JSC-1-LN) with low 
levels of LANA was created using puromycin selection. These cells showed a 
detectable decrease in LANA levels by Western blot 1 month after infection 
(Fig 5.4g). None of the other PEL lines tested could be propagated with a 
detectable LANA knockdown.
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Figure 5.4 Long term culture of LANA knockdown cell lines
(a) Western blots for LANA (top) and p-actin (bottom) of BC3-LN cells 2 
weeks, 4 weeks, 8 weeks and 6 months after infection with pSIN-shLANA at 
an MOI of 10 293tlU/cell in the presence of 1pg/pl polybrene. Infected cells 
were selected by culture in puromycin. Cell samples were equalised for 
protein concentration using the Bradford assay.
(b) Graph showing the LANA mRNA levels analyzed by TaqMan qRT-PCR in 
BC-3LN cells 2 weeks, 8 weeks and 6 months after infection with pSIN- 
shLANA at an MOI of 10 293tlU/cell in the presence of 1pg/pl polybrene. 
Infected cells were selected by culture in puromycin. Analysis was performed 
in triplicate and error bars indicate the standard error of the mean. mRNA 
levels are shown relative to wild type BC-3 cells.
(c) IFA for LANA in BC-3 cells. Cells were infected with pSIN-shLacZ (1, top 
row) or pSIN-shLANA (1, bottom row) at an MOI of 10 293tlU/cell in the 
presence of 1 jag/pl polybrene. After 14 days, IFA for LANA was performed 
(see materials and methods section 2.2.14). Although most cells displayed 
levels of LANA below the threshold for detection by this method, there were 
some cells which maintained expression (2).
(d) Graph showing the number of copies of the lentiviral packaging signal in 
cell after sorting for LANA expression. Cells were stained with rat a-LANA 
antibody (LN53) and a-rat-FITC as for preparation for IFA (see materials and 
methods). These cells were sorted using FACS for high expression of LANA 
(‘Sorted’). ‘Unsorted’ represents BC3-LN cells. TaqMan qPCRforthe lentiviral 
insert and GAPDH was used to determine the copy number per cell. Analysis 
was performed in triplicate and error bars indicate the standard error of the 
mean. Levels shown are relative to the unsorted population levels. Results 
indicate that those cells expressing high levels of LANA are infected with the 
lentivirus.
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(e) Graph of cell doubling time of Ramos, BC-3, JSC-1 and BCP-1 cells 2 or 7 
days after infection with pSIN-shLacZ or pSIN-shLANA. Infection was 
performed on 1 x 105 cells at an MOI of 10 293tlU/cell in the presence of 1 
pg/pl polybrene. Experiment was performed in duplicate and error bars 
indicate the range.
(f) Graph showing the cell doubling time (in days) and Western blot for LANA 
of JSC-1 cells 7 days after infection with pSIN-shLANA at increasing MOIs 
(indicated at bottom) in the presence of 1 pg/pl polybrene.
(g) Western blots for LANA (top) and p-actin (bottom) of JSC1-LN cells 2 
weeks and 4 weeks after infection with pSIN-shLANA at an MOI of 4 
293tlU/cell in the presence of 1 pg/pl polybrene. Infected cells were selected 
by culture in puromycin. Cell samples were equalised for protein 
concentration using the Bradford assay.
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5.5 Cellular effects of LANA knockdown
To determine the effect of the LANA knockdown on both BC3-LN and JSC1- 
LN cells, measurements of life cycle, the copy number of KSHV and ability to 
enter lytic replication were performed as these are key areas in which LANA 
is believed to have a role.
BC3-LN cells had no significant difference in BrdU uptake and MTT 
incorporation (Fig 5.5a) or cell cycle FACS (Fig 5.5b) compared to wild type 
BC-3 cells. These assays signify the rate of metabolism of these cells (BrdU 
and MTT) and the populations which are in each stage of the cell cycle. 
JSC1-LN cells had lower levels of BrdU uptake and MTT incorporation (Fig 
5.5c). The cell cycle FACS indicated also that the cells spent longer in phase 
G1 than wild type JSC1 cells (Fig 5.5d). This analysis fits with the difficulty in 
creating JSC-1 cell lines which are resistant to LANA knockdown.
Over 6 months in culture, BC3-LN and JSC1-LN cells did show a gradual 
decrease in the copy number of KSHV present. This is consistent with loss of 
viral episomes. A residual copy number remained despite the knockdown and 
no further decrease was seen after 2 months (Fig 5.5e).
The activation of the lytic life cycle on BC-3-LN and JSC-1-LN cells was 
assessed in terms of ORF-50 mRNA levels during normal culture and after 
stimulation with TPA (Fig 5.5f). This represents a standard method of 
inducing lytic cycle reactivation in PEL cells. These data indicate that BC-3- 
LN cells are almost completely uninducible, with no significant upregulation of 
ORF-50 even in the presence of TPA however JSC-1-LN cells proved to be 
hyperinducible, with significantly raised levels of ORF-50 mRNA (Fig 5.5f).
As the vcyclin and vFLIP are believed to be transcribed from the same 
tricistronic mRNA species as LANA, the levels of vFLIP and vcyclin mRNA in 
BC-3-LN cells 2 weeks, 1 month and 6 months after knockdown was 
assessed by qRT-PCR. The results indicate that there is a corresponding
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decrease in the production of vcyclin and vFLIP, although it is not in 
proportion to the knockdown and may only be due to the decrease in copy 
number of KSHV (Fig 5.5g).
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Figure 5.5 Cellular effects of LANA knockdown
(a) BrdU incorporation (top) and MTT assay (bottom) (see materials and 
methods) indicating no significant difference in growth between BC-3 and 
BC3-LN cells.
(b) Cell cycle FACS analysis (see materials and methods) of wild type BC-3 
and BC3-LN cells (top) and the proportion of cells in different stages of the life 
cycle (table, bottom). Results indicate no significant difference between wild 
type and BC3-LN cells.
(c) BrdU incorporation (top) and MTT assay (bottom) (see materials and 
methods) of wild type JSC-1 and JSC1-LN cells. Results indicate that JSC1- 
LN cells incorporate both BrdU and MTT significantly slower than wild type 
cells.
(d) Cell cycle FACS analysis (see materials and methods section 2.2.11) of 
wild type JSC-1 and JSC1-LN cells (top) and the proportion of cells in 
different stages of the life cycle (table, bottom). Results indicate JSC1-LN 
cells spend longer in phase G1, less time in G2 and have a higher rate of 
spontaneous apoptosis than JSC-1 cells.
(e) Graph showing the copy number of KSHV in BC3-LN cells (top) and 
JSC1-LN cells (bottom) assessed by TaqMan qPCR for LANA DNA. BC3-LN 
cells (see text for infection protocol) were analysed 1,2,4,8,12 and 24 weeks 
after creation to determine the copy number/cell of KSHV (see materials and 
methods 2.1.12). Copy number is relative to wild type BC-3 cells. Analysis 
was performed in triplicate and the error bars signify the standard error of the 
mean. Results indicate a reduction in the number of copies of KSHV up until 
2 months after infection with pSIN-shLANA. After this, a lower but stable 
number of copies exists.
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(f) TaqMan qRT-PCR for Orf50 levels in BC3-LN (left) and JSC1-LN cells 
(right) with or without TPA stimulation. Wild type cells (designated LANA+) or 
LANA knockdown cells (designated LANA-) were cultured with (TPA+) or 
without (TPA-) TPA at a concentration of 20 ng/ml for 48 hours and the cells 
subsequently analyzed for Orf50 mRNA levels. mRNA levels are relative to 
wild type BC3-LN or JSC1-LN cells with no TPA. Analysis was performed in 
triplicate and the error bars signify the standard error of the mean. These data 
indicate that the knockdown of LANA (columns 2 and 4) leads to higher Orf50 
mRNA levels both with (first two columns) and without (last two columns) lytic 
life cycle induction with TPA.
(g) TaqMan qRT-PCR for vcyclin (left) and vFLIP (right) mRNA levels in BC3- 
LN cells 2 weeks, 1 month, 2 months and 6 months after creation (see text for 
infection protocol). mRNA levels are relative to wild type BC-3 cells. Analysis 
was performed in triplicate and the error bars signify the standard error of the 
mean.
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5.6 Discussion and conclusions
The in vitro knockdown of the members of the oncogenic cluster 
demonstrates the efficacy RNAi both as a tool for research and potential 
therapeutic.
The varied response of PEL cell lines to LANA knockdown was completely 
unexpected. LANA is involved in tethering the episome, binding to both pRb 
and p53 and suppressing the lytic life cycle. We were expecting LANA 
knockdown to induce apoptosis, cell cycle arrest, and possibly activation of 
the lytic life cycle. Considering its presence on a tricistronic transcript, we 
were expecting a LANA knockdown to reduce expression of vFLIP and 
vcyclin as well. It seemed almost impossible that cells could be relatively 
unaffected by its knockdown, as our results in BC-3 cells indicate.
Several possible explanations for this lack of effect in BC-3 and JSC-1 cells 
were considered. Given the varied response of these cells during culture in 
the laboratory with the selection pressure of a LANA knockdown, these cells 
may have acquired a mutation in cellular gene expression which allowed 
them to survive with decreased LANA levels. This same pressure could also 
have cause the KSHV episome to integrate into the cells, therefore reducing 
their requirement for LANA to tether the episome.
LANA could also be so redundant in these cells that only a tiny proportion is 
required for its cellular effects- the knockdown is only around 80% efficient, so 
around 20% of the mRNA and therefore presumably the protein is still present 
in the cell. Lastly, several other KSHV proteins have been shown to be 
present during some programmes of latency, like LANA-2 (vlRF3), and novel 
functions for these proteins could compensate for the functions of LANA in its 
absence.
The residual number of episomes of KSHV DNA in BC3-LN and JSC1-LN 
cells after the knockdown (Fig 5.5e) combined support episomal integration or
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redundancy of function, while the fact that only BC-3 and JSC-1 cells seem to 
be able to survive reduction in LANA levels support mutations in host cells 
compensating for LANA functions. The limited change in vcyclin and vFLIP 
levels (Fig 5.5f) also support redundancy in LANA levels, implying that if the 
knockdown is sufficient to reduce LANA levels below a certain threshold, the 
cells go into apoptosis. Reduction of LANA expression to the threshold level 
still allows it to perform cellular functions and the cells are maintainable in 
culture. I would like to have performed a complete analysis of the effects of 
LANA and reduction in LANA levels. This could be accomplished by 
comparing wild type and BC-3-LN and JSC-1-LN cells using a gene 
expression microarray to determine what, if any, pathways are deregulated 
and affected by LANA knockdown.
We can theorise why LANA knockdown cells can maintain a low but stable 
copy number of KSHV DNA (Fig 5.5e). The low level of LANA may be 
sufficient to maintain some (but not 80-150) copies of the episome, therefore 
the copy number reduces, or as some publications have implied for other 
gammaherpesviruses, although never for KSHV, the DNA could have 
integrated. This would explain also the inability of these cells to produce 
functional virus when induced- the normal effect of a reduction in LANA is 
activation of the lytic life cycle, or the hyperinducibility we see with JSC-1-LN 
cells. I would like to have investigated this further, perhaps by inverse PCR, 
FISH (fluorescence in-situ hybridisation) or gardella gel analysis to determine 
whether or not the KSHV DNA had integrated.
The potential for knockdown of members of the oncogenic cluster for 
inhibiting the virus and therefore as a potential therapeutic was increased by 
the discovery that all PEL cell models of latent infection were inhibited by 
reducing the expression of the viral FLIP and vcyclin (Fig 5.3a). This proved 
extremely effective -  it was impossible to maintain cells even with a partial 
knockdown of vcyclin and vFLIP in culture. The importance of both of these 
proteins was demonstrated with attempts to rescue the expression of one 
after knockdown of both -  knockdown of the vFLIP provided the fastest and
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most complete apoptosis, however vcyclin was shown here to have a role in 
survival of these PEL models (Fig 5.3d+e).
The interesting nature of the knockdown with regards to its effect on the 
bicistronic but not tricistronic forms of the mRNA species is unexplained by 
my results. vFLIP and vcyclin were always knocked down together, however 
LANA knockdown was always independent. I was unable to isolate a target 
specific for vFLIP or vcyclin, or find a target which would knockdown all three 
genes (Fig 5.2d+e).
Both from the data in chapter 4 and the demonstration here of concomitant 
vFLIP and vcyclin knockdown there is evidence that knockdown of genes on 
a polycistronic strand is sufficient to reduce the expression of both genes. 
Why this should be different for LANA is unknown. From the current literature 
regarding the mechanism of RNAi it can be theorised that the secondary 
structure of the tricistronic strand may hide the targets. This is unlikely due to 
Figs 5.2d and 5.2e, where several separate targets all failed to knockdown 
vFLIP and vcyclin independently or all three latent genes together. Hiding all 
of these targets through modification of structure seems unlikely. Perhaps the 
5.1 kb mRNA strand containing all three messages is too large to bind with the 
RISC and be targeted for degradation, however there is no confirmed 
mechanism by which mRNA is targeted in RNAi and I have no way to prove 
this. Northern blots on BC-3-LN cells to determine the relative quantity of the 
three different species of mRNA present would be interesting - although this 
will not answer the question of how LANA is regulated separately it may 
provide more insight into the mechanisms involved.
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Chapter 6:
In vivo inhibition of PEL 
Chapter aims:
The aims of this chapter were to show that the pSIN lentiviral vector can be 
used as an in vivo therapeutic targeting KSHV-driven primary effusion 
lymphoma (PEL). The biodistribution of the lentiviral vector is shown to be 
limited when injected intraperitoneally and that therapeutic potential will be 
limited by transduction efficiency.
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6.1 in vivo model of primary effusion lymphoma
A study of the effect of latent gene knockdown on an in vivo model of KSHV 
associated morbidity could lead to a better understanding of whether this 
technique has therapeutic potential. There have been many advances 
regarding the use of RNAi as an in vivo therapeutic. As there are increasing 
numbers of effective targets one of the main barriers has been the delivery of 
the knockdown effect. Research has been directed towards modifying dsRNA 
molecules to increase their stability in the body (Layzer et al., 2004), allowing 
them to enter cells more easily by attaching them to proteins and therefore 
decreasing the dose required (Song et al., 2005) or chemically modifying the 
dsRNA themselves to make them more efficient (Hoshika et al., 2005).
Lentiviral delivery of shRNA is a possible method of inducing an in vivo 
knockdown. Although currently there are barriers to the in vivo use of lentiviral 
vectors (see Chapter 1.1), this should not be the case forever. In order to 
demonstrate the potential of lentiviral vectors for an in vivo therapeutic, the 
pSIN-shvcyclin vector was chosen. This vector has been shown to be 
effective and rapid in killing PEL cells (Chapter 5). The vector was modified to 
include an eGFP marker instead of a puromycin resistance cassette as this 
would allow easier visualization of infected tissues upon histology. This vector 
was called pSINeGFP-shvcyclin. The control vector for all infections was an 
empty vector expressing eGFP (pSIN-eGFP). Experiments throughout 
Chapters 4 and 5 have demonstrated no undesirable effects from infection 
with a hairpin targeting LacZ, and no significant difference between these 
vectors and one expressing no hairpin so it was decided that a pSIN-eGFP 
control would be sufficient.
First, an in vivo model of primary effusion lymphoma was assessed. Primary 
effusion lymphoma was chosen over the other two KSHV associated cancers 
(KS and MCD) as there are established models available and the route of 
administration for treatment would be simpler than for KS and MCD. Previous 
studies have shown that injecting PEL cells subcutaneously, intravenously or
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intraperitoneally can produce murine models of KSHV associated disease 
(Boshoff et al., 1998; Staudt et al., 2004; Staudt et al., 2004). We chose JSC- 
1 cells for the generation of our murine model because these cells were easy 
to infect with our lentiviral vector and showed suitable sensitivity to the 
knockdown of latent genes (Chapter 5).
Animal handling was performed at the Institute for Child Health, London, by 
John Anderson and Antigoni Papanastasiou. Immunodeficient mice were 
selected for the experiment. For this, and all subsequent experiments, mice 
were age matched (to within 4 weeks) and an equal number of male and 
female mice selected for each group. The mice chosen were an 
immunodeficient strain bred at the Institute of Child Health by Adrian Thrasher 
and John Anderson and had a genotype of RAG-/-, C3 -/- and common 
gamma chain -/-.
For the initial experiment to develop the model, two groups of 6 treated and 6 
untreated (weight control) mice were chosen. These data show that injection 
of 1x107 JSC-1 cells intraperitoneally caused rapid and reliable development 
of ascites, gaining as much as 50% of their bodyweight (Fig 6.1a). Girth 
measurements for these mice showed that this measurement, although an 
indicator of development of ascites was not a useful indicator of severity. This 
may be due to operator error, a factor which is difficult to remove from the 
experiment. For later experiments, it was therefore decided that using weight 
gain as an indicator of development of ascites and that culling these mice 
after a weight gain of 6 grams or the presence of a grossly enlarged abdomen 
inhibiting movement or function gave a more objective measure of suffering 
due to ascites development. These mice were easy to distinguish from normal 
mice (Fig 6.1b). These criteria also kept the experiment within ATCC 
guidelines for the humane treatment of animals.
Samples were taken from the 6 mice, all of whom had developed ascites. 
Western blots for KSHV latent genes were performed to show that the ascites 
contained KSHV positive PEL cells and the cellular density determined. The
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average value was 5x107 cells per ml (Fig 6.1c). The expression of LANA and 
vcyclin was checked, as ensuring this was a latent infection was critical to the 
efficacy of our therapeutic. Some variation in the expression of these genes 
was seen, especially in viral cyclin levels (Fig 6.1 d). Although the samples 
were equalized for protein content, variation in the numbers of murine cells in 
the samples may account for this. IFA for LANA confirmed that the cellular 
ascites contained LANA-positive cells presumed to be JSC-1 cells and small 
LANA-negative cells presumed to be murine (Fig 6.1 e). To confirm the origin 
of these cells, the samples were stained with a PE conjugated antibody 
specific to murine MHC. FACS showed that most of these smaller cells (low 
FSC-H) stained positive for murine MHC (high FL2-H) (Fig 6.1f). The other 
(non-staining) smaller components were likely to be cellular debris, however 
for this representative sample 15% of the cells present were shown to be 
murine in origin.
These results combined together led us to believe that the ascites these mice 
developed was a genuine model of latent KSHV infection containing a mixture 
of KSHV-positive human cells and KSHV(LANA)-negative murine cells. The 
latent genes were expressed and this model was therefore suitable for us to 
test our potential therapeutic.
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Figure 6.1 in vivo model of primary effusion lymphoma
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Figure 6.1 in vivo model of primary effusion lymphoma
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Figure 6.1 in vivo model of primary effusion lymphoma
Analysis of ascites from 6 immunodeficient mice (see Chapter 2 for details of 
murine genotype) inoculated with 1x107 JSC-1 cells. Two mice were injected 
with PBS to show that the injection procedure could not cause ascites 
formation in these mice. One sample was taken from each mouse with 
ascites on day 14, and these samples used for (c) and (d).
(a) Graph (top) showing the weight gain (in grams, to the nearest 0.1 g) of the 
6 mice inoculated with JSC-1 cells up to 3 weeks after injection. Error bars 
indicate the standard error of the mean of the group. Table (bottom) 
documenting the individual weight change (in grams, to the nearest 0.1 g) and 
girth measurements (in mm) of all eight mice 14 days after inoculation.
(b) Photograph of mice injected with 1 x 107 JSC-1 cells (right) and mice 
injected with PBS (left) culled after 21 days. The mice injected with JSC-1 
cells showed obviously distended abdomens.
(c) Table indicating the individual density (in cells/ml) of ascitic samples from 
these mice. Density was determined by counting the number of cells present 
in a 1/100 dilution of the sample using a haematocytometer.
(d) Western blot against LANA (top) and vcyclin (bottom) of ascitic samples 
from these mice. Lane 1 is a positive control (JSC-1 cells from tissue culture) 
and lane 2 a negative control (Ramos cells from tissue culture). Samples 
were equalized for protein content using the Bradford assay.
(e) IFA for LANA of Sample 1. IFA was performed (see Materials and 
Methods). Blue arrows indicate large, LANA positive cells presumed to be 
JSC-1 cells, and red arrows small LANA negative cells presumed to be 
uninfected murine cells. Result is representative of all 6 samples.
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(f) FACS analysis of Sample 1 before and after staining with rat anti-mouse 
MHC-PE conjugated antibody (see materials and methods). Tables indicate 
the percent of cells present in each quadrant.
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6.2 Lentiviral distribution after intraperitoneal injection
The biodistribution and availability of the lentiviral vector are important to 
determine the optimum dose and best administration route. The distribution of 
lentiviral vectors injected intraperitoneally both into mice with ascites and 
control mice was assessed in terms of lentiviral inserts using qPCR. 
Determination of the presence of lentiviral vector in a range of tissues from 
the mice allowed determination of the suitability of this route of administration 
for other purposes.
Three normal mice injected with 1x109 293tlU of pSIN-eGFP showed a 
distribution demonstrating that the vector remained broadly limited to the 
peritoneal cavity (Fig 6.2a). Some vector leaked out, possibly through the 
injection site and the only tissue in the mouse where no vector was detected 
was the brain.
Mice with established ascites were also injected and showed a similar but 
more limited distribution (Fig 6.2b). This was presumably due to the presence 
of PEL cells in the peritoneal cavity which acted to reduce the amount of virus 
leaking out of the cavity.
These data indicate that intraperitoneal injection of lentiviral vector is a good 
route of administration for therapy of ascites. It also shows that the vector is 
limited to the peritoneal cavity, and is therefore likely to be safe.
- 2 6 6 -
Figure 6.2 Lentiviral distribution after intraperitoneal injection
Untreated mice
Organ Viral inserts (relative to peritoneum)
Peritoneum 1
Liver 0.03 ± 0.01
Spleen 0.18 ± 0 .0 2
Tail 0.09 ±0 .01
Heart 0.0051 ±0 .0011
Brain Not Detected
Flank muscle 0.09 ± 0.017
Mice with ascites
Organ Viral inserts (relative to peritoneum)
Peritoneum 1
Liver 0.01 ± 0.003
Spleen 0.3
Tail 0.019 ± 0 .0 0 2
Heart 0.0032 ±0 .0 0 1 7
Brain Not Detected
Flank muscle 0.03 ± 0.004
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Figure 6.2 Lentiviral distribution after intraperitoneal injection
(a) Table indicating the number of lentiviral inserts per cell of samples taken 
from 3 mice, 3 days after intraperitoneal injection of 1x109 293tlU of lentiviral 
vector. Copies per cell was determined using TaqMan qPCR. Numbers 
indicate the mean and range of the three samples. Cell number was 
estimated using primers reacting to both human and murine GAPDH.
(b) Table indicating the number of lentiviral inserts per cell of samples taken 
from 3 mice inoculated with 1x107 JSC-1 cells, and then 1x109 293tlU of 
lentiviral vector 4 days later. Samples were taken on day 7 (3 days after 
injection with viral vector). Copies per cell was determined using TaqMan 
qPCR. Numbers indicate the mean and range of the three samples. Cell 
number was estimated using primers reacting to both human and murine 
GAPDH.
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6.3 Inhibiting primary effusion lymphoma engraftment
The effect of infection on the development of ascites was established. Six 
mice were inoculated with 1 x 107 JSC-1 cells (tumour), six mice inoculated 
with 1 x 107 JSC-1 cells and 1 x 108 293tlU of pSIN-eGFP (tumour + virus) 
and a further six mice left untreated (weight only). Infection with the lentiviral 
vector showed no significant effect on either the rate or amount of ascites 
developed (Fig 6.3a).
To demonstrate the potential of vectors expressing a short hairpin against 
vcyclin to inhibit the engraftment of primary effusion lymphoma in this model, 
1x108 293tlU of virions expressing the short hairpin and eGFP (pSINeGFP- 
shvcyclin) were coinjected with 1x107 JSC-1 cells intraperitoneally into 6 mice 
(‘sh-vcyclin’). This represents an MOI of 10 293tlU/cell. One control group, 
‘weight only’ (6 mice) was used only as weight controls to determine normal 
growth velocity. Another control group ‘empty vector’ (6 mice) was injected 
with JSC-1 cells and a lentiviral vector expressing eGFP but no short hairpin 
(pSIN-eGFP). Both control groups were necessary to demonstrate that the 
virus itself is incapable of inhibiting engraftment. A repeat administration of 
1x108 293tlU of appropriate vector (with or without a short hairpin) was given 
3 days after the start of the experiment. The weight gain of these mice was 
charted over the course of 5 weeks (Fig 6.3b). On this graph, mice who 
gained more than 2x mean weight gain of the weight only control group were 
considered to have failed treatment, and are marked on the graph as outliers 
(circles). Outliers are excluded from the ranges on the box and whisker plot 
but included in all statistical calculations.
These data indicate that 4 of 6 mice in the treated group showed no 
significant weight gain at the end of the experiment. The remaining mice did 
develop ascites, however this was at a reduced rate (statistical difference 
empty vector vs sh-vcyclin p<0.01). All 6 mice in the control group developed 
ascites in a similar fashion to the first experiment.
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Samples of ascites from the two affected mice were taken after the mice were 
culled. These ascites were positive for the viral cyclin by Western blot (Fig 
6.3c) and LANA by IFA (Fig 6.3d). A small number of cells expressed eGFP 
(Fig 6.3e), implying some infection with the lentivirus, but this was at a level 
sufficiently low that the viral cyclin knockdown did not kill the cells. The 
lentiviral insert was detected by qPCR (Fig 6.3f) but again at a low level. This 
would imply that enough uninfected cells survived in these mice to form an 
effusion despite the administration of treatment.
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Figure 6.3 Inhibiting primary effusion lymphoma engraftment
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Figure 6.3 Inhibiting primary effusion lymphoma engraftment
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Figure 6.3 Inhibiting primary effusion lymphoma engraftment
(a) Graph showing the weight gain in grams of groups of 6 mice left untreated 
(weight only), 6 mice inoculated with 1 x 107 JSC- cells in the midline and 
injected with 1x108 293tlU lentiviral vector encoding eGFP on the left lateral 
side (tumour + virus) and 6 mice injected with 1x107 JSC-1 cells in the midline 
(tumour only). Weight gain was assessed over the course of 3 weeks. At 3 
weeks, the experiment was ended and all mice were culled due to weight 
gain. Error bars indicate the standard error of the mean.
(b) Box and whisker plot indicating the weight gain (in grams) of groups of 6 
mice left untreated (Weight only), 6 mice inoculated with 1x107 JSC-1 cells in 
the midline and injected with 1x108 293tlU lentiviral vector encoding eGFP 
(Empty vector) on the left lateral side and 6 mice injected with 1x107 JSC-1 
cells in the midline and 1x108 293tlU lentiviral vector encoding eGFP and a 
short hairpin against vcyclin (sh-vcyclin) on the left lateral side. Repeat doses 
of virus were administered on day 3. Measurements were made until day 18, 
when all the mice in the empty vector group were culled due to weight gain. 
Lines indicate the range (top and bottom whiskers); 25th, 50th and 75th centiles 
(box and centre line). Outliers in the sh-vcyclin group (distinguished as weight 
gain 2 standard deviations above the median of the group) are marked with 
circles and excluded from the box and whisker plot, but included in statistical 
analysis indicating p(Empty vector vs. sh-vcyclin at day 18)<0.01.
(c) Western blot for vcyclin indicating the presence of v-cyclin in two samples 
from the ascites of two different mice. Samples were taken at the end of the 
experiment, when mice were culled.
(d) IFA for LANA of the two ascitic samples used in (b) to show presence of 
LANA in individual cells. The secondary antibody used was goat anti-rat-PE 
(Dako, 1:500). PE was used instead of FITC as cells may have been 
expressing eGFP.
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(e) FACS analysis of ascitic samples used in (b) and (c) showing the small 
proportion of cells expressing eGFP (0.9 and 1.2%)
(f) TaqMan qPCR for the lentiviral insert to assess quantitatively the level of 
infection in the ascitic samples used for (b)-(d). Cell number was assessed 
using primers to GAPDH and data represented as lentiviral copies/cell.
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6.4 Inhibiting established PEL
Prevention of engraftment does not represent an effective therapeutic, which 
is the aim of this chapter. Treating established ascites containing many more 
cells is required to demonstrate the potential of this technology.
The expected requirement from in vitro experiments of 10 days for cells to 
enter apoptosis and the data from in vivo experiments that mice begin to die 
from day 14 after inoculation imply that treatment would have to begin early in 
order to be successful.
Twelve mice were injected with 1x107 JSC-1 cells (T), and a further 6 mice 
taken as weight controls (W). The weight gain of the inoculated mice after 3 
days was established as greater than 2x the mean weight gain of the control 
group (Fig 6.4a). These mice were considered to have established ascites.
The mean weight gain of inoculated mice (corrected for the weight gain in the 
control group) was 1.1g, so this implied the presence of up to 8.5x107 cells 
(based on 6.1c). To determine the treatment dose required, this figure was 
taken to be 1x108, and an MOI of 10 293tlU/cell (required for efficient 
knockdown) was treated as 1x109 293tlU of vector. The assumption that all 
virus would remain effectively limited to the peritoneal cavity was made. The 
tumour cell inoculated mice were divided into two groups. 6 were ‘Treated’, 
receiving 1x109 293tlU of lentiviral vectors expressing eGFP and a short 
hairpin against viral cyclin (pSINeGFP-shvcyclin) , and the other 6 were 
‘Untreated’, receiving a virus expressing only eGFP (pSIN-eGFP). After 4 
days, a repeat dose of 1x109 293tlU of lentivirus was administered.
These results indicate that the injection of the lentivirus did not significantly 
alter the development of ascites in the treated mice (Fig 6.4b). Although the 
gain in weight seemed slower in the Treated group, the p value for this was 
0.76 (not significant). Two of the tumour challenged mice failed to develop 
ascites (1 in each group), and several were noted when culled to have formed
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solid tumours. Samples from these tumours were positive for LANA by 
Western blot (Fig 6.4c).
These results indicate both that in this particular experiment the development 
of ascites was not as reliable as in previous experiments and that the dose of 
administered lentivirus was insufficient. Samples from the peritoneum and the 
ascitic fluid of 2 mice from the untreated group (injected with pSIN-eGFP 
only) were tested by qPCR for the lentiviral insert (Fig 6.4d). It was found that 
the peritoneum contained almost 5 times the number of copies per cell of the 
lentiviral vector than the ascitic sample. It is difficult to estimate the number of 
cells in the murine peritoneum and also the dynamics of injection of human 
PEL cells within this environment, so we revised the experimental plan to 
involve treatment with 1x1010 293tlU of lentiviral vector and to increase the 
group size to 10 mice to allow for the possibility of failed engraftments.
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Figure 6.4 Inhibiting established PEL
Mouse Weight (g) Change (g) Mouse Weight (g) Change (g)
W1 23.2 +0.5 T1 24.7 +1.6
W2 21.1 +0.2 T2 25.1 +1.4
W3 22.3 +0.4 T3 23.1 +1.7
W4 22.4 +0.9 T4 22.9 +1.1
W5 20.9 -0.1 T5 26.1 +2.4
W6 26.7 +1.1 T6 27.1 +1.9
T7 22.1 +1.7
T8 26.4 +1.6
T9 25.2 +1.1
T10 24.1 +1.9
T11 23.4 +1.7
T12 21.1 +1.3
Mean weight change: +0.5g (+2.2%) Mean weight change: +1.61g (+7.4%)
b
p (Treated vs Untreated, day 21) = 0.76
0 3 5 7 10 12 14 17 19 21
Time (days)
Weight Control 
Untreated 
T reated
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Figure 6.4 Inhibiting established PEL
Experiment to assess the ability of lentiviral vector to treat established 
ascites. One group (W) are weight only controls, and were not tumour 
challenged. The other group (T) were challenged with tumour (1x107 JSC-1 
cells). The inoculated group was divided into two groups of 6, one of which 
was injected with 1x109 293tlU of lentiviral vector expressing eGFP but no 
hairpin (Untreated) and the remaining group injected with 1x109 293tlU of 
lentiviral vector expressing eGFP and a short hairpin against vcyclin 
(Treated). Viral injections were performed at day 3 and again at day 5.
(a) Table representing the individual weight and weight change of the mice 
used for the experiment 3 days after inoculation (before the first injection with 
virus).
(b) Graph representing weight of mice used for the experiment over the 
course of 21 days showing that there is no statistically significant benefit from 
administration of treatment virus (p=0.76).
(c) Western blot for LANA of 4 samples taken from treated mice at the end of 
the experiment (day 21) when the mice were culled.
(d) TaqMan qPCR for the lentiviral insert of ascitic samples and peritoneum 
from mouse 1 showing the presence of the lentiviral vector at relatively low 
levels in the ascites.
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6.5 Producing large quantities of high titre lentivirus
Aliquots of 1x1010 293tlU of lentiviral vector suspended in 300 pi for IP 
injection represents a considerable challenge both in terms of the 
concentrations and the overall yield of virus.
Optimisation of the length and the speed were an obvious first step. Current 
yields with ultracentrifugation are in the order of 10%. Optimisation showed 
that only 30 minutes at more than 20,000 RPM was required for recovery of 
lentivirus (Fig 6.5a). The yield was still low (typically around 25-30%) 
however, so the efficiency of resuspension was examined (Fig 6.5b). It was 
found that resuspension overnight with a small volume (200 pi) of PBS at 4 
degrees with agitation gave yields around 80%.
The use of gel ultrafiltration (Centricon) units with a 100 kDa molecular weight 
cut-off on the concentrated solution gave further increases in the final titre. 
This mixture, however was noted to be very viscous and had a proteinaceous 
component which emerged from solution. This was attributed to the presence 
of serum in the medium. This highly concentrated virus stock was also found 
to be toxic to 293t cells (data not shown). This precluded the use of centricon 
units at this stage of the process.
In order to allow the use of gel ultrafiltration, the ability of 293t cells to 
produce virus in low serum of serum free conditions was established. 
OptiMEM (Gibco) is designed to allow the growth of cells in low serum 
conditions through the addition of growth factors. I therefore investigated 
whether OptiMEM could be used instead of DMEM supplemented with 10% 
FCS either alone or as the manufacturer’s guidelines indicate with 2% FCS.
It was determined that the use of OptiMEM with 2% serum could produce viral 
titres equal to that of DMEM with 10% serum. OptiMEM with no FCS did
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facilitate production of virus, however the 293t cells adhered to the plate for 
only 24 hours after transfection in this medium.
The effective titre of the virus in the supernatant if the harvest period was 
shorter than 24 hours and more than 2 harvests were performed were 
assessed. This method has not been documented for lentiviral vectors. It was 
determined using several plates and medium changes at varying time periods 
that incubation in fresh medium for 8 hours gave both maximal titre and yield 
(Fig 6.5c). Harvesting in this manner also maintained the 293t cells for longer 
in culture, allowing for harvests up to 6 days after the initial medium change.
Using this low serum medium the possibility for using gel ultrafiltration 
(Centricon) units was reassessed. It was found that the overall viral volume 
could be reduced around 20-fold, and the titre increased correspondingly 
when used as described (materials and methods section 3.2.6) although the 
overall yield was variable between 50 and 80% (Fig 6.5d). This virus was also 
found not to be toxic to 293t cells (data not shown).
Ultracentrifugation and resuspension with agitation in small volume of the 
ultrafiltrate allowed the consistent production of high titre (>1010 293tlU/ml) 
virus required for the treatment of established ascites in mice. The use of 
multiple harvests from 293t cells also allowed the production of this quantity 
of virus using roughly 1/8 of the number of plates which would have been 
required using production methods previous to this optimization.
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Plate No. Harvested
every...
Average 1st 
24 hours 
(293tlU/ml)
Average 2nd 
24 hours 
(293tlU/ml)
Average 3rd 
24 hours 
(293tlU/ml)
Cumulative 
yield over 72 
hours 
(293tlU)
1 2 hrs 1x106 4x106 7x10® 1.7x10®
2 4 hrs 7x106 2x107 1.5x107 3.2x10®
3 6 hrs 2x107 5x107 7x107 4.7x10®
4 8 hrs 8x107 1.5x10s 1.4x10® 1.1x109
5 12 hrs 1x108 2.2x10® 1.7x10® 9.7x10®
6 24 hrs 1x108 2.1x10® 1.9x10® 4.8x10®
Before filtration After filtration
Volume (ml) Titre (293tlU) Volume (ml) Titre (293tlU) Yield (%)
80 1x10® 3.9 1.3x109 65
80 1.3x10® 4.2 2.1x109 81
80 7.5x107 4.2 7.7x10® 51
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Figure 6.5 Producing large quantities of high titre lentivirus
(a) Graph indicating the yield (%) of 20mls of lentiviral vector (pSIN-eGFP at 
1x10® 293tlU/ml) ultracentrifuged at 5,000, 10,000, 15,000, 20,000 or 25,000 
RPM in a Beckman SW41 rotor for 15, 30, 45, 60 or 120 minutes. After 
centrifugation the supernatant was discarded and pellets were resuspended 
by agitation using a pipette in 1 ml PBS and titre assessed again. Yield is 
expressed as (total virions in final sample/ total virions in starting 
sample)*100.
(b) Table comparing yield of lentiviral vector (20 mis of pSIN-eGFP at 1x108 
293tlU/ml) using different resuspension methods after ultracentrifugation at 
20,000RPM for 60 minutes with a Beckman SW41 rotor. ‘Agitation’ involved 
vigorous pipetting of volume of PBS, ‘overnight’ involves leaving the viral 
pellet overnight at 4°c in specified volume, ‘overnight with agitation’ involves 
resuspension overnight in specified volume at 4°c on a gyrating platform set 
to 30 rpm. Yield is expressed as (total virions in final sample/ total virions in 
starting sample)*100.
(c) Table showing the average titre of pSIN-eGFP virus produced by plates 
transfected under optimal conditions as describe in Chapter 3. Each plate 
was harvested every 2, 4, 6, 8, 12 or 24 hours for 72 hours. All harvests were 
stored at 4°c until the end of the experiment, where the average titre (in 
293tlU/ml) in each 24 hours period (average of 12 8ml samples for 2 hour 
harvests, 2 8ml samples for 12 hour harvests). The cumulative yield (in 
293tlU) is the total number of virions produced by that plate over the 72 hour 
period assessed by combining all harvests and measuring yield. This 
measure takes into account the volume of virus produced as well as the 
concentration in assessing yield.
(d) Table showing the use of Centricon-80 units (with 100kDa molecular 
weight cut-off) to gel filtrate 80ml samples of lentiviral vector (pSIN-eGFP) at 
stated titre using the manufacturers recommended protocol (see materials
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and methods). Titre and volume before and after the filtration step were used 
to calculate yield as (total virions in starting sample/ total virions in final 
sample)*100.
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6.6 Increased dosage for potential therapeutic
Three groups of 10 mice were allocated into ‘sh-vcyclin’, ‘Empty Vector’ and 
‘Tumour Only’ groups. One group of 6 mice was used as a weight control. All 
mice except the weight control group were inoculated with 1x107 JSC-1 cells 
and their weight after 3 days was assessed. The mice showed a significant 
weight gain, with a mean weight gain in each group 10% above the mean of 
the control group (data not shown).
1x1010 293tlU of lentiviral vector encoding eGFP and a short hairpin against 
vcyclin (pSINeGFP-shvcyclin) was administered to the sh-vcyclin group, 
1x1010 293tlU of vector expressing only eGFP (pSIN-eGFP) given to each 
mouse in the Empty Vector group and the Tumour Only and Weight Control 
groups were not treated further.
The revised treatment regime was based upon the available data from the 
previous experiment. It consisted of two large bolus doses of virus in order to 
increase infection in those cells which were escaping, and a maintenance 
dose thereafter in case any cells did escape. We assumed the majority of the 
cells in the ascites are infected with the two bolus doses, and then the 
remaining task of preventing further development of a much smaller number 
of PEL cells involves a smaller dose.
The weight change of the mice over the experiment showed a positive benefit 
from the treatment (Fig 6.6a) and the Kaplan-Meyer survival curve for the 
mice throughout the course of the experiment showed a large statistical 
benefit (p=0.004) from the administration of the treatment virus (Fig 6.6b).
It was observed that mice in the treated group were not developing ascites 
but dying of solid tumours. Since we know our treatment is effectively limited 
to the peritoneal cavity, and is unlikely to have an effect on extra cavity solid 
tumours, these data can be represented in terms of proportion of mice ascites
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free (Fig 6.6c), which shows this treatment has an even stronger effect in 
terms of specifically inhibiting established ascites.
As the mice in the sh-vcyclin group seemed to develop solid tumours at an 
increased rate it was proposed that the inhibition of vcyclin may simply alter 
the phenotype of the tumour rather than treat it.
To determine whether the rate of solid tumour development was actually 
higher, in all culled mice in the Empty Vector and sh-vcyclin groups full 
autopsies were performed looking for a solid tumour focus. Several of the 
untreated group developed both ascites and solid tumours (Fig 6.6d). 
Inclusion of these data suggests no significant difference in the phenotype of 
the tumour from the administration of the lentiviral vector.
In order to determine whether development of solid tumours was due to 
failure of treatment or failure of administration, and to prove that the inhibition 
was not altering the phenotype of the cancer, solid tumours from both sh- 
vcyclin and Empty Vector mice were sampled and analysed.
Four solid tumours were checked for the lentiviral insert by qPCR (Fig 6.6e). 
One was found to contain small number of lentiviral inserts (0.03 copies/cell), 
however the other three were negative. This implies the vector did not reach 
the solid tumours. Samples of the tumours were all positive for LANA on 
Western blot (Fig 6.6f), implying that they are PEL cell derived, rather than a 
coincidental murine tumour or one driven by insertional mutagenesis from the 
lentivirus.
Cells from these solid tumours did not grow well in culture. Apoptosis was 
clearly seen in all 4 samples when infected with pSINeGFP-shvcyclin at an 
MOI of 10 293tlU/cell (Fig 6.6g). This demonstrates that these cells had 
probably never been exposed to vector, and may be amenable to treatment. 
Importantly, they do not represent an altered phenotype for the cancer.
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Figure 6.6 Increased dosage for potential therapeutic
(a) Graph showing the weight gain of mice (in grams) divided into 3 groups of 
10 mice (sh-vcyclin, Empty Vector and Tumour Only) and one group of 6 mice 
(Weight Control) over 21 days. Mice in the sh-vcyclin, Empty Vector and 
Tumour Only groups were injected intraperitoneally with 1x107 JSC-1 cells in 
300pl of PBS on day 0. At day 3, mice in these three groups expressed a 
mean weight change of > 2x standard deviation of the mean of the weight 
control group (roughly 10% of bodyweight). These mice were assumed to 
have developed the first stages of ascites. At day3, 1x1010 293tlU of lentiviral 
vector in a volume of 300pl were injected into the sh-vcyclin (pSINeGFP- 
shvcyclin) and Empty Vector (pSIN-eGFP) groups. This was repeated at day 
5, and represented the two ‘treatment’ doses. The Tumour Only and Weight 
Control groups were left untreated. On days 7, 10, 12 and 14 mice in the sh- 
vcyclin and Empty Vector group were injected with 1x109 293tlU of 
appropriate lentiviral vector in a volume of 300pl. Weight was measured on all 
treatment days and the mice were checked every other day to ensure they 
were healthy. Mice were culled due to ascitic growth, cachexia or abdominal 
prolapse. The experiment was terminated at 46 days to autopsy the mice.
(b) Kaplan-Meyer survival curve for experiment outlined in (a) showing an 
increase in the median time of survival of 10 days and a p value for sh-vcyclin 
vs Empty Vector of p=0.004. The p value for Tumour Only vs Empty Vector 
was p=0.43 (not significant)
(c) Graph showing the number of mice ascites free in each group for 
experiment outlined in (a). Mice were considered ascites free if they remained 
asymptomatic with no significant weight gain (significant = > 2x standard 
deviation of the mean weight gain in weight control group) or mice who were 
culled for other reasons during the experiment (e.g. solid tumour). The graph 
represents the efficacy of the lentiviral vector at treating specifically ascites.
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(d) Table showing the development of solid tumour and ascites of the mice in 
experiment (a) determined by autopsy. ‘Ascites’ indicates mouse had 
significant ascites or was culled due to ascites during the experiment. Solid 
tumour indicates a solid tumour was found outside the peritoneal cavity. 
Several mice had both ascites and a solid tumour, and are therefore recorded 
in both columns. The number of mice in each group was 10. There were 3 
mice in the sh-vcyclin group alive at the end of the experiment, although all 
were found to have small extraperitoneal tumours.
(e) Table of analysis of four tumour samples taken from mice with solid 
tumours after autopsy. Samples 1 and 2 were taken from mice in the Empty 
Vector group, samples 3 and 4 from mice in the sh-vcyclin group. Analysis 
indicates the number of lentiviral inserts per cell found in the samples as 
determined by TaqMan qPCR using standard conditions (see section 2.1.12).
(f) Western blot of the samples taken in (e) for LANA. 10pg of cell lysates was 
equalized for protein concentration using the Bradford assay and Western 
blot for LANA performed as detailed in the materials and methods section. 
Results indicate that all four samples were positive for LANA by Western blot 
at levels comparable to the wild type cell (JSC-1).
(g) Graph showing the effect on cultures derived from the 4 tumour samples 
of vcyclin knockdown. The 4 samples were transported from the autopsy to a 
tissue culture facility. Two sections from each sample were they were agitated 
for 5 minutes in a trypsin/collagenase mixture. These cells were then placed 
in serum rich (20%) RPMI in an incubator at 5% CO2 and at 37°c. Cells were 
placed both on adherent dishes and in suspension. Only the suspension cell 
cultures grew. The most viable culture for each sample was selected and then 
cultured as normal for suspension cells outlined in the materials and methods 
section. A sample of 105 cells from each sample was then exposed to an MOI 
of 10 293tlU of pSINeGFP-shvcyclin (sh-vcyclin) or pSIN-eGFP (empty 
vector) and the percent of cells remaining viable (determined by AnnexinV- 
FITC staining) at day 7 was assessed.
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6.7 Discussion and conclusions
It is shown here that short hairpin RNA delivered using lentiviral vectors has 
potential to inhibit the growth of PEL in a murine model. All PEL are 
associated with latent gene expression (Dupin et al., 1999). These 
lymphomas are difficult to treat, being resistant to cytotoxic drugs and there 
are few therapeutic options. Unlike other KSHV associated morbidities, an 
animal model has been demonstrated for PEL (Boshoff et al., 1998; Staudt et 
al., 2004).
Reliable development of ascites using JSC-1 cells was relatively easy to 
achieve (Fig 6.1a). JSC-1 cells were chosen because they are amenable to 
infection with a lentiviral vector and are novel in this model. The use of girth 
measurement as an indicator of ascites proved unreliable.
The cellular component of the ascites was much denser than expected. 
Human effusions are mostly liquid, with a very limited cellular component 
driving the effusion by excreting inflammatory peptides whereas in this murine 
model the ascites are almost exclusively cells. This may represent an altered 
behaviour of these cells in the murine peritoneal cavity, however in both the 
human disease and the murine model it is these cells which are driving the 
effusion. The cellular density may also be a reflection of the immunodeficient 
nature of the mice, as it would be active immune cells in an 
immunocompetent host which inhibit cellular growth in the effusion. This is 
both a weakness in the model and a strength in the therapy- since the cellular 
component is targetted, an increase in cellular density represents more of a 
challenge. In culled mice with pure ascites, no intraperitoneal focus was 
found which might indicate the cells were shed from a primary site (although 
some had extraperitoneal solid tumours, see below). This implied the model is 
faithfully mimicking an effusion.
Lentiviral vectors are shown here to be efficient intraperitoneal gene delivery 
tools. Although this route has been shown effective for systemic gene
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expression (Kootstra et al., 2003) there has been little quantitative 
documentation of the distribution of virus delivered in this fashion. Of concern 
for RNAi, where -5-10 293tlU/cell are required to gain an efficient knockdown 
in gene expression, is the amount of virus which would be required. 
Production of this quantity of virus is difficult (Zhang et al., 2001; Pham et al., 
2001; Ikeda et al., 2003) and the injection of large amounts of viral vector can 
be problematic for the patient (Marshall, 2002; Marshall, 1999). My results 
indicate that although lentiviral vectors do distribute throughout the animal, 
the majority is limited to the peritoneal cavity. This is ideal for our purposes, 
but can indicate that this administration route is less suitable for other 
applications. The use of tissue-specific promoters in lentiviral vectors (De 
Palma et al., 2003) combined with accurate knowledge of vector distribution 
from this and other studies (MacKenzie et al., 2002; Peng et al., 2001) would 
allow calculation of optimum dose and administration route for a wider range 
of applications. This study also therefore adds to the growing knowledge 
regarding the use of these vectors in vivo.
Unfortunately, there may be other hurdles with the use of lentiviral vectors for 
in vivo studies. VSVG pseudotyped lentiviral vectors are inactivated by 
complement (DePolo et al., 2000; Strang et al., 2004), and the immune 
response to transgene products in transduced cells (Ghazizadeh et al., 1999) 
will act when these vectors are used in immunocompetent subjects. Recently, 
there has been progress with both modifications of the VSVG envelope 
(Croyle et al., 2004) and the use of alternative viral envelopes (Strang et al., 
2004; Strang et al., 2005; Guibinga and Friedmann, 2005) although these 
approaches have yet to be used in vivo.
These results indicate an overall benefit for tumour-bearing mice of treatment 
with a lentiviral vector encoding short hairpin RNA. RNAi has been used to 
target human viruses and human cancers, however this is the first 
demonstration that disruption of a single essential viral gene with shRNA has 
an in vivo survival benefit for virally-driven malignancy (Godfrey et al., 2004).
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Co-inoculation of the vector and PEL cells prevented formation of ascites in 
four of six mice, and slowed the development in the other two. We injected 
JSC-1 cells in the midline and the virus on one side of the peritoneal cavity to 
show this as a genuine in vivo interaction, and a second injection to infect any 
cells which escape the first treatment. The delayed development in two mice 
implies that some cells may either escape infection or escape apoptosis. 
Analysis of the ascites of these two mice (Fig 6.3) indicate that these cells 
were escaping infection rather than developing a mutation in the vcyclin gene 
which made them immune to the RNAi. A higher initial dose of treatment or a 
longer course of treatment may be required to overcome this effect.
The vector was assessed as a therapeutic for established PEL. As a weight 
cut-of, three criteria were assessed. A weight gain of 10% of body weight, an 
absolute weight gain of 1 g or a gain of > 2 times the mean weight gain in the 
control group were looked at. In practice, all three criteria gave very similar 
working groups and 2x the mean weight gain in the control group was 
chosen. These criteria should ensure that ascites had developed and allow 
early treatment. The data regarding cell density (Fig 6.1c) showed that even 
this represented a large number of cells. Although the accuracy of 
determining engraftment based on a 1 g weight gain over 3 days may not be 
ideal, the necessity for early treatment to see the benefit forced this 
assumption. Even for the first experiment the treatment was shown to be 
insufficient, and this would have been compounded by waiting for a more 
significant weight gain.
During the course of the first experiment, the developing ascites did not 
behave as anticipated and although the treatment was insufficient for an 
effect, at least part of the apparent failure could have been due to misinjection 
of the PEL cells. This highlighted the need for accurate injection and for the 
use of healthy PEL cells to establish the model. One of the largest problems 
with the data set as a whole here is that there seems to be very variable 
growth velocity of PEL derived ascites. In Fig 6.1a, mice had gained 
approximately 5 g in 14 days. In Figure 6.3a, some mice had gained almost
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triple that (14 g) in the same time frame and in 6.4b the mice had gained 25 g 
in 14 days. In our final figure, 6.4a, the mice gained 3-4 g in 14 days. These 
figures are hugely discrepant. The only explanation is that variations within 
the age of the mice (which were matched for each experiment, but not 
between experiments and were significantly older for that experiment) and the 
health of the cells injected may affect the outcome. It is also possible that 
unhealthy cells injected drive a much more fluid (exudate) based ascites, 
rather than a cellular one and therefore gave misleadingly large numbers. In 
retrospect, samples from the ascites of these mice would have been useful in 
determining this.
Another weakness in the model was several mice who developed solid 
tumours in the treated group. This was felt to be due to tracking of the JSC-1 
cells out of the peritoneal cavity along the injection site. This happens for 
some human tumours in clinical settings, where biopsy sites can become 
routes of metastasis. The evidence from the later analysis of the solid 
tumours from the final experiment (Fig 6.6e,f) are indicative that the lentiviral 
vector may also have leaked out in this fashion, but it did not represent a 
fraction which was significant enough to inhibit the establishment of PEL. In 
the second experiment (Fig 6.6a) all injections were performed in the midline, 
and it was found that most (3 out of 4) of the sampled solid tumours occured 
along the midline.
Another question which was raised with the results of the first experiment was 
whether an autocrine function of the viral cyclin or viral FLIP meant that 
knockdown of the expression of this gene resulted in an alteration of the 
phenotype of the disease from an effusion to a solid tumour. This was ruled 
out with the second experiment where solid tumour development was shown 
to occur independently of the treatment received, but was masked by the 
rapid development of the ascites (Fig 6.6d).
The failure of the first experiment due to insufficient titre led to the 
investigation of high scale production of lentiviral vector. Previous reports
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(Pham et al., 2001; Zhang et al., 2001; Kumar et al., 2003) all documented 
‘large-scale- production methods’ which still seemed insufficient for the 
requirements of the experiment. Performing multiple harvests every few hours 
allowed these quantities of viral vector to be collected (Fig 6.5d,e).
Despite this, however, virion production still remains a serious barrier to the 
use of this vector as a treatment. Even if it is assumed as stated earlier that 
the human manifestation of this condition is much less cellular, the volumes 
involved are measured in litres, not mis, and therefore it can reasonably be 
assumed that all of the virus harvested across all of the experiments 
performed over 12 months would still be insufficient to treat one human case.
The decision to use a revised treatment plan was based upon many 
chemotherapy regimes, which involve large bolus treatments followed by 
maintenance doses. The rapid reversal in the observed weight gain was 
surprising. After injection with 1x1010 293tlU of pSINeGFP-shvcyclin mice in 
this group dropped below their starting weight. There was some concern 
about the wellbeing of the mice because of this- it was presumed that the 
weight loss was due to a cachectic or metabolic effect in the treated mice. In 
support of this being a virus related (rather than cell death) issue, a similar but 
less pronounced effect was seen in the mice injected with empty vector. The 
mice did not seem to be affected in the long term, however, since by day 14 
their weights had normalised to relevant controls (treated to weight only, 
untreated to tumour only). This may be an artifact of harvesting the virus in 
serum containing medium. The weight loss may also have been an effect 
induced by the injection of a concentrated serum containing mixture.
This may represent a serious and as yet undocumented problem for the use 
of lentiviral vectors for gene therapy. The quantities of vector that would be 
used in an in vivo therapeutic in patients are being approached in this study. 
Concerns of limitations of lentiviral vectors centre around immune responses, 
insertional mutagenesis, or recombination with wild type virus but little 
mention is made of the potential side effects such as this one.
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Interestingly, even accounting for this effect, the virus acted much faster in 
vivo than it did in vitro. Some development of ascites and then resolution if 
the cells were unaffected until day 10 after infection was expected, whereas a 
complete absence of development of ascites was seen in this experiment. It is 
possible that the virus caused cellular arrest as well as inducing apoptosis. 
The conditions within the murine peritoneum in terms of growth factors and 
equivalent serum concentration are unknown, and it is possible that JSC-1 
cells growing in this environment are much more susceptible to the effects of 
the knockdown. These data could be further investigated by examining the 
knockdown of vcyclin and vFLIP under different serum conditions in vitro.
After treatment was stopped, the mice were followed-up and three long term 
survivors were still apparently tumour free after 45 days. It was disappointing 
to find so many of the mice develop solid tumours, however this may reflect a 
failure of the administration of the tumour load not of the treatment itself. This 
does not mean this would have been less of a problem in a human disease 
setting. Treatment of the solid tumours was not attempted for two reasons. 
The first was a lack of viral vector -  the requirements to generate a 
statistically significant result were beyond the means available and secondly it 
would be difficult to successfully distribute this virus across the tumour mass 
itself. Extra cavity solid tumours do represent an extremely rare complication 
of PEL (Chadburn et al., 2004) and may therefore warrant a further study 
involving this as a potential therapeutic, however this fell outside of the range 
of this study.
In summary, this chapter represents a novel approach to treating an animal 
model of primary effusion lymphoma using both novel technology and 
development of established technologies to successfully reach a goal. 
Several hurdles were overcome during this process, and several problems 
both within this study and for further studies were highlighted.
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Chapter 7:
Conclusions
This thesis outlines the accomplishment of the goals set out both at the 
beginning and during the course of my PhD. The major accomplishments 
included:
• Demonstrating that a pSIN lentiviral vector is able to infect MSC and 
HSC with a high efficiency and does not affect their ability to 
differentiate in vitro.
• Develop a system for lentivirally delivered shRNA based around a 
human U6 promoter and show that this system functions in DMVEC, 
MSC and HSC (Clements et al., 2006).
• Choosing and evaluating targets for RNAi within the KSHV oncogenic 
cluster which have therapeutic potential (Godfrey et al., 2003) and 
demonstrating their efficacy in vitro.
• Showing the distribution of lentiviral vectors after in vivo injection in 
immunodeficient mice.
• Determining the quantity of lentiviral vector required to form a 
therapeutic and optimizing both production and concentration of vector 
to achieve this.
• Using lentivirally delivered RNAi as a therapeutic in a murine model of 
PEL (Godfrey et al.,2004).
Although there are now several commercial options for virally delivered RNAi, 
there were none when this work was initiated.
The lentiviral system I developed can be improved upon further. The 
requirement for a subcloning step to produce the lentiviral vectors is 
something which I would have liked to have resolved to produce a simpler 
vector which is easier to use. Unfortunately, there are no sites within the 
lentiviral backbone which would allow this without modification. Furthermore,
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a lentiviral system where RNAi can be conditionally controlled, e.g. with 
tetracycline, will further expand the use of these vectors.
I have identified shRNA sequences against vcyclin and vFUP of KSHV that 
prove very useful to induce apoptosis of primary effusion lymphoma (PEL) 
cell lines. This work indicates that targeting these viral transcripts could have 
significant therapeutic potential to treat PEL, and perhaps also other KSHV- 
induced tumours, e.g. KS and MCD. A more puzzling conundrum is the 
observation that targeting LANA does not induce apoptosis, and in fact PEL 
cells continue to proliferate when small amounts of LANA are present. As 
LANA is essential to maintain the viral episome, and also to tether KSHV 
episomes to chromatin during mitosis, this observation could indicate that the 
amount of LANA in PEL cells are redundant, and only a small amount of 
LANA is necessary for its essential functions, or it could indicate that KSHV 
has integrated into the host genome, as can happen in certain EBV cell lines. 
I did not resolve this issue during this PhD. It is also of great interest that the 
knockdown of LANA did not have the same effect in all PEL cell lines. LANA 
is known to suppress the activity of ORF50, the viral protein involved in 
initiating KSHV replication. A system that only partly suppresses LANA (as 
shown here with RNAi) may result in an increase viral load, by suppressing 
the inhibition of ORF50, and promoting lytic replication. This would imply that 
LANA might not be a suitable therapeutic target.
I collaborated with John Anderson at the Institute for Child Health to establish 
a murine model for PEL and to test the therapeutic potential in this model of 
lentiviral-delivered RNAi. These experiments proved encouraging, showing 
that the vector has potential as an in vivo therapeutic
Lastly, it should be noted that this work is being pursued by others: the 
lentiviral system for RNAi is now being used for several projects. There are 
plans to investigate further why there are differences between BC3 and JSC1 
cell lines in their responses to LANA knock-down, and the effects of 
concurrent EBV infection on LANA knockdown.
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